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INTRODUCTION 
 
 Siddha system of medicine is primitive medicine. Hence it is unique when 
compared to any other Indian medical system. It has a rich treasure of medicinal 
knowledge that includes the use of herbs, metals, and minerals. siddha system is based 
on a combination of ancient medicinal practises and spiritual disciplenes. This 
specialized medical practice was created by the siddhars.They discovers many natural 
remedies which are  used for the wide range of diseases. 
 Siddha system emphasizes not only a healthy body but a peaceful mind and 
pure soul.  
!According to thiruvalluvar 
“lqgqEl<!GjxbqEl<!Ofib<!osb<Bl<!F~Ozii< 
utqLkzi!w{<{qb!&e<X”. 
If the three doshas are normal in function, health is maintained.  Any change 
in the proportions of vatham, pitham and kabam may leads to disease.  
In yugi Vaithiya Chinthamani - 800 Siddhar Yugi Munivar  has classified 
Vatha disease into 80 types . Cegana Vatham is one among them and the symptoms 
are pain in the neck, giddiness, pain in the limbs, burning sensation of the eyes, pain 
all over the body like a sting of a scorpion. 
 Most of the symptoms present in Cegana Vatham can be correlated to those of 
Cervical spondylosis. Nowadays pain in the neck has become a matter of major 
concern. It is mainly due to life style modification. Pain in the neck is experienced by 
many people, especially software professionals who spend most of their time in front 
of the computers. Apart from them Manual workers who have to lift heavy weight 
also undergo the same problem. So the chances of developing Cervical Spondylosis 
are also highly increased. The common age group affected by cervical spondylosis is 
geriatric age group. Repeated trauma to cervical spine related to specific occupation 
like carrying axial loads, typing computer operation, desk work jobs etc. Play an 
important role in producing even at lesser age group. 
Cervical spondylosis refers to normal age related degenerative changes that 
occur in the cervical spine. These changes become much more prevalent as individual 
age. Radiographic evidence of cervical disk disease is present in 25% of 
asymptomatic patients under age 40, and 85% of asymptomatic patients over 60 yrs of 
age cervical disk disease can remain asymptomatic in many cases. But symptoms can 
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include axial neck pain, cervical radiculopathy and cervical spondylotic myelopathy. 
At some point during life, nearly everyone will be affected by neck pain. 
 As elsewhere cervical spondylosis is extremely common in India. The 
management scenario of cervical spondylosis is confusing and many times irrational. 
Our belief in traditional system of medicine is extremely high. In siddha literature, 
several formulations have been indicated for the treatment of vadha disease. In 
AATHMARATCHAMIRTHAM a drug “MILAGU LEGIYAM” has been indicated 
for Vatha disease. Hence I have selected this polyherbal formulation MILAGU 
LEGIYUM-6grm twice a day to evaluate the synergic therapeutic efficacy in the 
treatment of “CEGANA VATHAM” (CERVICAL SPONDYLOSIS) and also I have 
selected the “SEERAGA THYLAM” (External)-30 ml from SARBENTHARA 
VAITHIYA MURAIGAL – VATHAROGA CHIKKICHAI. These medicines contain 
various ingredients which modify the vitiated vatham. 
 “Sirappu Maruthuvam” is one among the distinguished branches of siddha 
system where it consists of varmam, thokkanam, ottradam, yogam and kaya kalpam.  
Mainly the vatha diseases are treated through Internal medicine, external medicine 
and varmam. 
varmam is one of the best external therapies in siddha system in alleviating 
pain in Cegana Vatham is also evaluated as a complementary therapy with trial 
medicines.  
The purpose of this work is to provide an overview of evaluation and 
treatment of the patient with a special disorder cervical spondylosis. 
 The trial drugs were prepared by the author and were tried in 40 cases of 
Cegana vatham of varied aetiology and the clinical study was undertaken in the IP and 
the outpatient post graduate department of sirappu maruthuvam and the follow up 
study of all the cases was done in the post graduate out patient.  
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AIM AND OBJECTIVE 
 
AIM: 
 To evaluate the clinical efficacy of “MILAGU LEGIYAM” (internal) and 
“SEERAGATHYLAM”(external)  for the treatment of CEGANA VATHAM  
(CERVICAL SPONDYLOSIS). 
 
PRIMARY OBJECTIVE : 
 
 To evaluate the clinical efficacy of “MILAGU LEGIYAM” (internal) and 
“SEERAGATHYLAM”(external)  for the treatment of CEGANA VATHAM  
(CERVICAL SPONDYLOSIS). 
 
SECONDARY OBJECTIVE:   
• To study the Siddha basic principles like envagai thervukkal 
including neerkkuri and neikkuri. 
• To evaluate the safety profile of the trial medicine. 
• To Evaluate the pharmacological study of trial medicine  
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REVIEW OF LITERATURE 
SIDDHA ASPECT 
osgeuikl<<<<!
! sqk<k! lVk<Kuk<kqz<! uik,! hqk<k,! gh! Lg<Gx<xr<gjt! nch<hjmbigg<!
ogi{<M! Ofib<gtieK! 5559! ujggtigh<! hqiqg<gh<hm<Mt<te/! “B,gq! juk<kqb!
sqf<kil{q”!F~zqz<!%xh<hm<Mt<t!91!ujg!uikr<gtqz<!osgeuikLl<!ye<X/!
! cegana vatham details  are  distribute under the following headings. 
Definition 
 A kind of neurological pain (vadha disease) affecting the cervical vertebral 
region and extending to the upper limbs and is associated with heaviness of body, 
giddiness, burning sensation of the eyes, discharge of urine with pain (strangury of 
dysuria). 
  -T.V. Sambasivam pillai dictionary P.No.1752 
Aetiology 
 The siddha literatures portrays the reason for diseases are any alteration in 
vatha,,pitham,kabam (Mukutrangal) 
The most common causes for cegana vatham are same that of the etiological 
factors, which aggrevate vatha disease. The aetiological factors are explained by 
various authors in text books they are follows, 
2/ngk<kqbv<!ge<lgi{<ml<< < < < << < < < << < < < <-300 
uik!ge<l!uvziX<<< !
! “F~oze<x!uikl<!uf<k!ujgkiOeK!
! ! F{<jlbibg<!ge<lk<kqe<!ujgjbg<!OgT!
! gizqOz!Okie<xqbK!gMh<hOkK!
! ! jggizqz<!Lmg<gqbK!uQg<gOlK!
! OgizqOz!hMgqe<x!uqVm<slie!
! ! Gpf<jk!lvf<ke<je!oum<mz<!Olz<Okiz<!sQuz<!
! fiuqOz!sQuosf<K!giz<Lxqk<kz<! !
! ! fz<z!ogil<H!kijp!Lxqk<kz<!fzqk<kz<!giO{”!
. ngk<kqbi<!ge<l!gi{<ml<!< < < < << < < < << < < < < .411!himz<!67<<< !
 
 2.!B,gq!juk<kqb!sqf<kil{q< << << <  -800-z<<<<!
“we<eOu!uikf<ki!oe{<hkiGl<!
! -gk<kqOz!leqki<gTg<!ogb<BliX 
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hqe<eOu!ohie<kjeOb!OsivR<osb<K!
! ohiqObiIgt<!hqvil{jvk<!K~m{qk<Kl<!
ue<Okus<!osik<kqz<!OsivR<osb<K!
! liki!hqki!GVju!lxf<k!OhIg<Gl<!
ge<eOu!Oukk<jk!fqf<jk!osb<kiz<!
! gibk<kqx<!gzf<kqMOl!uikf<!kiOe”!
. B,gq!juk<kqb!sqf<kil{q!< << << < himz<!<<< .!354!
           “kioee<x!gsh<OhiM!Kui<h<Hjxh<H!
! !!!!sikglib<!lqR<sqgqZl<!sjlk<k!u{<{l<!
!!!!!Noee<x!uixqeK!Hsqk<kiZl<!
! !!!!Ngibk<!OkxzK!Gck<k!ziZl<!
!!!!!hioee<x!hgZxg<g!lqvi!uqpqh<H!
! !!!!hm<ceqob!lqgUXkz<!hivolb<kz<!
!!!!!Okoee<x!olipqbiI!Olx<!sqf<jkbikz<!
! !!!!sQg<gqvlib<!uiklK!oseqg<Gf<!kiOe”!
. B,gq!juk<kqb!sqf<kil{q!< << << < –!himz<!355<<< !
 “uikui<k<kq!kjegiz!OlOki!oue<eqz<!
! ! lVUgqe<x!uieqgi<g<!gmgliGl<!
! Nkjuh<!hsqObiM!giIk<kqjg!ke<eqz<!!
! ! nmVOl!lx<xli!kr<gt<!ke<eqz<!
! OhikOu!slqg<Ggqe<x!gizliGl<”/!
. B,gq!juk<kqb!sqf<<< <kil{q!<<< –!himz<!356<<< !
 “Neie!uve<xjeOb!lkqbi!lif<ki<!
! ! ngkq!hvOksqbi<gm<!ge<e!lQbiI!
! Ogieie!GVolipqjb!lxf<k!Ohi<gt<!
! ! ogijz!gtU!ohib<!gilr<!Gxqk<k!Ohi<g<G!
! Deie!smf<ke<eqz<!uikl<!uf<K!
! ! dx<huqg<Gl<!Oukk<kqe<!d{<jlkiOe”!
. B,gq!juk<kqb!sqf<kil{q!< << << < –!himz<!364<<< !
 “hgvOu!uiklK!Ogihqk<kh<Ohi!
! ! h{<high<!oh{<OhiglK!kie<!osb<bqz<!
! fgvOu!ouGK~v!upq!fmg<gqz<!
! ! ftqvie!gix<XOl!heqOlx<hm<miz<!
! lqgvOu!gib<gt<!geq!gqpr<G!ke<jl!
! ! lqg!uVf<kq!lQxqOb!kbqIkie<!ogi{<miz<!
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! LgvOu!LKogZl<jh!LXg<gq!ofif<K!
! ! Lpr<giZl<!gj{g<giZl<!gMh<H!d{<miGOl”!
. B,gq!juk<kqb!sqf<kil{q!< << << < –!himz<!356<<< !
4/!ngk<kqbv<!G{uigml<< < << < << < <!
 “uquvlmi!nskq!se<eq!&jt!OfiU!
! ! uqiquie!&jtbK!lqVKuigq!
! nueqkeqz<!kqmligh<!OhiukiZl<!
! ! nh<hOe!&k<kqvg<!G{<cg<gibb{<!uqbikqbiZl<!
! ku!Lequi<!kQIgig<jg!Olg!Ovigl<!
! ! ke<jlBt<t!Lk<k{<Mg<!ogic!uqbikq!
! nulqzih<!hiqs!fvl<hPk<kr<!g{<miz<!
! ! n[Glmi!uikOfib<!NGl<hiOv”!
 
To sum up 
 The causative factors for the manifestation of vatha diseases are the following 
intrinsic and extrinsic factors. 
Intrinsic factors 
1. Diet 
 Intake of food items which  are excessive in bitter, astringent and pungent 
taste, intake of previous day cooked food item, drinking rain water, harmful 
combination  like taking excessive curd after eating fruits, vegetables and tubers 
causes toxic factors which affects bones and muscle. 
2. Psycho social aspects 
 Breach of trust, cutting the living branches and removing leaves, cutting the 
trees, splitting the chastity of a women, abusing the holy men and vitualists, abusing 
the holy scripts, utilize the properties of charities, ungratefulness towards mother, 
father and teacher, ignore the divinity, refusing the food for destitute and saints, 
forgetting the advice of preceptors and wickedness such as murdering, stealing, 
involving in immoral activities, sexual perversion, removing the bark of living tree, 
breaking the leg of the animals. 
 Even though on the above lines our legends siddhars explain the common 
causes.  We cannot understand how it produces the distress of cegana vatham.  The 
author denotes that all this view should be for further analysis. 
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 Extrinsic factors 
 Exposure to dampness and cold. 
 Precipitation of the disease in the months from Aani to Karthigai (from june to 
December) 
 Sleeping during day time working throughout night. 
 Physical strain due to excessive weight lifting. 
 Walking for a long distance, exposing the body to dampness and cold. 
 
Clinical symptoms 
 The clinical features of this disease cegana vatham were explained by 
yugimuni and pararasasekaram as follows.  
 
1. B,gq!sqf<kil{q!911<<<  
 “OgTOl!gPk<kqe<!gQpjvg<G!OlZr<!!
! ! ogcbie!gvlqv{<M!lqgOu!ofif<K!
! uiTOl!siQvolz<zil<!gek<kqVg<Gl<! !
! uizqhIg<G!ler<g{<[!lbg<gliGl<!
WTOl!bqv{<M!g{<[!oliqs<sZ{<mi!
! ! Olx<xlib<!szf<kiE!lqXgqg<!gi[f<!
! OkTOl!ogim<ceK!Ohix<gMg<Gl<!!
! ! sgeui!kk<kqeqOm!kQIg<gf<!kiOe”!
. B,gq!sqf<kil{q!911<<< !
-f<Ofib<! gPk<kqe<! gQpqVf<K! njvbqe<! Olz<ujvBl<! dt<t! -mLl<?!
jggiz<gTl<!lqg!Ofikz<?!dmz<!LPuKl<!gek<Kg<!gi{z<?!lbg<gL{<mikz<?!
g{<gt<!wiqkz<?!sqXfQIgm<mz<?!dmz<LPjlBl<!Okt<!ogim<cbK!Ohie<X!gMk<K!
Ofikz<!Ngqb!Gxqgjt!ohXl</!
2. hvvisOsgvl<<<<!
   “g{<mOkiI!sge!uikr<!gPk<kqe<!gQpjvg<G!OlZl<!
! ! lq{<mzr<!gvlqv{<M!lqgofif<K!gek<kqVg<Gl<!
! l{<cOb!kqlqi<k<Kg<!Gk<Kl<!uzq!lqGk<KjtU{<miGl<!
! ! ‘’u{<mli<!GpzqeiOzi!lkqbqeiZe<EuiOb”!
 Pain in the neck 
 Mental depression 
 Radiating pain the upper limbs and upper limbs 
 Giddiness 
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 Constipation 
 Pain perceive like sting of scorpion 
 Burning sensation of the eyes 
 Tingling and numbness of the upper limbs 
Patho physiology 
 According to panchapootha theory when elemental composition is naturally 
altered uyir thathugal or the three humours, which are made up of these elements get 
deranged.  This simultaneously leads to derangement of seven udal thathugal which 
produce the symptoms.  This is the common reason for producing the cegana vatham. 
 Another theory which explains as follows, the etiological factors of cegana 
vatham are both diet that produce excessive vayu and other agents which cause 
vitiation of panchapootham depending upon this corresponding uyir thathu is affected. 
Here, 
 Aahayam + Air - Vatham 
 Earth + water  - Kabam 
 Fire    - Pitham 
So vatham, pitham and kabam are deranged simultaneously udal thathugal get 
deranged.  These  
Jl<H,kl<!< << << < .!Okgk<kqx<G!dt<t!yx<Xjlbiue< < < << < < << < < < !
!hqe<uVl<!himzqe<!&zl<!OkglieK!hR<sH,klblieK!we<hkje!nxqbzil</!
“n{<mk<kqz<!dt<tOk!hq{<ml<!
hq{<mk<kqz<!dt<tOk!n{<ml<!
n{<mLl<!hq{<mLl<!ye<Ox!!
nxqf<Kkie<!hiIg<Gl<OhiOk” 
- sm<mLeq!<<< !
! ! !
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PATHOPHYSIOLOGY 
 
! !
Kabam 
Tharpagam 
Burning Sensation of the  
eyes 
Thannilai Valarchi 
Vatham Vyanan 
Pain in the Cervical 
dorsal spine, 
Cruciating pain 
along the upper 
limb heavines of the 
body 
Abanan Constipation 
Devathathan Mental Depression 
Pitham Vetrunilai Valarchi 
Second degree derangement Sathagam 
Giddiness 
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! “fqzl<!fQIkQutq!uqSl<Ohijmf<Kl<!
! gzf<klbg<!gLzgl<!-K”!
. Ofib<fimz<!Ofib<Lkz<!fimz<!hGkq!< < < < << < < < << < < < < –!I!
2/!Earth (hqVkquq)!
! Gives shape to the body and release its energy.  Bones, muscles and tissues 
represent it in the body. 
2. Water (nh<H*<<< !
! Makes the earth flexible and helps in the transmission of energy, serum, 
lymph, saliva etc.  Represent it in the body. 
3. Fire (OkB*!
! Stabilizes the body and gives vigour and stimulation. Digestion and circulation 
represent it in the body. 
4. Air (uiB*!
! Catch the fire and works as a life carrier and is the support of all contact and 
exchange.  Respiration and nervous system represent it in the body. 
5. Ether )outq*!
! Ether is the creator of life itself in the body. 
 A harmonious, combination and function of these five elements in the body 
produce a healthy and beautiful life. 
 Man has gross physical body (^<K~zl<*! and subtle physical body 
($m<Sll<*/The subtle physical body is immediately behind the gross physical body 
and is closely connected with it. 
 Vatham = Air + Ether 
In cegana vatham both air and ether are affected. 
 The life-force which is different from material energy derived.  From the food, 
prevades the gross physical through the subtle physical. 
 
Jl<H,kr<gm<Gl<?!nXSjugTg<G!Lt<t!yx<Xjlbiue< < < < < < << < < < < < << < < < < < < !
! “l{<[mOe!Hez<kQg<giz<!
! ! Ljxbigs<!Osi<f<kqm<miz<!uVOl!-eqh<H!
! kq{<{lqzl<!Kui<h<hqvsl<!
! ! skigkqObi!miIkQuq{<!!kqmliLjxh<Hl<!
! w{<{iqb!gsh<H!L{<mif<!
! ! k{<{Qiqz<!geuqj{h<hi!ozPli!Lui<h<H!
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! d{<{iqb!nXSjubqe<!
! ! hqxh<hqokEl<!GVsqk<kVjvk<k!ljxOb”!
.!Okix<xg<gqvl!Nvib<s<sqBl<?!sqk<klVk<Ku!uvziXl<< < < < < < < << < < < < < < << < < < < < < <!
!
-eqh<H!! .! hqVk<uq!!+   nh<H!
Htqh<H!! .! hqVk<uq!!+   OkB!
dui<h<H! .! nh<H! !!+   OkB!
jgh<H!! .! uiB! !!+   Ngibl<!
giIh<H!! .! OkB! !!+   uiB!
Kui<h<H! .! hqVk<uq!!+   nh<H!
!
!! -s<Sjugtqe<! lqGkqjbg<! ogi{<M?! Okgk<kqz<! wh<H,kr<gtqetuig!
wg<Gx<xr<gt<!hq{qg<gh<hm<cVg<gqe<xe!we<hjk!nxqbzil</!
!
sgeuikk<kqz<< << << <!
! jgh<H?! giIh<H?! Kui<h<H! Ngqb! Sjugt<! hikqg<gh<hMukiz<! nkx<G!
giv{lie!H,kr<gTl<!hikqg<gh<hMgqe<xe/!
!
Jl<H,kl<!< << << < .!Lg<Gx<xk<kqx<G!Lt<t!yx<Xjlbiue< < < < < << < < < < << < < < < < !
! utq!! = utq!+ uq{<!
! npz<!= kQ!
! Jbl<! = fQI!+!l{<!
!
-v{<cv{<M!H,kr<gtqe<!Osi<g<jgbiz<!dbqi<k<kiKg<gt<!d{<migqe<xe/!
! H,kr<gt<!hikqg<gh<hMl<!dbqi<k<kiKg<gt<!OhiK<!hikqg<gh<hMgqxK/!
Vatham: Represents vayu, mind, dryness, pain flatulence, sensitiveness, 
lightness and also air. 
Pitham: Represents gastric juice, bile, energy, heat, inflammation, anger and 
irritation etc. 
Kabam: Represents feeling of cold, heaviness running of the nose, passing of 
mucous discharge and also the saliva. 
 
Diagnosis 
 sqk<k! lVk<Ku! nch<hjmbqz<! Ofib<! g{qh<hqz<! w{<ujgk<! Oki<U!
Lke<jlbieK/!!lx<x!Oki<Ugtiue/!
2/!ohixqbix<Oxi<kz<!
3/!Hzeizxqkz<!
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4/!uqeiUkz<!
5/!dbqi<kiKg<gt<!
6/!dmz<!kiKg<gt<!
7/!RiOef<kqiqbl<!
8/!ge<Olf<kqiqbl<!
9/!kqj{gt<!
:/!hVugizl<!
2/!ohixqbix<Oxi<kz<< < << < << < <!
2/!&g<G!
3/!fi!!
4/!g{<!
5/!Okiz<!!
6/!osuq!
!! lVk<Kui<!Jl<ohixqgjtg<!ogi{<M!Ofijb!g{qg<gLcBl</!!
sgeuikk<kqz<< << << <!
!! g{<!wvqs<sz<!gi{h<hMl<!weOu!Jl<ohixqgtqz<!g{<!hikqg<gh<hMgqxK/!!
3/!Hzeizxqkz<<<<!
2/!fix<xl<!)l{l<*!
3/!Sju!
4/!ytq!
5/!DX!
6/!Yjs!
lVk<Kui<!Jl<Hze<gjtg<!ogi{<M!Ofijb!g{qg<g!LcBl</!
sgeuikk<kqz<< << << <!
! uzqbieK! gPk<Kh<! hGkq! lx<Xl<! jggtqz<! hvUkz<! gi{h<hMgqxK/!!
-V! jggTl<! lvk<Kh<Ohikz<! gi{h<hMgqxK/! weOu! Jl<Hze<gtqz<! DX!
hikqg<gh<hm<Mt<tK/!
4/!uqeiUkz<<<<!
! lVk<Kui<! Ofibitqbqml<! uqeiUkz<! &zl<! Ofijb! g{qg<gLcBl</!!
Ofibitqbiz<! Ohs!Lcbik! Ofvk<kqz<! nue<! Sx<xk<kiiqmLl<! uqeiUkz<! &zl<!
Ofijb!g{qg<gLcBl</!
w{<ujgk<Oki<U< < << < << < < !
! “fich<hiqsl<!fifqxl<!olipquqpq!
! lzl<!&k<kqvlqju!lVk<Ku!viBkl<”!
. Ofib<fimz<!Ofib<!Lkz<fimz<!hGkq!< < < < << < < < << < < < < –!I!
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“olb<g<Gxq!fqxf<okieq!uqpq!fiuqVlzl<!jgg<Gxq”!
!!!!.!!!!!!!Okjvbi<< <<!
2/ fic!)Pulse reading),!
3/ ^<hiqsl<!)Tactile sensation)!
4/ fi!)Tongue)!
5/ fqxl<!(Colour)!
6/ olipq!)Speech or voice)!
7/ uqpq!(Eye)!
8/ lzl<!(Faeces)!
9/ &k<kqvl<!(Urine)!
!
2/!fic!
 dmzqz<!dbqi<!kiqk<kqVh<hkx<Gg<!giv{lie!sg<kq!wKOui!nKOu!kiK!
nz<zK!fic!weh<hMl</!
! -KOu!sQusg<kq!uikl<?!hqk<kl<?!ghl<!we<x!&e<X!dbqv<k<kiK!njmf<K!
&e<X!G{r<gjth<!ohx<X!dmjzBl<?!dbqjvBl<!ye<Xhm!uti<k<K!gih<hix<xq!
uVgqe<xK/!
sgeuikk<kqz<< << << <!
2/!uikhqk<kl<< << << <!
! “ohiVtie!uikk<kqz<!hqk<kR<Osi<f<kiz<!
! ////////////////////////////////////////////////////////////////////////////!
! jggiz<!kiqh<H!fig<gsg<Gl<!ne<el</”!
3/!hqk<kuikl<< << << <!
! “hqk<kk<kqz<!uikligqz<!hqmiqBr<gEr<!jgBl<!
! Gk<kK!OhiOzbiGl<!GXgqolb<hkEl<!hqe<Oe”!
4/^<hiqsl<!)okim<Mh<hiIk<kz<*< < < < < << < < < < << < < < < < !
! dmz<! ouh<hfqjz?! SvSvh<H?! Okiz<! dzi<f<kqVk<kz<?! Oklz<?! ogih<htl<?!
gm<cgt<?! gpjz?! osixq?! sqvr<G?! hjm! uqv{l<?! uQg<gl<?! Dkz<! Ngqbju!
okim<Mh<hiIk<kz<!&zl<!nxqbzil</!
! In ‘cegana vatham’ patients, general body temperature – slightly warmth but 
diffuse tenderness may be present in neck and upper extremities. 
3. fi/!
 lih<hcf<kqVk<kz<?!ouTk<kqVk<kz<!
 uib<fQI!ux{<cVk<kz<!
 hqtU!hm<cVk<kz<!
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 H{<{ibqVk<kz<!
 Sju!liXhiM!
  In cegana vatham patients, the tongue is normal. 
4. fqxl<<<<!
 Okiz<fqxl<!
 stqs<su<U!
 lbqi<!lx<Xl<!fgl<!Lkzqbux<xqe<!fqxl<!
  In cegana vatham patients, colour of the skin appears normal. 
5. olipq!
 yzq!OuXhiM!)Low or high pitched) 
 hqkx<xz<?!Gtxz<!
 Gvz<!gl<lqb!Ohs<S!
  In cegana vatham patients, no change of voice is found. 
6.uqpq!
 g{<!hiIjubqe<!fqjzjl!
 g{<!squf<kqVk<kz<?!ouTk<kqVk<kz<!
 g{<!wiqs<sz<!
  In cegana vatham patients, burning sensation of eyes is present. 
  In aged patient acuity of vision is diminished. 
 
7.lzl<<<<!
 lzl<!we<hK!dmzqeqe<Xl<!gpqgqe<x!ohiVt<!
 fqxl<?!Fjv!
 -Xgz<?!-tgz<!
 lzg<gm<M!
 Cegana vatham patients have constipation 
8.&k<kqvl<< << << <!
 fQIg<Gxq!
 ofb<g<Gxq!
fQIg<GxqQ <Q <Q < !
! “nVf<Klixq!vkLl<!nuqOviklib<!
! n0gz<!nzi<kz<!ngizU,e<!kuqi<f<kpx<!
! Gx<xtuVf<kq!dxr<gq!jugjx!
! Ncg<!gzsk<!kiuqOb!giKohb<!
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! okiV!L%Ik<kg<!gjzg<Gm<hM!fQiqe<!
! fqxg<Gxq!ofb<g<Gxq!fqVlqk<kz<!gmOe”!
. Ofib<fimz<!Ofib<Lkz<fimz<!hGkq!< < < < << < < < << < < < < –!I!
!! fil<! d{<[gqe<x! nXSjuh<! ohiVt<gTl<! ye<Xg<ogie<X!
OuXhijlbjmbilZl<?! hsqg<Gk<! kg<ghc! Gjxkz<?! nkqgiqk<kz<! gizf<kuxq!
d{<[kz<! Lkzqb! Gx<xr<gT{<migi! u{<{l<! Hsqk<K! dxr<gq?!
uqcbx<gizk<kqz<! hcg! hik<kqvk<kqz<! ohb<k! fQjv! NuqOhigikhc! 3 ¾ 
fipqjgg<Gt<! nke<! fqxg<GxqjbBl<! nkqz<! w{<o{b<uqm<Mh<! hiIk<K!
gi{h<hMgqe<x! GxqjbBl<! gueqk<K! hq{qgtqe<! kQVl<?! kQvig<! Gxqgjt!
g{qg<gzil</!
!
sqXfQiqe<!ohiKg<G{l<Q < < <Q < < <Q < < <!
! “uf<k!fQIg<giqwjm!l{l<!FjvwR<soze<!
! jxf<kqbZtuju!bjxGK!LjxOb”!
. Ofib<fimz<!Ofib<!Lkz<fimz<hGkq!< < < < << < < < << < < < < –!I!
-bx<jg!fQI!-zg<g{l<!
! “lqgk<!kch<Hl<!lqgk<!OkxZl<!-e<oxeqz<!
! Sgk<jkk<!kVl<!olb<Shiu!fQI!fe<Ox”!
. Okve<!fQIg<Gxq!ofb<g<Gxq< Q < < << Q < < << Q < < < !
According to theriyar, urine should be of low density and with discoloration.  In 
cegana vatham, urine is yellow colour with low density. 
!
ofb<g<Gxq< << << < !
! “fqxg<Gxqg<!Gjvk<k!fqVlie!fQiqx<!
! sqxg<g!ou{<o{b<ohiI!sqXKtq!fMuqMk<!
! oke<Xxk<!kqxk<okizq!Obgikjlk<kkq!
! eqe<x!kqujz!Ohil<!ofxquqpqbxqUl<!
! ose<xK!HgZf<!osb<kqjb!B{Ov”!
. Ofib<fimz<!Ofib<Lkz<fimz<!hGkq!< < < < << < < < << < < < < –!I!
!! fQIfqxg<! Gxqbiz<! Ofijbg<! g{<M! hqck<kx<ohiVm<Ms<! osiz<zqbqVg<gqe<x!
uqkq! ohiVf<kqb! sqXfQiqz<! yV! sqxqbKtq! w{<o{b<! fMuqz<! jgbjsuqeiz<!
w{<o{b<Ktq!sqkxilz<!uqm<M!oub<bqzieK!nf<fQiqz<!hMl<hc!kqxf<K!gix<xieK!
nkqz<! uQsq! nf<k! w{<o{b<k<! Ktq! Nmikhc! juk<K! ns<sqXfQiqz<!
uqmh<hm<cVg<gqe<x! w{<o{b<k<!KtqbieK!osz<Zgqe<x!upqbqz<! g{<{xqjuBl<!
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dbqvxqjuBl<! osZk<kq?! nk<Ktq! okiquqg<Gl<! Ofib<! uqtg<gk<jk! fQ! okiqf<K!
ogit<tzil</!
! “nvoue!fQ{<ce0Ok!uikl<”!
! Npq!Ohix<hvuqe<!n0Ok!hqk<kl<”!
! Lk<okik<K!fqx<gqe<!olipquoke<!ghOl”!
. Ofib<fimz<!Ofib<< < << < << < <!Lkz<fimz<!hGkq< << << < .I!
  In cegana vatham patients during neikuri examination the oil spreads 
like snake and sometimes like ring and pearl. 
 
ACCESSORY EXAMINATION 
UYIR THATHUKKAL 
Vatham 
 Pranan: 
Physiological function: Inspiration and expiration responsible for sneezing 
coughing and belching 
 Features in Ceganavatham: Not affected 
 Abanan:  
   Physiological function: Act with downward movement 
  Features in Ceganavatham: Affected constipation present. 
 Viyanan: 
  Physiological function: Helps in various movements of body, responsible for 
 sensation 
Features in Ceganavatham: Affected Restricted neck movements radiating  
pain in shoulder and arm with tingling sensation. 
 Udhanan: 
Physiological function: Regulates the higher functions of brain.  Responsible  
for physiological reactions like hiccough and vomiting 
  Features in Ceganavatham: Not affected 
 Samanan: 
   Physiological function: Regulates all other vayus 
   Features in Ceganavatham: Affected 
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 Nagan: 
Physiological function: Responsible for intelligence helps in opening and 
closing of eyes 
  Features in Ceganavatham: Affected in aged patients.  Acuity of vision is 
 diminished. 
 Koorman: 
Physiological function: Responsible for lacrimation.  Helps to visualization of    
all things in the world. 
Features in Ceganavatham: Affected in aged patients.  Acuity of vision is  
diminished. 
 Kirugaran: 
   Physiological function: Drippling of Saliva, Yawning 
  Features in Ceganavatham: Not Affected 
 Thevathathan: 
  Physiological function: Responsible for laziness. Rotation of eyeballs 
  Features in Ceganavatham: Affected (Sleeplessness present due to pain). 
 Thananjeyan: 
   Physiological function: Responsible for tinnitus oedema. 
  Features in Ceganavatham: Not affected 
Pitham 
 Anar pitham: 
 Physiological function: Digests all the ingested particles. 
 Features in Ceganavatham: Affected 
 Ranjaga pitham: 
 Physiological function: Increases the blood and gives blood colour 
 Features in Ceganavatham: Affected 
 Saathaga pitham: 
 Physiological function: Makes the work to complete what mind thinks  
 to do 
 Features in Ceganavatham: Affected neck pain and restricted   
 movement 
 Aalosaga pitham: 
 Physiological function: Responsible for clear vision. 
 Features in Ceganavatham: Affected in old age peoples. 
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 Prasaga pitham: 
 Physiological function: Gives colours to skin 
Features in Ceganavatham: Not affected 
 
Kabam 
 Avalambagam: 
 Physiological function: Controls other 4 types of kabam 
 Features in Ceganavatham: Affected (santhigam affected) 
 Klethagam: 
 Physiological function: Moistens the food 
 Features in Ceganavatham: Not affected 
 Pothagam: 
 Physiological function: Helps to know the taste 
 Features in Ceganavatham: Not affected 
 Tharpagam: 
 Physiological function: Gives cooling effect to the eyes 
 Features in Ceganavatham: Affected burning sensation of eye present 
 Santhigam: 
 Physiological function: Gives lubrication to joints 
 Features in Ceganavatham: Affected (pain in cervical region) 
 
SEVEN PHYSICAL CONSTITUENTS OF BODY 
 Saaram: 
 Physiological function: Strengthens the body and mind  
 Features in Ceganavatham: Affected 
 Senneer: 
 Physiological function: Preserves brightness, boldness, power&   
 knowledge 
 Features in Ceganavatham: Affected 
 Oon: 
 Physiological function: Gives structure and shape to the body. 
 Features in Ceganavatham: Early stage  - Not affected 
 Later stage  - Affected 
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 Kozhuppu: 
 Physiological function: Responsible for movement lubricants   
 the joint 
 Features in Ceganavatham: Affected 
 Enbu: 
 Physiological function: Responsible to joint movements 
 Features in Ceganavatham: Affected 
 Moolai 
 Physiological function: Present inside the bones and gives    
 strength to  the  bones 
 Features in Ceganavatham: Not affected 
 Sukkilamor suronitham: 
 Physiological function: _ 
 Features in Ceganavatham: Not affected 
 
GNANTHRIYAM 
 Mei: 
Physiological function: Feels the sensation of touch 
 Features in Ceganavatham: Affected parasthesia present in    
 upper limb 
 Naa: 
 Physiological function: Analyse the taste 
 Features in Ceganavatham: Not affected 
 Kan: 
 Physiological function: For vision 
 Features in Ceganavatham: Not affected  
 Mooku: 
 Physiological function: For smell 
 Features in Ceganavatham: Not affected 
 Sevi : 
 Physiological function: For hearing 
 Features in Ceganavatham: Not affected 
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Kanmenthiriyam 
 Kai 
 Physiological function:  Handling the things 
 Features in Ceganavatham: Affected radiating pain with    
 tingling sensation 
 Kal 
 Physiological function:  Walking 
 Features in Ceganavatham: Not affected 
 Vaai 
 Physiological function: For speaking 
 Features in Ceganavatham: Not affected 
 Eruvaai 
 Physiological function: For defaecation 
 Features in Ceganavatham: Affected constipation present 
 Karuvaai 
 Physiological function: For reproduction 
 Features in Ceganavatham: Not affected 
 
Thinaigal  
 Kurinji: 
 Place : Mountain and its surroundings 
 Common disease: Kabanoi liver disease are common 
 Mullai: 
 Place : Forest and its surroundings 
 Common disease: Pitha and vatha disease liver    
 disease and common 
 Marutham: 
 Place : Field and its surroundings 
 Common disease: Safest place to maintain good    
 health 
 Neithal: 
 Place : Sea and its surroundings  
 Common disease: Vatha disease and liver     
 enlargement are common 
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 Paalai: 
 Place : Desert and its surroundings 
 Common disease: Vatha pitha and kabha disease and   
 common 
 Most of the patients came from Marutha nilam.  Patients were   
 also reported from neithal nilam. 
 
Paruva Kaalangal 
 Kaarkaalam  
  Aavani and Purattasi(August 16 – October 15)  
 Kuttram- Vatham ↑ ↑Pitham  ↑ 
 Koothirkaalam     -       
 Ayppasi and karthigai(October16 – December15) 
 Kuttram - Vatham (-)Pitham  ↑ ↑ 
 Munpanikaalam     -      
 Maargali and Thai(December 16 – February 15*       
 Kuttram- Pitham  (-) 
 Pinpanikaalam        -     
 Maasi and Panguni(February 16 – April 15* 
 Kuttram- Kabam  ↑ 
 Elavenilkaalam        
 Aani and Aadi(April 16 – June 15)  
 Kuttram- Kabam ↑↑ 
 Muduvenilkaalam      
 Aani and Aadi(June 16  - August 15*!
! Kuttram- Vatham ↑Kabam (-) 
↑ Thannilai valarchi 
↑↑ Vetrunilai valarchi 
(-) Thannilai adaithal 
  According to alteration of kalam (Thannilai valarchi, Vetrunilai valarchi) the 
disease can be diagnosed. 
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DIFFERENTIAL DIAGNOSIS 
1.Gl<h!uikl<< << << <!
! “fuqzOu!Okit<lQKr<!gvk<kqe<!lQK!
! ! fzqf<K!olk<kuigqOb!fsU{<miGl<!
! guqzOu!ge<eoliM!fbef<!kiEr<!
! ! gMk<KOl!uqXuqXh<H!oliqUr<!gi[l<!
! KuqzOu!Kch<hiGR<!sqvS!ke<eqx<!
! ! Spx<xqOb!fihqg<gQp<!uzqB!L{<mil<!
! nuqzOu!bcfig<gq!zpe<X!gi[!
! ! lzVOl!uVGl<h!uikf<!kiOe”!
. B,gq!juk<kqb!sqf<kil{q< << << < !
Okit<hm<jm?!jg!Lkzqb!-mr<gtqz<! lqg<g! OfiB{<migq!njugjt!fQm<mUl<?!
Lmg<gUl<!ym<milz<!OfikZl<?!ge<eLl<!g{<[l<!gMk<K!uqXuqXk<K!wiqkZl<?!
dmz<! Kck<Kk<! kjzSx<xq! lqg! SvL{<mib<! fihqbqe<! gQp<! uzqBl<! ncfig<gqz<!
npx<sqBl<!Ngqb!GxqG{r<gt<!-f<Ofibqx<!gi[l</!
!
Mimic features Altering features 
Burning pain in shoulder joint and                
upper limb 
Twitching over the scalp 
Burning sensation in the cheek and eyes Pain in the lower abdomen, glossitis. 
 
3/!hi{qg<gl<h!uikl<< < << < << < <!
! “liIg<glib<!uib<Ulib<!olb<fqjxf<K!
! ! ubqXkeqx<!hsqbqzi!K~[lx<X!
! fiIg<glib<!Rizk<K!fmg<jgbx<X!
! ! fMg<glib<!jgbqv{<Mf<!kqVlqV{<mil<!
! DIg<gli!Bxg<glqz<zi!K{i<s<sq!bx<X!
! ! dkxqOb!siQv!olr<G!Lzi<f<K!gi[f<!
!
! hiIg<glib<!uib<uqm<M!nzi<k<kziGl<!
! ! hi{qg<gl<h!uikk<kqe<!hir<GkiOe”!
. B,gq!juk<kqb!sqf<kil{q< << << < !
!! -f<Ofib<! dmz<! Lx<xqZl<! utqg<Gx<xk<jk! fqjxk<Kh<! hsqk<kQjbg<!
ogMk<K! fmg<g! Lcbijl?! jg! giz<! fMg<gl<?! jgkqlqi<kz<?! K~g<glqe<jl?!
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d{i<s<sqbqe<jl?!dmz<!ux<xqh<Ohikz<?!uib<hqkx<xz<!Ngqb!GxqgjtBl<!gim<cg<!
gijz!lmg<g!Lcbilx<!ogil<jhh<!Ohiz<!fqjzg<gs<!osb<KuqMl</!
!
Mimic features Altering features 
Loss of sensation in both upper limb Anorexia 
Numbness in upperlimb, sleeplessness Shivering of upper limbs. 
!
4/g{<mgqvg!uikl<< << << <!
! “ujgbit!Gvzkjeh<!hx<xq!ofif<K!
! liIOhiM!hqmiqkeqz<!uzqB{<migq!
! Fgvie!siQvolz<zil<!ofif<k!pzix<xq!
! F{g<glib<!SuislK!Hxh<hmilz<!
! Ljgbie!fiuiOz!&s<S!lixq!
! Lgk<kqOz!uqbi<uigq!uqziOfi!U{<mil<!
! hjgbie!ue<ek<jkh<!hVogim<miK!
! hiqb!g{<m!gqvigk<kqe<!h{<H!kiOe”/!
. B,gq!juk<kqb!sqf<kil{q!< << << < –!911!
Mimic features Altering features 
Pain in the throat, chest and occipital 
region 
Anorexia 
Breathing through mouth, backache, 
sweating on face 
Loss of appetite. 
COMPARATIVE STUDY 
 The word “ceganam” denotes the entire vertebra, hence ceganavatham denotes 
pathology in vertebra due to the derangement of vadham. 
 “OgTOl!gPk<kqe<!gQp<!njvg<G!Olz<< < Q < < << < Q < < << < Q < < <”!
Our body has 33 vertebrae, in which there are 7 cervical vertebrae.  Spondylosis occur 
mostly in the lower half i.e C4, C5, C6, C7.  The above line states that the pain occurs 
in the lower half of the cervical vertebrae and  just above the lumbar region. 
 “ogcbie!gvlqv{<M!lqgOu!ofif<K< << << < ”!
! This line indicates the radiating pain in both the upper limbs.  This pain is due 
to the pathological changes occuring in the cervical vertebrae.  There are 31 pairs of 
spinal nerves, in that 8 pairs are cervical nerves, having dorsal and ventral nerve roots.  
These nerve roots transverse through the intervetebral foramina.  While passing 
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through the foramina compression of these nerve roots can occur due to the narrowing 
of the foramina.  This narrowing occurs in cervical spondylosis.  Because of the 
formation of abnormal osteophytes and ligamental calcification.  This compression 
causes neurological dysfunction and radiating pain in the nerve plexus. 
 “uiTOl!siQvolz<zil<!gek<kqVg<Gl<Q < < < < <Q < < < < <Q < < < < <”!
! Neurological examination reveals paraesia in the affected dermatome.  
Gradual sensory loss in form of numbness occurs because of mural sheath 
compression and neurological dysfunction,  
 “uizqhi<g<G!ler<g{<[!lbg<gliGl<< < < < < << < < < < << < < < < <”!
! The vertebral artery commences from the first part of subclavian artery and 
passes through the foramen transversorium of the upper six cervical vertebrae.  
Osteophytes formed in cervical.  Spondylosis compress the vertebral artery causing 
vertebrobasilar artery insufficiency.  the blood supply to the brain is decreased due to 
this insufficiency resulting in gliddiness. 
 “WTOl!bqv{<M!g{<[l<!wiqs<sZ{<mil<< < < < < << < < < < << < < < < <“ 
 This line indicates burning sensation in the eye.  Spasm of sub occipital 
muscles may cause a decided impediment of venous drainage from the sub occipital 
area via vertebral an deep cervical veins.  The result is passive congestion, with 
consequent pressure on the sensory nerves in the area.  This derangement can cause 
burning sensation. 
 “Wx<xlib<!lzf<kiEl<!-Xgqg<!gi[l<< < < < < << < < < < << < < < < <”!
! Cervical sympathetic nerve is affected by neighboring irritation and damage, 
resulting in the nerve excitement which causes the gastrointestinal peristalsis slow 
down, leading to abdominal distension and constipation. 
 “OkTOl!ogim<ceK!Ohiz<!gMg<Gl<< < < << < < << < < <”!
! In cegana vatham the pain is felt like scorpion bite.  in early stage pain and 
rigidity is due to muscle spasm.  Later ligamental calcification leads to neck stiffness. 
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VARMAM 
 Apart from the internal and external medicines,siddha system has some special 
therapies like varmam, yogam and kayakarpam which are distinguish to this 
system.Varmam refers to vital points in the body that act as energy transformers.They 
form centers for boosting the vital pranan flow through the intricate nadi system of the 
body.Nature,by its design , has protected these vital centers by placing them deep 
inside the body or by covering them with tissues inaccessible to normal attempts of 
breach. 
 Varmam is a holistic therapy on its own tackles the body, mind and spirit. 
Varmam forms a link between the body, prana and the mind. Varmam have been 
classified based on the type of pressure needed to apply  
 
 (i).Padu varmam-varmam due to injury 
 (ii).Thodu varmam-by touch 
 (iii).Thattu varmam-by blows 
 (iv).Thadavu varmam- by massage 
 (v).Nakku varmam-by licking 
 (vi)Nokku varmam-by staring 
 
 The widely used and recognized ones are the 12 Padu varmam and 96 Thodu 
varmams. there is less consistency with the other categories simply because of the 
way of application or the most awe-generating and is rarely seen practiced,as those 
masters who were able to do this are almost exinct. 
 Vital points are located over arteries,veins,nerves,joints,bony prominence, 
ligaments, etc.The changes occurring in the body on being hit at some specific points 
on the body directly or indirectly with particular force is Varmam. 
  By manipulating the following Varmam points,the symoptoms of 
Ceganavatham can be reduced  
 Mudichi Varmam 
 Kakkattai kaalam 
 Manibantham 
 Kai viral madakkuvarmam 
 Kavulikaaalam 
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Mudichi Varmam: It is located in nape at the bony prominence of cervical region. 
 
Kakkataikaalam:It is located at the shoulder,two finger breadth lateral to the 
junction of neck and head. 
 
Manibanthagam:It is situated in dorsal aspect of wrist. 
 
Kai viral madakku varmam:It is located in medical aspect of arm just below the 
shoulder. 
 
Kavulikaalam: It is located above the web space of fingers.For ceganavatham 
pressure is applied in kavuli between thumb and index finger. 
 
VAMAM THERAPY:  
 Mudichi Varmam (Varma odivumuraisarasoothiram-1200) 
 Kakkattai kaalam (Varma Beerangi-100) 
 Manibantham (Varma Beerangi-100) 
 Kai viral madakkuvarmam(Varma vilakkam) 
 Kavulikaaalam(Varma soothiram-101) 
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MODERN ASPECT 
 
ANATOMY OF SPINE: 
  The human spine as a whole is also known as vertebral column it appears 
straight and upright when viewed from the front are from the back. The vertebrae are 
stacked like wooden blocks in between the intervertebral discs. When viewed from 
the side it shows to gentle curves in the cervical and lumbar spine, lordotic in nature 
to provide maximum flexibility while providing all the strength that is required to 
transmit the weight of the body. 
 
THE CERVICAL SPINE: 
 The cervical portion of the spine has seven cervical vertebrae. The first two 
vertebrae, the atlas and axis have atypical features while the remaining five has 
typical features. 
 
The first cervical vertebra: 
  The first cervical vertebra, the atlas, is ring shaped and has four parts 
1. The anterior arch  
2. The posterior arch  
3. Right lateral mass 
4. Left lateral mass 
 
It has five articular surfaces.  
I. superior articular surfaces-connect to occipital bone. 
II. Inferior articular surfaces-form lateral atlando axial joint. 
III. The inner surface-form joint with dens. 
 
The second cervical vertebra: 
  The second cervical vertebra,the axis, has five articular surfaces. Three 
surfaces connect it to the atlas and the remaining two connect it to the third cervical 
vertebra. The atlandoaxial joint is like wheel and axle allowing rotational movements 
thus allowing for a wide range of motion. At times the dens which are realy the 
vertebral body of c1 separates from c2 and forms separate os odontoideum. 
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Third to seventh cervical vertebrae: 
   Remaining five cervical vertebrae are similar in shape. The vertebral bodies 
are small and the canal large in comparison with the thoracic and lumbar spines. The 
spinous processes are small and bifid except C7. Bifid spinous processes allow more 
extension without interfering with each other. The intervertibral joint are horizontal 
and transmits the weight of the head. Each transverse process is composed of two 
tubercles. The anterior tubercle is the representative of rib and at times a cervical rib 
is actually seen. The posterolateral corner of the upper surface of lower vertebra is 
elevated and is called the uncus or uncinate process. The uncus is not found 
inquadrupends. It is only found in those who have to support their head. The uncus 
forms a joint with the lower surface of upper vertebral body called the neurocentral 
joint of luschka. The uncus actually is a part of the arch and there is no disc tissue in 
that joint. The spinal canal is relatively broad. The average value is 17 to 18 mm in 
normal adults but is under 15 mm is case of myelopathy. The smallest canal is found 
in Japanese people being at times less than 13 mm. 
  The articular processes of facet joints do not have uniform direction. At times 
the superior articular process is process is positioned more anteriorly then the 
vertebral foramen and the canal at this place becomes narrow causing radiculopathy. 
The position can easily be observed on lateral X-ray of the cervical spine. 
 
THE INTERVERTERAL DISC 
  The vertebral disc is thicker in infants than in adults. At birth the discs occupy 
half the length of the cervical spine. In adults the length is one third of the cervical 
spine and after age of 50 years it is reduced further. The nucleus changes its shape to 
accommodate the changes due to motion. It bears loads during movements of the 
spine. The dense collagen fibers of the annulus are running vertical in the front and 
are strong. Posteriorly they run horizontally and are prone to be fissure.  
 
THE LIGAMENTS OF CERVICAL VERTEBRAE: 
 There are two longitudinal ligaments, 
1. Anterior longitudinal ligaments – covers the anterior surface of the vertebral body 
and its lateral margins sptead under the longus colli muscles. 
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 2. posterior longitudinal ligaments – composed of two layers 
 Superior 
 Deep  
  Both layers unite firmly in the central part and laterally the separate and the 
superficial layer invests the dura and the nerve root. The periosteum is lying under the 
ligaments. 
 The ligamentum flavum varies slightly in its attachment in comparison to 
lumbar spine. It covers the anterior one-third of upper lamina and posterior one-third 
of lower lamina. With this arrangement the ligament buckles in during extension of 
the neck.  
  The interspinous ligament in the cervical spine is less well developed and 
week. The supraspinous ligament is extremely well developed and forms the 
ligamentum nuchae.  
 
THE BONY CERVICAL SPINAL CANAL: 
  The conus medullaris ends at the lower border ofL1 vertebra. Beyond that the 
dural sheath contains only the cauda equine. The shape of the cervical canal varies 
significantly from C1 to C7. The canal is almost round at C1 and slowly transforms 
into trifoliate pattern at C7. The sagittal diameter of the canal is always measured to 
give an indication of the size of the canal. It is measured from the posterior surface of 
the vertebral body to the junctional point between the lamina and the spinous process. 
This point is not always easy to define and one has to resort at times to tomography to 
define this point. A canal of 20 mm is capacious at C1 measurement from 17 to 14 
mm are normal. A sagittal diameter of 13 mm at C5 is on the border line. A canal of 
less than 13mm diameter is definitely narrow. The cervical spinal canal is many times 
known to be narrow in patients with cervical spondylotic myelopathy. 
 
SPINAL CARD: 
  The spinal cord in the cervical region is thick with well developed grey matter 
and is oval in shape its blood supply comes from one anterior and posterior spinal 
arteries. Branches of these vessels which form the Coronal artery surround the card. 
The central artery, a branch of anterior spinal artery, enters the cord from the anterior 
fissure. Additional radicular arteries come from vertebral artery supply blood to this 
network. The function of the card is compromised either by direct mechanical 
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pressure or vascular insufficiency. Compression anteriorly comes from prolapsed 
disc, osteophytes or ossification in the posterior longitudinal ligament. posteriorly  the 
cord can be compressed by the ligamentum flavum. Fibrous around the root and 
pathological anchoring of the denticulate ligaments can cause further the compressive 
damage to the cord. when the career developmentally narrow and the space around the 
cord is compromised any friction occuring during daily activities can cause damage to 
the cord. the shape of the cord is oval and the shape of the canal is triangular resulting 
in crowding of nervous tissue posterolaterally in the canal. 
 
THE NERVE ROOTS  
  of 31 pairs of nerve roots the first and the last nerve roots are not available on 
the surface for examination. the first cervical nerve root is entirely motor without 
sensory branches and it serves the suboccipital muscles. the posterior branch of 
secondary nerve is thick and is called the Great occipital nerve. the first two cervical 
nerves (C1 and C2) do not come out through the intervertebral foramina like the rest 
but they come out throw a narrow fissure between occiput and C1 posterior arch and 
C1 / C2 posterior arches. they are frequently compressed in hyperextension injuries. 
 
Important nerve root supply to muscles: 
NERVE ROOT SUPPLY TO MUSCLES 
3rd nerve root Pectoralis muscles 
4rd nerve root Diaphragm 
5rd nerve root Deltoid muscles 
6rd nerve root Muscles of thumb 
7rd nerve root Muscles of middle finger 
8rd nerve root Muscles of ring and little finger 
 
  In the lower cervical spine sometimes the discrepancy can be found When the 
seventh cervical road leaves through the foramina between 5th and 6th cervical 
vertebra. Pathology in this region can cause radiculopathy in both 6th and 7th cervical 
roots.  osteophytes without Disc prolapse are known to produce pure motor weakness 
with atrophy without pain and without sensory disturbance and needs to be 
differentiated from progressive spinal muscular atrophy. 
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  The vertebral artery enters the transverse foramina of the sixth cervical 
vertebra. Presence of osteophytes on the joints of luschka can compromise the cana 
width. Being in the foramen at this level the vessels cannot slide laterally resulting in 
stricture in the vessels. In elderly with established spondylotic changes the cervical 
spine is shortened and the vertebral artery is forced to persue a tortuous course and it 
can then cave into the vertebral body. Two or three radicular arteries supply the spinal 
cord. Usually they enter the spinal cord at the level of 6th cervical vertebra. The artery 
usually runs on the ventral side of the nerve root and it can be compressed much 
earlier by the osteophyte than the Nerve Root. 
 
THE MUSCULATURE 
  The musculature of the neck is broadly divided into three groups the three 
groups are: 
1. muscles involved in the movements of head and neck  
2. muscles involved in the movements and suspension of arms  
3. muscles involved in the movement and suspension of thoracic cage 
  When a load is applied to the arms, say, for example, while lifting a weight to 
be placed on the head the weight of the load is transferred to the cervical spine 
through the muscles of the arms and hence this group of muscles deserve special 
attention. raising something by the hand means raising it by the cervical spine. this 
explains why cervical spine degenerates early in workers doing heavy manual work. 
  To hold the head in proper position it is essential to have a delicate balance of 
contraction and relaxation among neck muscles. the free Nerve endings in the cervical 
spinal musculature is disproportionately large and their discharges control not only 
the head position but also controls the posture of the whole body. the small 
suboccipital muscles play a vital role in this function and the concentration of spindle 
density in this muscles is much higher than the density in the lumbrical muscles of the 
hand. 
 
THE LIGAMENTS: 
  The following biochemical properties are observed in the ligaments: 
Resistance:  
  Ligaments offer resistance to stretch (tension) 
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Relaxation:  
  On continued stretch there is gradual relaxation in tension in the ligaments 
Creep:  
  Gradual lengthening in the ligament during stretch manoeuvres  
Elastic deformation:  
  The creep of gradual lengthening can be reversed totally on elimination of 
stretch suggesting that there has been no structural damage sustained to the ligament 
during stretching. It is seen best in the ligamentum flavum and very little in scar 
tissue. 
Plastic deformation: 
   The ligament does not return to normal on elimination of stretch. This 
property can be clinically used to stretch stiff ligaments and muscles during 
postoperative period. 
Break point: 
   if the stretch is continued after plastic deformation the ligament breaks as the 
stress becomes more than the inherent capacity of the viscoelastic property of the 
ligament. The spine as a whole is an excellent example of viscoelastic properties of 
ligaments and demonstrates creep or lengthening with continued stress. 
  The spine is elastic but there is a difference between a metallic spring and the 
spine composed of bone, cartilage, muscles and joints. Unlike metallic spring which 
exhibits linear deformation, the spine exhibits non linear deformation. 
 
FACTOR INFLUENCING STABILITY IF THE SPINE: 
The factor influencing stability in the spine are: 
1. Passive stability 
• shape of the vertebral bodies 
• shape of the facets 
2. Dynamic stability 
• Linking of viscoelastic ligaments 
3. Active stability  
• Deep postural muscles 
4. Hydrodynamic stability 
• Turgid nucleus distributes load uniformly  
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DEVELOPMENT:  
  The skin of the neck is derived from cervical dermatomes which arise from the 
second to the sixth cervical segments. 
  The sternocleidomastoid, strap muscles and trapezius originate from cervical 
myotomes. 
 
MUSCLES OF NECK: 
 Sterno-cleidomastoid muscle.  
 Trapezius muscle.  
 Platysma muscle.  
 Splenius capitis muscle.  
 Levator scapulae muscle.  
 Scalenus medius muscle.  
 Scalenus anterior muscle.  
 
MAJOR BLOOD VESSLES: 
 Common Carotid artery 
 Internal & external carotid artery 
 External carotid artery 
 Internal Jugular Vein 
 External Jugular Vein 
 
NERVES: 
 glassopharyngeal nerve 
 tympanic nerve  
 lesser petrosal nerve  
 carotid branch pharyngeal branch  
 muscular branch  
 tonsillar branch  lingual branch  
 
 vagus nerve 
 accessory nerve 
 hypoglossal nerve 
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MOVEMENTS OF THE CERVICAL SPINE 
 The cervical spine is the most mobile segment of the whole spine. Maximum 
range of motion is possible in this portion of the spine. Therefore it is also subject to 
significant injury being extremely mobile. The range of motion and its reduction with 
increasing age has been described in the section on age related changes in the cervical 
spine. The spine as a whole and particularly the cervical spine is made of several 
segments. Thus there are eight motion segments related to the cervical spine. Any 
motion simply cannot occur in one given motion segment. When a movement has to 
occur all motion segments cooperate to produce a smooth gliding coordinated motion. 
 
Movements of the cervical spine 
1. Flexion and extension 
2. Lateral bending 
3. Rotation  
 It is important to understand the different between one motion and range of 
motion. In range of motion two parameters are involved and hence range of motion is 
different from motion in one movement. All motions have multiplanar coupling, e.g. 
ratio of rotation in rotation in lateral bending varies at different levels depending on 
orientation of facets. Inclination of facet joints at 45 to 80 degrees with respect to the 
horizontal plane of intervertibral disc causes simultaneous sliding and rotation. The 
orientation of facet joints is partly responsible for this multiplaner coupling. It has 
been shown that at the level of C3 and C4 the superior articular facets are displayed 
posterolaterally and it correlate well with the pattern of cervical movements. 
 
AXIAL ROTATION: 
 Axial rotation to the tune of 24 degrees is possible at occiput/ C1 junction and 
46 degrees at C1 /C2 Junction. The lower cervical spine is locked in Flexion and open 
in extension. there is no rotation in flexion but in neutral position or extension it can 
given 14 degrees rotation. 
 
FLEXION/ EXTENSION 
  Total extension is relatively less than total flexion. Total flexion possible in 53 
degrees and total extension is 38 degrees with range of motion in flexion/ extension in 
normal adults below the age of 50 years being 130 degrees in male and slightly more 
in females. 
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LATERAL BENDING 
  There is very little lateral bending in the upper cervical spine. all the lateral 
bending is done in the lower cervical spine.  the range of motion in males is 88 
degrees and in females about 5 degrees more than males in normal adult. 
 
CLINICAL BIOMECHANICS OF CERVICAL SPONDYLOSIS: 
 Spondylotic changes defined as a condition of progressive degeneration that 
beings in an intervertebral disc and leads to changes in the apophyseal joints and 
related ligament-  capsular tissue of the spine. The degeneration initiated in the 
intervertebral disc progress to pathology events leading to growth of bone at the 
margins of vertebrae. fibrosis at first starts in the annulus leading to delamination  in 
the laminated structure and finally causing focal disruption. the progression of fibrous 
tissue extended to the nucleus leading to loss of annular nucleus demarcation. 
vertebral bodies then become rough and start showing osteophytes.  It is now believed 
that delamination in the annulus is the most important event in the initial pathological 
changes in spondylosis. 
 
STRUCTURAL DEGENERATION IN THE INTERVERTEBRAL DISC 
 When the cervical spine is subjected to bending forces, one side of the disk is 
compressed and the other side is subjected to tension. During tortional movements as 
in flexion rotation or extension rotation there are shear stresses in the horizontal as 
well as axial planes of the annulus. The intervertebral disc is obviously subjected to 
various patterns of loading in different circumstances. The forces created are: 
1. Generation of tensile strength in the annulus 
2.  Friction between various lamellae of the annulus and  
3. Increased pressure within the nucleus. 
 Load has to be observed and energy has to be dissipated.  this is done by 
tension and friction in the annulus and free water shift in the nucleus.  in studying the 
mechanics of functioning of intervertebral disc two things are important 
1. One is the speed of load and  
2. The other is the acceleration of speed  
 In normal subjects there is a definite and constant gradient descending down 
along the spine between the centre of each vertebra for both speed and acceleration. in 
patients with abnormal moments like athetoid moments a sudden level of increase in 
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both speed and acceleration occurred at certain segments during flexion/extension 
moments and the cervical spine displayed a large range of motion than normal 
subjects. 
 This knowledge has important clinical significance. A spine which is 
continuously subjected to motion with increased range, speed and acceleration for a 
period of more than 20 years results in reduction of mechanical strength in the 
intervertebral disc. The sequelae of such abnormal persistent load on the spine causes 
structural degradation starting in the annulus fibrosus just as it occurs in disc 
degeneration at a later age. 
 Mechanical overuse of spine has been studied in animal models by producing 
repeated flexion/extention motion in the cervical spine. The intervertebral disc was 
examined between 15 and 70 days of continuous cyclic loading. Structural 
degradation was most commonly encoundered at C7/C8 level and in the margins of 
adjacent vertebral bodies. The annulus was delaminated and focally disrupted. There 
was early osteophyte formation at the anterior margin of C7 vertebra. 
 Increasing the load in the cycles resulted in more advanced degradation and 
degeneration similar to what is seen with spondylosis. Irrespective of age of the 
subject disc degeneration advanced with increasing load on the disc. At least 
experimentally, overuse appeared to produce fatigue failure in the structures of the 
intervertebral disc. 
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CERVICAL SPONDYLOSIS 
  The term cervical spondylosis describes chronic degenerative lesions 
of single or multiple intervertibral discs with formation of osteophytes in related 
vertebral bodies. Cervical spondylosis is a leading cause of musculoskeletal disability 
in humans. The sequence of disc degeneration leads to the clinical syndrome of 
cervical pain, radiculopathy and myelopathy. The The aetiology was thought to be 
related to aging process and or mechanical overload applied to the spine. However the 
fact that an unexpectedly high incidence of early spondylosis has been seen in patients 
with thetoid cerebral palsy and other such disorders precludes age related process as 
the only pathology. Accelerated segmental hypermobility sets in very early 
degenerative changes in the intervertebral disc. 
 Cervical spondylosis is more common in the elderly where advanced changes 
leads to disaling pain and paresis the number of elderly people in the world is growing 
at an unprecedented rate. 
CERVICAL SPONDYLOSIS CAUSES 
 The bones and protective cartilage in your neck are prone to wear and tear that 
can lead to cervical spondylosis. Possible causes of the condition include: 
Bone spurs 
 These overgrowths of bone are the result of the body trying to grow extra bone 
to make the spine stronger. However, the extra bone can press on delicate areas of the 
spine, such as the spinal cord and nerves, resulting in pain. 
Dehydrated spinal discs 
 Spinal bones have discs between them, which are thick, pad-like cushions that 
absorb the shock of lifting, twisting, and other activities. The gel-like material inside 
these discs can dry out over time. This causes your bones (spinal vertebrae) to rub 
together more, which can be painful. According to the Mayo Clinic, this process can 
begin around age 40. 
Herniated discs 
 Spinal discs can develop cracks, which allows leakage of the internal 
cushioning material. This material can press on the spinal cord and nerves, resulting 
in symptoms such as arm numbness and pain that radiates down an arm. 
Injury 
 Had an injury in neck, such as during a fall or car accident, this can accelerate 
the aging process. 
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Ligament stiffness 
 The tough cords that connect your spinal bones to each other can become even 
stiffer over time, which affects your neck movement and makes the neck feel tight. 
Overuse 
 Some occupations or hobbies involve repetitive movements or heavy lifting, 
such as construction work. This can put extra pressure on the spine, resulting in early 
wear and tear. 
Risk factors 
 The greatest risk factor for cervical spondylosis is aging. Cervical spondylosis 
often develops as a result of changes in your neck joints as you age. Disc herniation, 
dehydration, and bone spurs are all results of aging. 
 Factors other than aging can increase your risk of cervical spondylosis. These 
include: 
 Neck injuries 
 Work-related activities that put extra strain on your neck from heavy lifting 
 Holding your neck in an uncomfortable position for prolonged periods of time 
or repeating the same neck movements throughout the day (repetitive stress) 
 Genetic factors (family history of cervical spondylosis) 
 Smoking 
 Being overweight and inactive 
  
SYMPTOMS OF CERVICAL SPONDYLOSIS: 
 Most people with cervical spondylosis don’t have significant symptoms. If 
symptoms do occur, they can range from mild to severe and may develop gradually or 
occur suddenly. 
 One common symptom is pain around the shoulder blade. Some complain of 
pain along the arm and in the fingers. The pain might increase when: 
 Standing 
 Sitting 
 Sneezing 
 Coughing 
 Tilting your neck backward 
 Another common symptom is muscle weakness. Muscle weakness makes it 
hard to lift the arms or grasp objects firmly. 
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Other common signs include: 
 A stiff neck that becomes worse 
 Headaches that mostly occur in the back of the head 
 Tingling or numbness that mainly affects shoulders and arms, although it can 
also occur in the legs 
 Symptoms that occur less frequently often include a loss of balance and a loss 
of bladder or bowel control. These symptoms warrant immediate medical 
attention. 
 
TESTING AND DIAGNOSING  
 Making a diagnosis of cervical spondylosis involves ruling out other potential 
conditions, such as fibromyalgia. Making a diagnosis also involves testing for 
movement and determining the affected nerves, bones, and muscles. Your primary 
care physician may treat your condition or refer you to an orthopedic specialist, 
neurologist, or neurosurgeon for further testing. 
 
PATHOPHYSIOLOGY: 
  The intervertebral disk is composed of an inner nucleus pulposus and an outer 
annulus fibrosus. The nucleus consists of a mesh of type II collagen and an 
extracellular matrix of proteoglycans that are hydrophilic, maintain a high water 
content, and resist compressive forces. The annulus is comprised of a concentric 
series of interwoven fibrous lamellae that provide tensile strength to the disk. They 
attach to the anterior and posterior longitudinal ligaments and the superior and inferior 
endplates. As individuals age there is a characteristic degenerative cascade that 
develops in the intervertebral disks. Typically, in the third decade there is a change in 
the proteoglycan content leading to reduced levels of condrotin sulphate and increased 
levels of keratin sulphate. These changes diminish the disks ability to maintain its 
normal fluid concentration and leads to a decreased ability of the nucleus to resist 
normal compressive [forces. This places additional stress on the outer annular fibers. 
The disk then looses a portion of its normal height. This causing buckling of the 
ligamentum flavum, facet joint capsules, and annulus into the spinal canal and 
neuroforamen. This increases the resultant loading of the facet joints and leads to 
facet joint degeneration. Additional bone spurs can form and cause further narrowing 
of the spinal canal and foramen. 
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  One of the most common manifestation of cervical disk disease is a disk 
herniation. Disk herniation can be categorized as soft or hard. A soft disk herniation is 
the result of a disruption of the outer anular fibers with protrusion of the inner nucleus 
material causing compression of the exiting nerve roots. Soft disk herniations are 
most commonly seen in patient between 30 years and 50years of age. A hard disk 
herniation is the result of osteophyte formation or calcification of disk material and 
typically causes chronic symptoms in patients greater than 55 years of age. Soft disk 
herniations can be further categorized as a bulge, protrusion, extrusion or 
sequestration. A disk buldge is a caused by the nucleus pushing on the annulus but 
without any distribution of the annular fibers. A protrusion is a  small defect in the 
outer annular fibers with a portion of the nucleus dis[placed outside the annulus. The 
base of the protrusion is wider than the material displaced beyond the borders of the 
annulus. A disk extrusion consists of further displacement of the nucleus beyond the 
borders of the annulus where the diameter of the displaced material is greater than at 
the base. A sequestered disk herniation is a completly live piece of disk that has 
separated from the reminder of the disk. 
  In the cal spine the nerve rootsexit above the pedicle as compared to the 
lumbar spine where the nerve roots exit below the pedicle of the same number. For 
example the c6 nerve root will exit above tec6 pedicle at the c5-c6 disk space. The c8 
nerve root exits at the c7 –T1 disk space. 
  Axial neck pain can be caused by muscular or ligamentous deconditioning or 
injury. This can result from poor posture, fatigue, stress, and a poor ergonomic 
environment. Degenerative disk disease can also directly cause axial neck pain. The 
outer annular fibers are innervated by the sinuvertebral nerve, which is composed of 
fibers of the ventral nerve root and sympathetic plexus. Studies have described a 
reproducible pattern of axial neck pain associated with provocation discography at 
each cervical disk level. The facet joints can also contribute to axial neck pain through 
their innervations from the medial branches of the ventral rami. 
  Cervical radiculopathy most commonly occurs due to compression of the 
exiting nerve root in the intervertebral foramen either due to disk herniation, 
osteophyte formation, or loss of disk height and subsequent foraminal height 
narrowing. Other known causes of cervical radiculopathy comprise of the normal 
blood supply to the nerve root and chemical radiculitis. A constriction of the venous 
blood flow from the nerve root can lead to oedema and fibroses of the nerve root. 
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Various neurogenic and non-neurogenic chemical pain mediators have also been 
reported to be released from the degenerative disk that can result in radicular 
symptoms. There include substance P, somatostatin, vasoactive intestinal peptide, 
calcitonin gene-related peptide, angiotensin II, bradykinin, serotonin, histamine, 
acetylcholine, and prostaglandin E1 and E2.    
 
PHYSICAL EXAMINATION 
1. Spurling sign 
Radicular pain is exacerbated by extension and lateral bending of the neck 
toward the side of the lesion. Which result in further foraminal compromise. 
2. Lhermitte’s sign 
The generalized electric shock sensation is associated with neck extension. 
3. Hoffman sign 
Reflex contraction of the thumb and index finger occurs in response to nipping of the 
middle finger. This sign is evidence of an upper motor neuron lesion. A Hoffman sign 
may be insignificant if present bilaterally. 
4. Axial compression test 
Pain that is elicited by axial compression. 
5. Shoulder abduction test 
Relief of cervical radiculopathy by abduction. 
6. Valsalva manouevre 
Increase the radicular symptoms. 
7. Phalynx wrist flexion test 
 Full passive flexion of the patients wrist for 30-60 seconds and looking for 
reproduction or worsening of worsening of finger dysthesiasis 
8. Tinel’s sign 
 Elicited by tapping over the median nerve at the carpal tunnel. 
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9. The elbow flexion test 
 Fully flex the elbow and observe for ulnar nerve distribution. 
 
 
10. Adson’s test 
 Turns his head to the involved side, raises the chin and holds a deep 
inspiration and while the ipsilateral radial pulse is palpated with the arm slightly 
abducted from the side if pulse diminishes test positive for thoracic outlet syndrome. 
Complications 
1. Pseudo arthrosis 
2. Graft displacement. 
3. Neurological injury 
4. Spastic gait 
5. Quadriplegia  
6. Injury to other structures. 
 Recurrent laryngeal Nerve. 
 Superior laryngeal Nerve. 
 Carotid artery. 
DIFFERENTIAL DIAGNOSIS 
1. Thoracic outlet syndrome 
There is compression of lower trunk of brachial plexus by an anomalous band 
that connects the transerve process of C7 within the first rib. Neurologic deficit 
include weakness of intrinsic muscles of the hand and diminished sensation over the 
palmar aspect of fourth and fifth digits. 
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2. Brachial plexus and nerve injury 
Pain from injury to the brachial plexus or peripheral nerves can be confused 
with pain of neck origin. Infiltration of peripheral nerves by neoplasm may occur in 
lower trunk of brachial plexus and produce shoulder pain that radiates down the arm. 
There is numbness of the fourth and fifth fingers with weakness of intrinsic muscles 
of the hand supplied by ulnar and median nerves. 
3. Refered pain 
Cardiac ischemia causes left sided brachial neuralgia. In those patients, 
diagnosis depends on the history, examination and abnormal findings in ECG. Sub – 
diaphragmatic lesions cause right sided pain. 
Gall bladder lesions causes right sided brachial neuralgia. The diagnosis 
depends upon the history examination and investigations. 
4. Syringobulbia: 
Dissociated sensory loss on the face, palatal palsy, Horner’s syndrome, 
nystagmus, Kyphoscoliosis, pescavus and spina bifida are then found. 
5. Syringomyelia: 
Long history of neck and arm pain, depending on the site of the syrinx, 
ascending or descending spinal pathways may be affected which can lead to a spastic 
paraparesis or sensory deficit in the upper and lower extremities pressure on the 
anterior horn cells can lead to fasciculation and atrophy of the upper limb muscles. 
In the lower extremities hyperflexia in the legs and extensor plantar responses 
are common. Charcot joint in the shoulders, elbows or knees are common in advances 
cases. 
6. Tumours of the spinal canal 
 (a)Extra dural or epidural tumour 
Commonest extra dural tumours are the spinal metastasis. The symptoms are  
local pain, radiating pain which is exacerbated by coughing, sneezing or straining pain 
and local tenderness often proceed. 
 (b) Intra dural Tumours: 
 (i) Intra medullary tumours: 
  Dissociated sensory loss in the segments of tumour origin and spring of 
posterior column sensory function. Later spinothalamic tracts may be involved. The 
sacral segments may be spared. Atrophy in the appropriate segments due to anterior 
horn cells involvement. 
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(ii)  Extra medullary tumours: (Meningiomas neurofibroma) 
Local back pain, sensory loss below the level of the pain, weakness and 
bladder and bowel dysfunctions. 
7. Tabesdorsalis: 
Fleeting and respetitive shooting pains occurring mostly in the legs. Loss of 
reflexes in the legs, impaired position and  vibration sense gives severe ataxic gait. 
Romberg,s test is positive. Aygyll Robertson pupils constitute a typical tabetic facies. 
8.  Epidural abscess: 
This condition can occur as a complication of operation or lumbar puncture. 
Spinal osteomyelitis  cause abscess formation Unexplained fever and mild spinalache, 
later radicular pain occurs. As the abscess expands it causes and compression with 
transverse and usually complete transaction syndrome. 
IMAGING TESTS 
 X-rays can be used to check for bone spurs and other abnormalities. 
 A CT scan can provide more detailed images of your neck. 
 An MRI scan, which produces images using radio waves and a magnetic field, 
helps your doctor locate pinched nerves. 
 In a myelogram, a dye injection is used to highlight certain areas of your 
spine. CT scans or X-rays are then used to provide more detailed images of 
these areas. 
 An electromyogram (EMG) is used to check that your nerves are functioning 
normally when sending signals to your muscles. This test measures your 
nerves’ electrical activity. 
 A nerve conduction study checks the speed and strength of the signals a nerve 
sends. This is done by placing electrodes on your skin where the nerve is 
located. 
 
MANAGEMENT: 
1.Medication:   
a) Analgesic and muscle relaxant 
b) Corticosterone injection 
2. Physiotheraphy : To relieve pain and enchance movement of the neck. 
    3. Conservative methods 
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(i) Cervical Traction: 
 Vertebral traction should be the first choice of pain relief for patients suffering 
nerve root pain. Intermittent sustained traction is carried out after careful positioning 
has localized the involved segment in such cases the treatment atleast once a day is 
essential prolonged pain relief will take several days to obtain. 
 Cervical traction provides positive patient response and can relieve the pain 
associated with certain neck disorders. It applies a stretch to muscles, ligaments and 
tissue components of the Cervical spine. It provides relief by promoting.  
 Seperation of the intervertebral joint space which contains the disc and may 
reduce a “bulge” or impingement of structures for use in the foramen. It is not 
indicated for use in condition of instability such as with “Whiplash” injury. It is most 
commonly used when the patient is in the supine position with the neck placed at 200-
300 of flexion. Using traction in this position helps stretch the posterior neck muscles 
and facilitate intervertebral seperation, Which relieves pressure that may be pinching 
nerves, therefore promoting muscle relaxation and intervertebral separation. 
 
(ii) Cervical collar/ Cervical Bracelet: 
 Cervical collar are advised to wear temporary collar for day time to restrict 
movement and a soft collar for support at night. A patient who is given a collar should 
be advised that the restriction in neck movement will alter other proprioception, for 
example he will need to take care in the dark or on entering darkened rooms when he 
may lose his balance. A patient wearing a collar should  not drive because judgement 
of relative distance will be impaired. In the case of vertebrobasillar insufficiency 
cervical collar may be advised to the suffers according to the severity. 
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MATERIALS AND METHODS 
 The clinical study on Ceganavatham was carried out in the post graduate 
sirappu maruthuvam department of Government siddha medical college and 
Palayamkottai In this study 40 patients (who are selected by inclusion and exclusion 
criteria) were treated as OP and IP patients. 
 
Selection of the patients: 
Age:  
           20 years to 65 years  
Sex: 
          Male and Female 
Clinical Findings: 
             The patients were selected on the basis of the following clinical findings 
• Pain and restricted movements of the neck 
• Radiating pain in the upper limbs 
• Feeling of heaviness in the body and weakness of the limb 
• Burning sensation of eyes 
• Constipation 
• Mental depression 
• Tingling sensation and numbness in the upper limbs 
• Giddiness and head ache 
 
The history details were taken from the patient about:  
• Occupation. 
• Social economic status. 
• Psychological condition. 
 
  
51 
 
UNIVERSAL PAIN  SCALE ASSESSMENT:
 
A.   0    : No Pain  
B. 1 -3  :  Mild pain 
C. 4-6  :  Moderate pain 
D. 7-10 :  Severe pain 
 Reference: Clinical Manual for Nursing Practice. (National Institute of Health 
Warren Grant Magnuson Clinical Center) 
 
GRADATION OF MOVEMENTS: 
Grade 1 :  Fit for all activities to do their work without  
   support (Normal). 
Grade 2          :   Mild Pain and Mild restriction of Movements. 
Grade 3 :  Moderate Pain with or without radiation to lower limbs  
and   Moderate restriction of Movements. 
Grade 4 :  Severe Pain with or without radiation to lower limbs  
and  Severe  restriction of Movements. 
Diagnosis: 
   The diagnosis was made by following Siddha diagnosis methods 
Nilam,Kaalam,Pulanal arithal Poriyal arithal vinaathal Mukkutra Nilaigal Udal 
Thathukal Nilai and Envagai thervugal,and the diagnosis of cegana vatham were 
obtained which correlated with diagnosis of cervical Spondylosis by the X-Ray 
findings. 
 
EXCLUSION CRITERIA: 
• Cervical rib 
• Trauma 
• Spina bifida 
• Liver Disease 
• Pregnancy and lactation 
• Ankylosing spondylosis 
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• Renal Disease 
• Congenital anomalies of spine 
• Patient with any other systemic illness 
• Recent Dislocation/ trauma 
 
Investigation: 
  The following investigations were done in all selected patients in the 
laboratory of Government Siddha Medical College, Palayamkottai.  
 
LABORATORY INVESTIGATIONS: 
Blood: 
• TC 
• DC 
• ESR 
• Hb 
• Blood Sugar 
  Fasting 
  Random  
Post prandial 
• Blood urea 
• Serum Creatinine 
• Serum Cholesterol 
• C-RP 
Urine: 
 Albumin 
 Sugar 
 Deposits 
 
SPECIFIC INVESTIGATIONS: 
RADIOLOGICAL INVESTIGATION: 
 X- Ray:  Cervical spine AP view and lateral view. 
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TREATMENT 
     On the first day of treatment 15 ml of Vellai ennai was given at morning with 
hot water was given.  
  All the patients were treated with the following medicines. 
1.Milagu legiyam   
  6 grms twice a day 
2.Seeraga thylum: 
     As External application 
 
    Varmam was given as a complementary therapy for 15 Ip patients . All the 
patients were advised to follow dietary regimen (or) pathiyam. The Bio-Chemical 
analysis was done in the Biochemistry Department and Pharmacological analysis was 
done in the Pharmacological laboratory of KMCH college of Pharmacy. 
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RESULTS AND OBSERVATION 
For the clinical study 40 patients were selected and treated in PG-III Sirappu 
Maruthuvam Department, Government Siddha Medical College and Hospital, 
Palayamkottai.  Results were observed with respect to the following criteria. 
1. Age distribution 
2. Sex distribution 
3. Kaalam 
4. Thinai 
5. Paruva kaalam 
6. Etiological Factors 
7. Socio-economic status 
8. Occupation 
9. Clinical Manifestations 
10. Duration of illness 
11. Disturbance in vadha 
12. Disturbance in pitha 
13. Disturbance in kabha 
14. Udal Thathukkal 
15. Envagai Thervugal 
16. Pulse reading (Naadi) 
17. Neikuri 
18. Provocative test 
19. Progress chart 
20. Patients treated only with trial drugs 
21. Trial drugs along with complementary therapy (Varmam) 
22. Effect of Trial drugs along with complementary therapy. 
23. Comparison between effective of trial drug and trial drug with complementary 
therapies 
24. Effect of therapy 
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1. AGE DISTRIBUTION 
   Out of 40 patients, 40% were 51 – 60 age group  and second most 30% were 
41 – 50 age group. 
S.no Age No. of patients Percentage(%) 
1 16 – 20 - - 
2 21 – 30 1 2.5 
3 31 – 40 7 17.5 
4 41 – 50 12 30 
5 51 - 60 16 40 
6 Above 60 4 10 
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2. SEX DISTRIBUTION  
   Out of 40 patients, 42.5% were males and 57.5% were females. 
S.no Sex No. of cases Percentage 
Op Ip 
 Male  9 8 42.5 
 Female 16 7 57.5 
 Total  25 15 100 
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3.KAALAM 
  Out of 40 patients, 12.5% of cases were in the vadha kaalam, 87.5% of cases 
were in the pitha kaalam, 0 % of cases were in the kabha kaalam 
S.no kaalam No. of patients  Percentage(%) 
1 Vatha kaalam (1-33yrs) 5 12.5 
2 Pitha kaalam (34-66yrs) 35 87.5 
3 Kaba kaalam (67-100yrs) - - 
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4. THINAI (THE HABITAT OF THE PATIENTS) 
 
  Among the 40 patients 87.5% were from marutham and 12.5 % cases were 
from Neithal thinai. 
S.no Thinai or Land No. of patients Percentage(%) 
1 Kurinji - - 
2 Mullai - - 
3 Marutham 35 87.5 
4 Neithal 5 12.5 
5 paalai - - 
6 Total - - 
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5. PARUVAKALAM 
 
  Among 40 cases, 7.5% of patients were affected in Munpani kaalam 10% of 
patients were affected in pinpani kaalam and 35% patients were affected in Elavenil 
kaalam and 5% of patients were affected in Koothir kaalam 22.5% were affected in 
mudhuvenirkaalam patients. 20% were affected in kaarkalam patients. 
 
S.no Paruvakalam Month No. of patients  Percentage(%) 
1 Kaarkalam Avani-puratasi 
(16 aug – 15 oct) 
8 20 
2 Koothirkaalam Ippasi-karthigai 
(16 oct – 15 dec) 
2 5 
3 Munpanikaalam Margazhi-thai 
(16 dec – 15 feb) 
3 7.5 
4 Pinpanikaalam Maasi-panguni 
(16 feb – 15 apr) 
4 10 
5 Elaveenirkaalam Chitthirai-vaigasi 
(16 apr – 15 jun) 
14 35 
6 muthuvenirkaalam Aani-aadi 
(16 jun– 15 aug) 
9 22.5 
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6. DISTRIBUTION BASED ON ETIOLOGICAL FACTORS 
  It was noted while taking the history of the patients that Ceganavatham was 
caused mainly (80%) due to the nature of the occupation.  The remaining was due to 
other factor like senility and exposure to cold. 
S.no Precipitating 
factors 
No. of patients Percentage(%) 
1 Exposure to cold 4 10 
2 Senility 4 10 
3 Occupation 32 80 
4 Metabolic - - 
5 total 40 100 
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7. SOCIO - ECONOMICAL STATUS 
  The above study consisted of  0% of cases from rich class, 95% of cases from 
middle  class and  5% of low class 
S.no Socio - Economical 
status 
No. of patients Percentage(%) 
1 Low class 2 5 
2 Middle class 38 95 
3 High class - - 
4 Total 40 100 
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8. OCCUPATION  
  Out of 40 cases, in this study the rate of incidence is higher in agricultural 
labour (35%) , hotel workers (7.5%) , Beediworkers (0%), Tailors(5%),  weight lifters 
(2.5%) 
S.no Occupation No. of patients  Percentage(%) 
1 Agricultural labours 14 35 
2 House wives 12 30 
3 office employee 2 5 
4 Hotel worker 3 7.5 
5 Beedi worker - - 
6 Weight lifters 1 2.5 
7 Tailors 2 5 
8 Others 6 15 
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9. CLINICAL MANIFESTATION 
  Among the 40 cases, all of them had pain in the neck 100% and 20% of 
patients stiffness in neck, 20% of patients had constipation and 95% of patients had 
radiating pain in upper limb. 
S.no Clinical features No. of patients  Percentage(%) 
1 Pain in nape of neck 40 100 
2 Stiffness in the neck 8 20 
3 Radiating pain in the upper 
limbs 
38 95 
4 Headache 2 5 
5 Diddiness 7 17.5 
6 Numbness in upper limb 23 57.5 
7 Constipation 8 20 
8 Feeling of heaviness of the 
body 
5 12.5 
9 Tingling sensation 13 32.5 
10 Burning sensation of the eyes 12 30 
11 Weakness of the upper limbs - - 
12 Mental depression - - 
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10. DISTRIBUTION ACCORDING TO THE DURATION OF ILLNESS 
 
  From the present study it was studied that the disease Cegana vatham reflected 
its symptoms mostly over a period of 0-1 months which was confirmed during the 
history taking while 35% of the patients reported the data 
 
S.no Duration of illness 
(in months) 
No. of patients  Percentage(%) 
1 0 - 1 14 35 
2 1 - 3 8 20 
3 3 - 6 6 15 
4 6 - 12 7 17.5 
5 12 - 24 3 7.5 
6 24 - 36 2 5 
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11. DISTURBANCE IN VATHAM 
  Among the 10 types of vatha, Samanan and viyanan were affected in all the 
cases (100%).  Abanan was noted to be deranged in 20% and Devathathan was 
abnormal in 30%. 
S.no Vatham No. of patients  Percentage(%) 
1 Piranan - - 
2 Abanan 8 20 
3 Vudhanan - - 
4 Viyanan 40 100 
5 Samanan 40 100 
6 Naagan - - 
7 Koorman - - 
8 Kirukaran - - 
9 Devathathan 12 30 
10 Thananjayan  - - 
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12. DISTURBANCES IN PITHAM 
  The five types of pitham were analyzed in all 40 cases, Sathaga pitham was 
altered in all cases (100%) evidenced as difficulty in handling their regular duties 
because of pain and stiffness in neck and upper limb.  Ranjaga pitham was affected in 
5% patients denoting low haemoglobin count. 
S.no Pitham No. of patients  Percentage(%) 
1 Anarpitham 2 5 
2 Ranjagapitham 2 5 
3 Sathagapitham 40 100 
4 Aalosagapitham - - 
5 pirasagapitham - - 
 
 
5 5
100
0 0
0
20
40
60
80
100
120
Anarpitham Ranjaga 
pitham
Sathaga 
pitham
Alosaga 
pitham
Prasaga 
pitham
p
e
rc
e
n
ta
g
e
%
pitham
67 
 
13. DISTURBANCES IN KABAM 
  Santhigam was observed to be affected in all the cases.   
S.no kabam No. of patients  Percentage(%) 
1 Avalambagam  - - 
2 Kilethagam  - - 
3 Pothagam  - - 
4 Tharpagam  - - 
5 Santhigam  40 100 
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14. INVOLVEMENT OF UDAL KATTUKAL 
  It was diagnosed during the study  Enbu 100%, Moolai 87.5%  cases were 
affected.  
S.no Udal kattukal No. of patients Percentage(%) 
1 saaram - - 
2 senneer 2 5 
3 oon - - 
4 kozhuppu - - 
5 enbu 40 100 
6 Moolai 35 87.5 
7 Sukkilam / 
suronitham  
- - 
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15. CONDITION OF ENVAGAI THERVUGAL 
  It was learnt during the study that thontha naadi was noted in all 40 cases, 
malam was affected in 62.5% of cases  
S.no Envagai thervugal No. of patients Percentage(%) 
1 Naa - - 
2 Niram - - 
3 Mozhi - - 
4 Vizhi - - 
5 Malam 25 62.5 
6 Moothiram - - 
7 Naadi(thontha naadi) 40 100 
8 Sparisam  - - 
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16. NAADI 
  As mentioned above thontha naadi was noted in all cases and among them 
55% were vatha pitha naadi 45% were pitha vatha naadi  
S.no parameters No. of patients Percentage(%) 
1 Vatha pitham 22 55 
2 Pitha vatham 18 45 
3 Kaba vatham - - 
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17 NEIKURI 
  In neikuri analysis 57.5% of the cases presented with vatha neer, 22.5% with 
pitha neer, 20% with kaba neer 
S.no Inference No. of patients  Percentage(%) 
1 Spreading like 
snake 
23 57.5 
2 Spreading like ring 9 22.5 
3 Stants like a pearl 8 20 
4 Others  - - 
5 Total  40 100 
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18. PROVOCATIVE TESTS 
  Based on modern aspect, for the diagnostic purpose and to determine the 
differential diagnosis few provocative tests were done and noted in all 40 cases 
spurling test, axial compression sign were positive in all cases (100%) and tinel’s 
sign, adson’s test. Roo’s test were negative in all cases. 
S.no Test No. of patients Percentage 
1 Spurling test 40 100 
2 Axial compression test 40 100 
3 Phalanx wrist flexion tet 6 15 
4 Elbow flexion test 0 0 
5 Finger escape sign 0 0 
6 Tinels sign 0 0 
7 Adson test 0 0 
8 Roos test 0 0 
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19.  PROGRESSIVE CHART 
  It was noted that, clinical manifestations like pain in the neck, restriction of 
movements and radiation of pain to other parts were remarkably reduced after 
treatment when compared to that of before treatment, Numbness and tenderness 
showed moderate reduction after treatment. 
 
S.no 
 
 
Clinical feature 
Before treatment After treatment 
No.of 
cases 
Percentage No.of 
cases 
percentage 
1 Pain in neck 40 100 1 2.5 
2 Pain in shoulder 38 95 2 5 
3 Radiating pain in the right 
upper limb 
22 55 2 5 
4 Radiating pain in the left 
upper limb 
16 40 - - 
5 Numbness 23 57.5 - - 
6 Tenderness - - - - 
7 Restriction of 
movement(ROM) 
5 12.5 - - 
8 Burning sensation 12 30 - - 
9 Giddiness 7 17.5 - - 
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Table 20. Assessment of curative effects in patients treated only with trail drug 
(internal and external medicines) 
  From the above study, it was inferred that severe pain that was noted in 
patients before treatment (47.5%) had a remarkable decline after treatment  (5%), 
similarly moderate and mild pain (7.5%) were also observed to have decreased after 
treatment 
symptoms Initial readings Final readings 
No of patients percentage No of patients Percentage 
No pain - - 19 47.5 
Mild 9 22.5 3 7.5 
Moderate 12 30 2 5 
severe 4 10 1 2,5 
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Table 21. Assessment of curative effects in cervical spondylosis patients treated 
with trail drugs along with complimentary therapy (Varmam) 
 
  Administration of trial drug along with complementary therapy reduced severe 
pain in almost all the cases pain reduced in mild and moderate cases. 
symptoms Initial readings Final readings 
No of patients percentage No of patients Percentage 
No pain - 15 12 30 
Mild 6 17.5 2 5 
Moderate 7 5 1 2.5 
severe 2  -  
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Table 23.  Effect of trail drug along with complementary therapies 
  Administration of trial drug along with complementary therapies had a marked 
response 77.5% moderate with 7.5% and mild with 12.5% 
S.no Effect of therapy No. of patients  Percentage(%) 
1 Marked effect 31 77.5 
2 Moderate effect 3 7.5 
3 Mild effect 5 12.5 
4 No effect 1 2.5 
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Table 24. Comparison between effective of trail drug and trail drug with 
complementary therapies 
  From the above data, it can be concluded that administration of trial drug 
along with complementary therapies had comparatively more effect than 
administering trial drug alone. 
 
S.no 
 
Effect of therapy 
Trail drug alone 
Trail drug with 
external therapy 
No.of 
cases 
percentage 
No.of 
cases 
percentage 
1 Good 19 47.5 12 30 
2 Moderate 3 7.5 2 5 
3 Mild 2 5 1 2.5 
4 No 1 2.5 - - 
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LIST OF OUT PATIENTS OF PG III SIRAPPU MARUTHUVAM DEPARTMENT GIVEN  
1.MILAGU LEGIYAM – INTERNAL    2.SEERAGA THYLAM – EXTERNAL 
S.no Op.no Name Age/sex Occupation Date of 
admission 
Date of 
discharge 
Total no. of 
days treated 
Results 
1 62553 Parvathy 33/F House wife 22.07.17 07.09.17 48days Good 
2 107393 Mareeswari 45/F House wife 5.12.17 21.01.18 48 days Mild 
3 109483 Noorjahan 57/F House wife 11.12.17 27.01.18 48 days Good 
4 11994 Musthafa 58/F Weight lifter 15.12.17 31.01.18 48 days Good 
5 1000 Sankaran 40/F Former 03.01.18 13.02.18 42 days Good 
6 1509 Papathy 45/F Former 04.01.18. 17.02.18 45 days Good 
7 1510 Parvathy 33/F House wife 04.01.18 20.02.18 48 days Good 
8 21946 Mariyammal 51/F House wife 05.01.18 19.02.18 47 days Good 
9 2682 Selvarai 60/F Former 06.01.18 22.02.18 48 days Moderate 
10 3748 Balasubramaniyan 55/F Former 09.01.18 14.02.18 37 days Mild 
11 5690 Rahumath 52/F Clerk 17.01.18 28.02.18 43 days Good 
12 2834 Sivakumar 35/F Former 07.02.18 26.03.18 48 days Good 
13 13314 Chokalingam 51/F Former 08.02.18 20.03.18 41 days Good 
14 14911 Saraswathy 47/F Clerk 13.02.18 30.03.18 46 days Good 
15 15103 Parvatham 49/F Former 15.02.18 31.03.18 45 days Moderate 
16 16008 Thasmi 47/F Tailor 15.02.18 03.04.18 48 days Good 
17 16475 Ramachandiran 62/F Former 17.02.18 05.04.18 48 days Mild 
18 16735 Saraswathi 45/F Former 17.02.18 02.04.18 45 days Good 
19 18255 Chithambaram 54/F Former 22.02.18 02.04.18 40 days Good 
20 19068 Balasubramaniyan 50/F Photographer 24.02.18 09.04.18 45 days Good 
21 20687 Ruthra 23/F Backery worker 01.03.18 17.04.18 48 days Good 
22 27047 Seyathoon 31/F Tailor 21.03.18 30.04.18 41 days Good 
23 24475 Jayarani 50/F Teacher 15.03.18 30.04.18 47 days Good 
24 28486 Meena 38/F Shop keeper 25.03.18 09.05.18 46 days Good 
25 32624 Alagammal 45/F Teacher 08.04.18 25.05.18 48 days Good 
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LIST OF IN PATIENTS OF PG III SIRAPPU MARUTHUVAM DEPARTMENT GIVEN  
1.MILAGU LEGIYAM – INTERNAL    2.SEERAGA THYLAM – EXTERNAL 
 
S.no Ip.no Name Age/sex Occupation Date of 
admission 
Date of 
discharge 
Total no. of 
days treated 
Results 
1 3196 Selvarani 45/F House wife 06.12.17 29.12.17 24 days Good 
2 3206 Krishnaveni 42/F House wife 07.12.17 26.12.17 20 days Good 
3 3327 Somu 60/M  Hotel worker 10.12.17 25.01.18 47 days Good 
4 3346 Alagusundari 56/F House wife 26.12.18 18.01.17 24 days Moderate 
5 72 Masilamani 60/M Former 17.01.18 05.02.18 20 days Good 
6 147 Revathy 32/F House wife 22.01.18 25.02.18 35 days Good 
7 153 Latchmanasamy 52/M former 23.01.18 28.02.18 37 days Good 
8 491 Murugan 50/M Hotel worker 22.02.18 13.03.18 20 days No improvement 
9 627 Manuvel 53/M Former 08.03.18 26.03.18 19 days Moderate 
10 672 Palraj 54/M Hotel worker 12.03.18 28.03.18 17 days Good 
11 677 Chinnathai 62/F House wife 13.03.18 02.04.18 21 days Good 
12 696 Manikavel 60/M Former 14.03.18 02.04.18 20 days Good 
13 746 Thiruveni 63/F House wife 19.03.18 21.04.18 34 days Good 
14 1141 Sornam 58/F House wife 26.04.18 07.06.18 43 days Moderate 
15 1144 selvaraj 65/M watchman 27.04.18 07.06.18 42 days Good 
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BLOOD INVESTICATION BEFORE AND AFTER TREATMENT – OP PATIENT 
 
S.N OP.NO TC DC HB ESR BLOOD SUGAR BLOOD  SERUM 
        N L E B M   F PP UREA CHOLESTEROL 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 62553 8200 8100 76 78 20 22 4 - 0 0 0 0 11.5 12 15 12 90 80 120 125 27 25 165 169 
2 107393 7600 7800 68 70 29 28 3 2 0 0 0 0 9.7 11.5 18 13 84 85 111 120 32 31 167 171 
3 109483 7400 7600 73 73 23 25 4 2 0 0 0 0 12.6 12.6 7 14 83 90 121 128 25 27 207 201 
4 11994 8000 8200 65 68 33 30 2 2 0 0 0 0 11.7 12.1 14 11 88 85 130 120 31 29 115 125 
5 1000 7800 8000 78 78 21 22 1 - 0 0 0 0 10.9 12 20 24 96 80 120 130 29 32 170 157 
6 1509 8000 7800 69 69 30 29 1 2 0 0 0 0 11.8 10.9 22 17 82 82 112 120 38 35 155 159 
7 1510 6800 6600 72 73 23 24 5 3 0 0 0 0 12.8 12.7 18 19 80 83 124 126 33 31 163 161 
8 21946 7200 7200 60 61 38 39 2 1 0 0 0 0 12 11.8 20 18 86 82 118 120 25 23 157 153 
9 2682 7300 7900 67 67 28 30 5 3 0 0 0 0 12.2 12.8 17 15 89 88 120 111 23 27 147 151 
10 3748 7500 7600 76 77 22 23 2 - 0 0 0 0 10.2 10.6 18 16 88 86 118 100 24 23 143 147 
11 5690 7800 7600 57 59 36 36 7 5 0 0 0 0 9.8 9.9 15 19 79 83 120 125 28 30 151 153 
12 2834 8000 8000 73 75 25 25 2 - 0 0 0 0 11.6 12.5 21 18 83 85 115 120 33 31 148 151 
13 13314 8200 8100 72 72 27 26 1 2 0 0 0 0 12.7 12.7 24 20 79 83 118  36 33 157 159 
14 14911 8400 7200 65 67 31 32 4 1 0 0 0 0 11.8 10.9 14 7 86 77 130 128 31 29 155 155 
15 15103 7600 7400 61 63 37 37 2 - 0 0 0 0 12.5 12.3 13 18 79 83 118 120 34 35 129 131 
16 16008 7500 7600 67 69 38 38 5 3 0 0 0 0 11 12.5 12 15 88 70 120 112 29 31 199 197 
17 16475 6800 8000 69 71 28 28 3 1 0 0 0 0 10 11.5 24 22 80 86 130 110 26 30 187 181 
18 16735 7400 7800 62 63 35 36 3 1 0 0 0 0 9.8 12.0 18 17 83 90 125 115 22 27 181 179 
19 18255 7800 8000 68 66 27 29 5 5 0 0 0 0 11.8 12.5 20 18 95 100 110 120 36 31 179 174 
20 19068 6800 7200 67 69 30 31 3 - 0 0 0 0 10.5 11.6 18 17 86 84 123 118 25 23 171 169 
21 20687 7200 7400 67 69 28 30 5 1 0 0 0 0 10.5 12.3 21 19 94 90 113 120 38 37 167 165 
22 27047 7300 7600 73 73 26 25 1 2 0 0 0 0 12.6 12.8 18 15 88 81 125 110 33 28 169 171 
23 24475 7600 7800 77 75 23 24 - 1 0 0 0 0 11.7 11.8 21 17 81 88 123 110 21 20 159 160 
24 28486 7800 8200 71 73 26 26 3 1 0 0 0 0 10.6 11 18 16 90 85 110 120 27 27 161 162 
25 32624 8600 8800 72 72 28 25 - 1 0 0 0 0 12.0 12.3 17 15 85 93 118 130 31 30 205 201 
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BLOOD INVESTICATION BEFORE AND AFTER TREATMENT – IP PATIENT 
 
  
S.NO OP.NO TC DC HB ESR BLOOD SUGAR BLOOD  SERUM 
        N L E B M   F PP UREA CHOLESTEROL 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1. 3196 8500 9100 66 65 29 31 5 4 0 0 0 0     80 83 120 125 15 18 150 153 
2. 3206 8500 8400 68 67 32 32 - 1 0 0 0 0 8.9 9.2 15 17 90 95 116 121 18 21 155 167 
3. 3327 8200 8500 54 61 43 36 3 3 0 0 0 0 9.2 10.5 9 11 96 99 135 132 35 33 190 189 
4. 3346 8400 8700 59 67 41 29 - 4 0 0 0 0 12.2 13 21 19 86 85 110 117 16 19 126 131 
5. 72 6900 6900 66 65 29 31 5 4 0 0 0 0 11.6 12.5 12 10 92 92 116 119 13 17 215 205 
6. 147 7300 7200 64 62 32 36 4 2 0 0 0 0 13.1 13 14 13 88 87 108 113 11 15 175 179 
7. 153 9100 9400 76 71 20 28 4 1 0 0 0 0 9.5 10.7 9 11 92 93 125 127 25 29 166 169 
8. 491 6900 7100 64 63 29 31 7 6 0 0 0 0 12.1 11.6 8 9 95 94 128 131 27 31 150 159 
9. 627 8100 8700 64 69 25 26 9 5 0 0 0 0 12.8 12.2 6 7 84 86 130 139 16 19 175 177 
10. 672 7200 7100 71 70 27 28 2 2 0 0 0 0 11 11.5 23 21 89 92 116 123 26 27 147 151 
11. 677 6400 6300 76 69 20 28 4 3 0 0 0 0 10.5 12.9 27 25 81 87 120 127 14 18 245 235 
12. 696 7000 7300 60 62 34 34 6 4 0 0 0 0 12 12.2 17 18 99 98 132 135 18 21 135 191 
13. 746 9000 9100 57 59 36 37 7 4 0 0 0 0 11.1 11.9 19 20 90 93 111 127 12 13 397 390 
14. 1141 8200 8400 62 60 34 35 4 5 0 0 0 0 12.4 13.1 23 21 73 81 114 135 26 24 185 189 
15. 1144 7300 7200 64 66 33 31 3 3 0 0 0 0 9.5 10.8 11 8 92 93 129 138 22 20 220 221 
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URINE EXAMINATION BEFORE & AFTER TREATMENT – OP PATIENTS 
S.no 
 
OP.no Before treatment After treatment 
Albumin  Sugar Deposit Albumin  Sugar Deposit 
1 62553 Nil Nil NAD Nil Nil NAD 
2 107393 Nil Nil NAD Nil Nil NAD 
3 109483 Nil Nil NAD Nil Nil NAD 
4 11994 Trace 1-2 Puscells NAD Nil Nil NAD 
5 1000 Nil Nil NAD Nil Nil NAD 
6 1509 Nil Nil NAD Nil Nil NAD 
7 1510 Nil Nil NAD Nil Nil NAD 
8 21946 Nil Nil NAD Nil Nil NAD 
9 2682 Nil Nil NAD Nil Nil NAD 
10 3748 Nil Nil NAD Nil Nil NAD 
11 5690 Nil Nil NAD Nil Nil NAD 
12 12834 Nil Nil NAD Nil Nil NAD 
13 13314 Nil Nil NAD Nil Nil NAD 
14 14911 Nil Nil NAD Nil Nil NAD 
15 15103 Nil Nil NAD Nil Nil NAD 
16 16008 Nil Nil NAD Nil Nil NAD 
17 16475 Nil Nil NAD Nil Nil NAD 
18 16735 Nil Nil NAD Nil Nil NAD 
19 18255 Nil Nil NAD Nil Nil NAD 
20 19068 Nil Nil NAD Nil Nil NAD 
21 20687 Nil Nil NAD Nil Nil NAD 
22 27047 Nil Nil NAD Nil Nil NAD 
23 24975 Nil Nil NAD Nil Nil NAD 
24 28486 Nil Nil NAD Nil Nil NAD 
25 32624 Nil Nil NAD Nil Nil NAD 
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URINE EXAMINATION BEFORE & AFTER TREATMENT – IN PATIENTS 
S.no 
 
IP.no Before treatment After treatment 
Albumin  Sugar Deposit Albumin  Sugar Deposit 
1 3196 Nil Nil NAD Nil Nil NAD 
2 3206 Nil Nil 1-2 Epithelial cells Nil Nil NAD 
3 3327 Nil Nil NAD Nil Nil NAD 
4 3346 Nil Nil NAD Nil Nil NAD 
5 72 Nil Nil NAD Nil Nil NAD 
6 147 Nil Nil NAD Nil Nil NAD 
7 153 Nil Nil 1-2 Epithelial cells Nil Nil NAD 
8 491 Nil Nil NAD Nil Nil NAD 
9 627 Nil Nil NAD Nil Nil NAD 
10 672 Nil Nil 1-2 Epithelial cells Nil Nil NAD 
11 677 Nil Nil NAD Nil Nil NAD 
12 696 Nil Nil NAD Nil Nil NAD 
13 746 Nil Nil NAD Nil Nil NAD 
14 1141 Nil Nil NAD Nil Nil NAD 
15 1144 Nil Nil NAD Nil Nil NAD 
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X- RAY – CERVICAL SPINE  PA  - LATERAL 
OP.NO : 32624 
Name :  Alagammal        45 / F 
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DISCUSSION 
 
 Based on the clinical manifestations discussed in Yugi vaithiya chinthamani- 
800. 40 cases were enrolled for the study.  Envagaithervugal the siddha diagnostic 
method was used to diagnose the disease and it was confirmed with the modern 
investigations.  After confirmation of the diagnosis the trial drug was administered 
along with the special therapies.  Observations were noted and analysed.  They are 
discussed here under. 
Age distribution 
 The statistical study shows high incidence of Cegana vatham in the age group 
between 51-60 years as it is one of the degenerative disease and lowest incidence in 
the age between 21-30. 
Most of the patients belong to pithakalam. 
 This information is best owed by our siddhars as the wordings. 
 “Ou{<mi!Jl<hkil<!ubKke<eqz<!
! uqjvf<KhqVkquqbqz<!nh<HOlUl<!hiOv”/!
The target sites affected in cervical spondylosis are generally bones, muscles, 
nerves, hairs, blood, urine, fat which are the components of appu and prithiviboothas 
(Appu+ prithivi = kabam  responsible for destruction).  Hence they begin to 
degenerate above fifty. 
Sex distribution 
 There is a slight variation in the male and female ratio and it is noted 
obviously in the study. 
Thinai 
 About 87.5% of patients from maruthanilam.  It may be due to altered food, 
lifestyle,habits etc. 
Seasonal distribution 
 Most of the patients came during, Elavenil kaalam,Muthuvenil kaalam, 
Pinpani kaalam, Munpani kaalam,  . 
Etiological factors 
 Majority of patients of the Ceganavatham was caused mainly (80%) due to the 
nature of occupation. The remaining was due to other factor like senility and exposure 
to cold. 
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Socio-economic status 
 During the study, 95% of cases were middle class and 5% of lower class. 
Occupational status 
 The rate of incidence is higher in occupational group which includes 
Agricultural labour (35%) and house wifes(30%) Hotel workers, Tailors, Weight 
lifters, others(35%).  Due to Agricultural labours are mostly affected. 
Clinical Manifestations 
 Pain in the nape of the neck is present in all 40 cases (100%), 95% of cases 
had radiating pain in upper limbs 20% of cases had stiffness in the Neck.  Hence 
symptoms associated very well with the disease as proved by the statistical tests. 
Duration of illness 
 Most of the patient with the disease Cegana vatham reflected its symptoms 
over a period of 0-1 month which was confirmed during the history taking while 35% 
of the patients reported the data. 
Derangement in vatha 
 Viyanan and Samanan was affected in all 40 cases (100%).Abanan affected in 
8 cases 20% Devathathan affected in 12 cases (30%). 
Disturbances in Pitha 
 Mostly Sathagapitham was affected in all 40 cases (100%). 
Disturbances in Kabha 
 Almost Santhigam was affected in all 40 cases (100%). 
Udal Thathukkal 
 Saaram affected in 5% Enbu 100%  and Moolai affected in 87.5%.  
 Envagai Thervugal 
 In this study thontha naadi was noted in all 40 cases, malam was affected in 
62.5% of cases and. 
 In naadi 55% were vatha pitha naadi, 45% were pitha vatha naadi. 
Investigation 
 Laboratory investigations were done in all the cases before and after treatment.  
The significant variation occurs in parameters like ESR and HB, while other 
parameters have insignificant variation. 
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Pre clinical studies 
 The Bio chemical analysis of “MILAGU LEGIYAM” contains Calcium, 
Sulphate, Chloride, Ferrous iron,  Unsaturated compound, Reducing sugar, Amino 
acid. 
Pharmacological studies 
 The pharmacological studies done in MILAGU LEGIYAM revealed the 
presence of actions such as 
1. Anti – inflammatory action 
2. Analgesic activity. 
Toxicity studies 
 Acute toxicity and subacute studies in rats for “MILAGU LEGIYAM” 
revealed that it has no toxicity effect. 
Treatment 
 The treatment was aimed to retain the Deranged thoshas and providing relief 
from symptoms.  Before treatment the patients were advised to take vellai ennai 15ml 
with hot water during morning for first day of treatment. 
 From the second day onwards Internal medicine MILAGU LEGIYAM  6gm 
two times a day after food and Seeraga thylam is given as external. 
 At the time of treatment the patients were advised to follow pathiyam and 
specifically advised to avoid foods which increase vadha. 
 Along with the course of treatment the complementary therapy like Varmam is 
given additionally to some of the patients. 
 The outcome of this study is mainly assessed by reduction in pain in cervical 
region.  Increased range of reduction of restricted movements and improvement in 
quality of life universal pain assessment scale was also used to detect proper outcome.  
No adverse effect was noted for both internal and external medicine along with the 
course of treatment. 
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SUMMARY 
 40 cases with Cegana vatham were diagnosed clinically based on yugi - 800 
and admitted in the Inpatient ward and Outpatient ward of post graduate department 
of sirappu maruthuvam, Government Siddha Medical College Hospital, palayamkottai 
and treated by the trial medicines. 
 Laboratory diagnosis of Ceganavatham was done by siddha diagnostic 
principles and endorsed by modern methods of investigations. 
 The various siddha aspects of examination of the disease were carried out and 
were recorded in the proforma. 
 The trial medicine chosen for both internal and external treatments were 
Milagu legiyam – 6gms/days BD doses for forty eight days as per the severity 
of the diseases,Seeraga thylam (External) 
 Before starting the treatment careful detailed history was carried out and 
recorded for the forty selected cases. 
 During the period of treatment all the patients were put under pathiyam (A 
specific dietary regimen) 
 A periodical laboratory investigation was made for all the cases along with the 
radiological investigations. 
 The observations made during the clinical study shows that the main internal 
drug MILAGU LEGIYAM is clinically effective. 
 Though there was appreciable clinical improvement, there were not much 
remarkable radiographic changes. 
The action of external application Seeraga  thylam with Varmam as a 
Complementory therapy is also quite remarkable. 
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CONCLUSION 
 All 40 patients (25 OPD and 15 IP – 25 Cases with trial medicines and 
Massage, 15 Cases varmam along with trial medicines). Were treated for this 
dissertation work with Milagu Legiyam 6gm/day in twice a day divided doses and 
Seeraga thylam (externally) 
 In the preclinical study pharmacological evaluation of the trial drug shows. 
Significant analgesic effect 
Significant Anti inflammatory effect (Internal medicine) 
In the preclinical study toxicity study of “Milagu Legiyam” shows that the trial 
drug had no acute toxicity. 
The overall effect of the clinical trial drug are  
 Marked effect  - 77.5 % 
 Moderate effect - 12.5 % 
 Mild effect  - 7.5 % 
 No effect  - 2.5 % 
 This result of the clinical trial illustrates the marked effect of the drugs and 
complementary therapy. 
 The trial drug Milagu Legiyam and external Seeraga thylam is effective.  No 
adverse effects were noticed during the treatment period.  So the trial medicine is safe 
and easily preparable medicine.  
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Ingredients of  MILAGU LEGIYAM 
INTERNAL MEDICINE 
Milagu Akkirakaram 
Athimathuram Seeragam 
Kirambu Elakkai 
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Vaividangam Kostam 
Narukku Moolam Sathipathiri 
Thaen Kalkandu 
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Nei 
93 
 
  
  
  
  
Ingredients of  SEERAGA THYLAM 
EXTERNAL MEDICINE 
Seeragam Kostam 
Kichilikizhangu Karkadagashingi 
Arathai Omam 
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Valuzhuvai Karboga Arisi 
Kadukkai Pinchu Kadagurohini 
Indhuppu Kirambu 
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Ennai Aattupal 
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INTERNAL MEDICINE 
Milagu Legiyam 
 
EXTERNAL MEDICINE 
Seeraga Thylam 
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ANNEXURE - I 
PREPARATION AND PROPERTIES OF THE TRIAL DRUG 
TRIAL DRUG FOR THE TREATMENT 
INTERNAL DRUG: MILAGU LEGIYAM 
(Reference:Athmaratchamirtham-Page No:445) 
  
SOURCE OF RAW DRUG:  
      The drugs for the preparation of trial medicine are purchased from authorised 
centers. The raw drugs are identified and authenticated by medicinal botanist and 
staffs of Gunapadam department of government siddha medical college, palay. Then 
the raw drugs are purified and the trial drug will be prepared in PG Gunapadam lab of 
GSMC-Palayamkottai. 
 
INGREDIENTS: 
1. Milagu (Piper nigrum)                                -               100palam (3500grams) 
2. Akiragaram ( Anacyclus pyrethrum )         -               1palam (35 grams) 
3. Athimathuram ( Glycyrrizha glabra)           -               1palam (35 grams) 
4. Seeragam (Cuminum cyminum)                  -              1palam (35 grams)  
5. Aelam (Eletaria cardamomum)                    -              1palam (35 grams) 
6. Kirambu (Syzygium aromaticum)               -               1palam (35 grams) 
7. Vaividangam (Emblica ribes)                      -              1palam (35 grams) 
8. Kostam (Saussuria lappa) -              1palam (35 grams) 
9. Sathipathiri (Myristica fragrans)                  -               1palam (35 grams) 
10. Narrukku moolam ( Piper longum)            -               1palam (35 grams) 
11. Karkandu                                                   -              10 palam (350 gram) 
12. Then (Honey)                                            -               1/2padi (700 ml) 
13. Nei (Ghee)                                               -                1 padi (1400 ml) 
14. Thaneer (Water)                                        -               1 Thooni (21.5 lit) 
 
PURIFICATION OF RAW DRUGS  
MILAGU  :  Soak in butter milk for 3 days. Then fry the clay plate.       
AKIRAKARAM   :  Remove the adulterant and make it to dry on the 
    shade light                   
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SEERAGAM   :  Soak in Ca(OH)2 water on 21 hours then  dried in  
sun light. 
KIRAMBU   :  Remove the adulterant and fry it                                             
VAIVIDANGAM : Remove the adulterant and make it to dry on the shade  light 
 AELAM  :  Remove the adulterant and fry it  
THIPPLI     :  Remove the adulterant and fry it      
OMAM    : Soak in Ca (OH)2 water on 3 hours then sun dried                                                                                              
KOSTAM    :  Just remove the adulterant and make it dry on the  
shade  light   
THIPPILI MOOLAM :  Just remove the adulterant and make it to dry on the sun    
                                         light. 
JATHIPATHIRI   :  Just remove the adulterant and make   it to dry on the  
shade light.     
 
PREPARATION OF THE TRIAL DRUG 
                  Take the above raw drugs are powdered separately except Milagu mixed 
all together. Add milagu powder to 1 Thooni(21.5Lit.) of water and make Decoction 
(1:8), 10 palam(350g) of karkandu is added to the above decoction and make the 
sugar solution. Add the powdered raw drugs to the sugar solution stir well. Add 1padi 
(1400 ml) nei and stir well until it reaches the required consistency. Add ½ padi (700 
ml) honey and stir well. Store it in a separate dry airtight container. 
 
DRUG STORAGE AND DISTRIBUTION: 
                The trial drug “MILAGU LEGIYAM” is stored in clean and dry air tight 
containers. 
 The Legiyam is dispensed in airtight packets 
 For Outpatient one packet is given for seven days once. (to be taken 
twice daily) 
 For Inpatient every day the medicine packets will be dispensed in 
person. 
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PROPERTIES OF THE INGREDIENTS OF TRIAL DRUG 
2/lqtG;!
OuX!ohbv<gt<;< << << < !gxq, gibl<, Ogitgl<, sVlhf<kl<,!lisl<,!ljzbitq,!kqvr<gl<. 
Botanical Name: Piper nigrum 
Family Name: Piperaceae 
English Name: Black pepper 
Part Used: Dried unripe fruit 
Sju;!jgh<H,!giv<h<H/!!
ke<jl;<<< !ouh<hl</!
hqvqU;!giv<h<H/!
osb<jg;<<< !uiklmg<gq,!uQg<gr<gjvs<sq/!!
ohiKG{l<;<<< !
!
!!!Ogi[gqe<x!hg<guzq!Gb<bUOvi!gl<uik!
!!!Osi{qkr<g!Pk<kqx<Gt<!Okie<XOfib<.gi{vqb!
!!!giKOfib<!likv<Ge<ll<!gilijz!lf<kole<xQv<!!
!!!WKOfib<!gibqVg<gqz<!=r<G/!
!! .Okjvbv<!G{uigml<!
Chemical constituents: 
  Alkaloids-Piperine,piperidine,chavicin (Present in Masocarp), Dipiperamides D&E 
 
2.!ng<gqvgivl<;< << << < !
OuX!ohbv<gt<;< << << < !ng<gqvgivl<!
Botanical name: Anacyclus pyrethrum 
Family name: Asteraceae  
English name: Pelitory 
Sju;!giv<h<H!
ke<jl;<<< !ouh<hl<!
hqvqU;!giv<h<H!
ohiKg<G{l<;!< << << < !
!!!ng<g!vgivl<!nke<Ohv<!djvk<kg<giz<!
!!!dg<gqvgiz<!nk<Okiml<!YMr<gi{<.Lg<gqblib<g<!
!!!ogi{<miz<!szl<DXl<!ogil<hjeOb"!kigSvl<!
!!!g{<miz<!hbrf<OkiMr<!gi{<!
! .ngk<kqbv<!G{uigml<!
Chemical Constituents: Pellitonin, pyrethrin. 
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4/!nkqlKvl<<<<!
OuX!ohbv<gt<;< << << < !nkqr<gl<?!nm<c,!lK~gl<?!Ge<xqOuv/<!
Botanical Name: Glycyrrhiza glabra 
Family Name: Fabaceae 
English Name: Indian liquorice 
Part Used: Root 
Sju;!-eqh<H!
ke<jl;<<< sQkl<!
hqvqU;!-eqh<H!
ohiKg<G{l<!;!< << << < !
!!!!!!gk<kqbvq!Lh<hq{qbiz<!uVH{<!kigr<!
!!!!!!g{<O{ib<de<!likl<uqg<gz<!uzqou{<!Gm<ml<!
!!!!!!hqk<kolZl<!HVg<gq!gqvqs<svl<!Nuv<k<k!!
!!!!!!hqk<klk!&v<s<js!uqm!higl<!ouh<hf<!
!!!!!!kk<kquV!uikOsi!{qkr<gi!lijz!
!!!!!!sVuuqmr<!gilqbOfib<!kiK!fm<mr<!
!!!!!!Gk<kqVlz<!Nsqbr<gl<!-kp<Ofib<!-f<K!
!!!!!!Gbh<H[l<Ohil<!lK~goleg<!%Xr<!giOz/!!
! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.Okjvbv<!G{uigml</!
Chemical Constituents: Glycyrrhizin, Asparagin, Sugar, Starch, Acid resin, Gum, 
Mucilage, Phosphoric, Shulphuric & Malic acid, Calcium & Magnisium Salts. 
osb<jg;<<< !Ogijpbx<xq,!sqXfQv<!ohVg<gq,!lzlqzg<gq, dvlig<gq/!
!
5/!sQvgl<;Q <Q <Q < !
OuX! ohbv<gt<;< << << < ! njs,! sQvq,! dhGl<hQsl<,! fx<sQvq,! Kk<ksil<hzl, <! hqk<k! fisqeq,!
Ohise!GOmivq,!Olk<kqbl</!
Botanical Name: Cuminum cyminum 
Family Name: Apiaceae 
English Name: Cumin seeds 
Part Used: Seeds 
Sju;!giv<h<H!
ke<jl;<<< !km<hl<!
hqvqU;!-eqh<H!
! !
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ohiKg<G{l<!;< << << < !
!!!!!!!!!!!uiBouiM!fisqOfib<!ue<hqk<kR<!OsviK!
!!!!!!!!!!!gibl<!ofgqpiK!g{<GtqVf<!.!K~blzv<g<!
!!!!!!!!!!!givtgh<!oh{<lbqOz"!jgg{<m!kqk<kjeBR<!
!!!!!!!!!!!sQvgk<jk!fQkqeLf<!kqe<!
! !!!!!!!!!!!!!!!!!!!!!!!!!!.ngk<kqbv<!G{uigml<!
!
osb<jg;<<< !ngm<Muib<ugx<xq,ouh<hL{<mig<gq,hsqk<kQk<K~{<c/!
Chemical Constituents: Essential oil-thymene, cuminol, cumic aldehyde. 
 
6/!Wzl<;< << !
OuX!ohbv<gt<;< << << < !NR<sq,!Ogivr<gl,<!Kc/!!
Botanical Name: Elettaria cardamomum. 
Family Name: Zingiberaceae 
Part used: Fruit 
Sju;!giv<h<H!
ke<jl;<<< !ouh<hl<!
hqvqU;!giv<h<H!
ohiKg<G{l<!< << << < !
!!!!!oki{<jm!uib<gUt<!kiZG!kr<gtqz<!
!!!!!Okie<Xl<!Ofibkq!sivl<!Olgk<kiz<!
!!!!!d{<jm!Ohiz<wPr<!gm<c!gvqs<svl<!
!!!!!dpjz!uif<kq!sqzf<kq!uq]R<Svl<!
!!!!!h{<jm!oug<jg!uqkigOfib<!gisLl<!
!!!!!hiPR<!Osilh<!hq{quqf<K!fm<mLl<!
!!!!!n{<jm!bQjtue<!hqk<kl<!-jug<ogz<zil<!
!!!!!Nz!lir<glp<!Wz!lVf<Ok/!
osb<jg;<<< !ouh<hL{<mig<gq,!ngm<Muib<ugx<xq,!sqXfQv<h<ohVg<gq/!
Chemical constituents: Fixed oil, Essential oil, Volatile oil, Terpinyl acetate, 
Terpineol,Limonene. 
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6.!gqvil<H<<< !
OuXohbv<gt<;< << << < !nR<Sgl, <!dx<gml< ,!gVuib<g<gqvil<H,!Osisl, <!kqvtq,!uvir<gl</!
Botanical name: Syzygium aromaticum 
Family name: Myrtaceae 
English name: Cloves 
Part used: Flower 
Sju;!giv<h<H!
ke<jl;<<< !ouh<hl<!
hqvqU;!giv<h<H!
ohiKg<G{l<;< << << < !
!!!!!!!!!!hqk<k!lbg<gl<!OhkqobiM!uif<kqBl<Ohil<!
!!!!!!!!!!Sk<kuqvk!<kg<gMh<Hf<!Okie<XOli.olk<k!
!!!!!!!!!!-zur<gr<!ogi{<muVg<!Ogx<!SgliGl<!
!!!!!!!!!!lzlr<Og!gm<Mole!uip<k<K/!
osb<jg;<<< !-squgx<xq,!ngm<Muib<ugx<xq,!hsqk<kQk<K~{<c/!
Chemical Constituents: Essential oil, B-caryophyllene, Eugenyl acetate 
 
8/!uib<uqmr<gl<;< < << < << < < !
!
OuXohbv<gt<;< << << < !Ogvtl< ,!uv<eje/!
Botanical name    : Emblica ribes  
Family name : Primulaceae 
English name : False black 
Part used :  Dried fruit  
Sju;!jgh<H!
ke<jl;<<< !ouh<hl<!
hqvqU;!giv<h<H!
ohiKg<G{l;<< << << <!
!!!!!!!!!!hi{<MGm<ml<!Ge<ll<!hVf<K~z!Ofib<uikf<!
!!!!!!!!!!kQ{<M!kqvquqmf<!sqvf<K{<ml<.H,{<mlc!
!!!!!!!!!!Ofib<uqtr<gg<!gim<mik!F{<gqVlq!biseh<H{<!
!!!!!!!!!!uib<uqtr<gr<gim<muqVliv</!
osb<jg;<<< !Hpg<ogiz<zq,!ngm<Muib<ugx<xq,!ouh<hL{<mig<gq/!
Chemical constituents: Emblic acid, Tanin, Alkaloids-Cristembine, Vidangin, 
Emblin. 
103 
 
9/!Ogi]<ml<< << << <!
OuX!ohbv<gt<;< << << < !Gvi,!yzq/!
English name: Costus root 
Botanical name: Saussuria lappa 
Family name: Asteraceae 
Part used: Root 
Sju;!jgh<H,!uqXuqXh<H!
ke<jl;<<< !ouh<hl<!
hqvqU;!giv<h<H!
ohiKg<G{l<;< << << < !
!!!!!!!!!!kqm<cgUt<!ngMgtR<!ose<eq!fiuib<!
!!!!!!!!!!osxqhq{qouh<!hjkh<Hki!uv<k<kl<!Djk!
!!!!!!!!!!Lm<MobP!Ljtuqv{l<!Suis!gisl<!
!!!!!!!!!!&cgk<Oki!mvUlv!uqmr<gt<!Olgg<!
!!!!!!!!!!gm<cn\!gz<zquqm!higl<!H,k!
!!!!!!!!!!g{l<hiz!gqvgoliM!kiK!fm<mR<!
!!!!!!!!!!osim<cuV!hqvlqhqk<kl<!-juobi!Vr<Og!
!!!!!!!!!!okijzBl<uqv!{ivqg<Gs<!Sgh<OhvxiOl/!
osb<jg;<<< !ouh<hL{<mig<gq,!dvlig<gq,!ouh<hL{<mig<gq/!
Chemical constituents: Alkaloid-Saussurine, Terpene alcohol, Costol, Costic acid, 
Aplotaxene, a costene B costene 
 
9.!sikqhk<kqvq< << !
OuX!ohbv<gt<;< << << < !\ikqhk<kqvq,!uSuisq/!
English name: Arillus of the nut 
Botanical name: Myrstica fragrans 
Family name: Myrstaceae 
Part used: Arill 
Sju;!giv<h<H!
ke<jl;<<< !ouh<hl<!
hqvqU;!giv<h<H!
! !
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ohiKg<G{l<;< << << < !
!!!!!!!!!!sikqkVl<!hk<kqvqg<Gk<!kihs<!Svf<k{qBl<!
!!!!!!!!!!YKgqe<x!hqk<kl<!dbVr<gi{<.kiKuqVk<kq!
!!!!!!!!!!B{<mir<!gqvg{qObi!Omikg<!gpqs<szXl<!
!!!!!!!!!!H{<mir<!GjxOb!hgv</!
Chemical constituents: Fixed oil (Butter of nut mug), Myristicene, Myristirol, 
Myristic acid, Myristin. 
10.!kqh<hqzq!&zl<;< << << < !
OuX!ohbv<gt<;< << << < !gqvf<kqgl< ,!gqvf<kqOuv< ,!g{<mkqh<hqzq,!Olic!Ouv< ,!fXg<G&zl< ,!
fXg<G!kqh<hqzq/!
English name: Long pepper root 
Botanical name: Pipper longum 
Family name: Piperaceae 
Part used: Root 
Sju;!giv<h<H!
ke<jl;!ouh<hl<< < << < << < <!
hqvqU;!giv<h<H!
ohiKg<G{l<;< << << < !
!!!!!!!!!!kighqk<kR<!Osigf<!k{qbis<!SvlqVlz<!
!!!!!!!!!!Olgr<!Gvx<gl<lz<!olb<g<gMh<Hl<.WGr<gi{<!!
!!!!!!!!!!kqh<hqzq&!zr<e{<mk<!kqh<hqzqb!kil<fXg<Gk<!
!!!!!!!!!!kqh<hqzqobe<!OxobiVg<gix<!osh<H/!
Chemical constituents: Piperin, resin, Starch, Gum. 
 
11.Yll<;< << !
OuXohbv<gt<;< << << < !nsOlikgl, <!kqh<hqbl/<!
Botanical name:Trachyspermum ammi. 
Family name:Apiaceae 
English name: The Bishops seeds 
Part used:!Seeds 
Sju;!giv<h<H!
ke<jl;<<< !ouh<hl<!
hqvqU;!giv<h<H!
!
!
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ohiKg<G{l<;< << << < !
!!!!!!!!!!!!!sQkSvr<!gisR<!osvqbilf<!kl<ohiVlz<!
!!!!!!!!!!!!!Ohkqbqjvs<!szgMh<H!Ohvill<.YkqVlz<!
!!!!!!!!!!!!!hz<oziMhz<!&zl<!hglqjuOfi!obe<osBOli@!
!!!!!!!!!!!!!osiz<oziMhl<!Yloles<!osiz</!
osb<jg;<<< !hsqk<kQk<K~{<c,!npgzgx<xq,!ouh<hL{<mig<gq,!dvlig<gq, -squgx<xq/ 
Chemical Constituents: Essential oil,Thymol. 
 
11.!ofb<;< << !
English Name:Ghee 
ohiKg<G{l<;/< << << < !
!!!!!!!!!!!kigLp!jzgm<gl<!uif<kq!hqk<kl<!uiBhqv!
!!!!!!!!!!!Olgl<!ubqx<oxvqU!uqg<gzpz<.ligisr<!
!!!!!!!!!!!Ge<ll<!uxm<sq!Gmx<Hvm<m!z^<kqgm<gR<!
!!!!!!!!!!!osie<&zl<!Ohig<gfqjxk<!Kh<H/!
!
23/!Oke<;<<< !
ohiKg<G{l<;< << << < !
NBTm!Em<c{l!Ovisq!bgg<ghL!
Olb!upgl<!utv<k<kqMr<gi{<.Kib!!
lkqb!olEuke!likvOs!fiTl<!
Hkqb!fXf<Okeix<!Hgz</!
Sju;!-eqh<H!!
osb<jg;<<< ! dt<tipx<xq,! lzlqtg<gq,! Kuv<h<hq,! npgzgx<xq,! Ogijpbgx<xq,!
hsqk<kQk<K~{<c,!dvlig<gq,!K~g<gL{<mig<gq/!!
External Medicine: 
       (Reference:Sarabenthirar vaidya Muraigal) 
sQvgk<jkzl<;Q < <Q < <Q < < !
gf<klqG!sQvgl<ui!ZTjuOgim<mr<!!
giv<Ohig!uvqsqgx<!gmgsqr<gq!
bqf<Kh<Hg<!gs<Osizr<!gMGOvigq{q!
obpqOzilr<!gqvil<HKuv<s<!sqjgbvk<jk!
bqf<kujg!ujgbqEg<Ogiv<!gpR<Sfipq!
ob{<o{Bm!eim<Mh<hi!eipq%m<c!
ouf<kUm!uqXk<Kg<ogi{<!Mmzqx<H,sqz<!
ouGuikf<!kQVlQ!kxqf<Kosb<Ob.!
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Ingredients: 
1. Seeragam (Cuminum cyminum) 
2. Kostam (Costus speciousus) 
3. Karkadaga Shingi (Rhus succedanea) 
4. Kichilik-Kizhangu (Curcuma zedoaria) 
5. Omam (Trachyspermum ammi) 
6. Arattai (Alpinia galanga) 
7. Valuzhuvai (Celastrus painculatus) 
8. Karpokarisi (Psoralea corylifolia) 
9. Kadugurohini (Picrorhiza kurroa) 
10. KadukkaiPinchu (Terminalia chebula) 
11. Kirambu (Syzygium aromaticum) 
12. Indhuppu ( Rock salt) 
13. Ennai (Gingley oil) 
14. Aattuppaal (Goat milk) 
METHOD OF PREPARATION OF SEERAGAM THYLAM  
Grind the above raw drugs to powder.  Mix the powder with goat milk and oil 
then boil it. Then filter the oil and kept it in air tight container. 
2/!sQvgl<Q <Q <Q <!
OuX! ohbv<gt<;< << << < ! njs,! sQvq,! dhGl<hQsl<,! fx<sQvq,! Kk<ksil<hzl, <! hqk<k! fisqeq,!
Ohise!GOmivq,!Olk<kqbl</!
Botanical Name : Cuminum cyminum 
Family Name: Apiaceae 
English Name: Cumin seeds 
Part Used: Seeds 
Sju;!giv<h<H!
ke<jl;<<< !km<hl<!
hqvqU;!-eqh<H!
ohiKg<G{l<!;< << << < !
!!!!!!uiBouiM!fisqOfib<!ue<hqk<kR<!OsviK!
!!!!!!gibl<!ofgqpiK!g{<GtqVf<!.!K~blzv<g<!
!!!!!!givtgh<!oh{<lbqOz"!jgg{<m!kqk<kjeBR<!
!!!!!!sQvgk<jk!fQkqeLf<!kqe<!
! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.ngk<kqbv<!G{uigml<!
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!
osb<jg;<<< !ngm<Muib<ugx<xq,ouh<hL{<mig<gq,hsqk<kQk<K~{<c/!
Chemical Constituents: Essential oil-thymene, cuminol, cumic aldehyde. 
 
2.!Ogi]<ml<< << << <!
OuX!ohbv<gt<;< << << < !Gvi,!yzq/!
English name: Costus root 
Botanical name: Saussuria lappa 
Family name:Asteraceae 
Part used: Root 
Sju;!jgh<H,!uqXuqXh<H!
ke<jl;<<< !ouh<hl<!
hqvqU;!giv<h<H!
ohiKg<G{l<;< << << < !
!!!!kqm<cgUt<!ngMgtR<!ose<eq!fiuib<!
!!!!osxqhq{qouh<!hjkh<Hki!uv<k<kl<!Djk!
!!!!Lm<MobP!Ljtuqv{l<!Suis!gisl<!
!!!!&cgk<Oki!mvUlv!uqmr<gt<!Olgg<!
!!!!gm<cn\!gz<zquqm!higl<!H,k!
!!!!g{l<hiz!gqvgoliM!kiK!fm<mR<!
!!!!osim<cuV!hqvlqhqk<kl<!-juobi!Vr<Og!
!!!!okijzBl<uqv!{ivqg<Gs<!Sgh<OhvxiOl/!
osb<jg;<<< !ouh<hL{<mig<gq,!dvlig<gq!!
Chemical constituents: Alkaloid-Saussurine,Terpene alcohol,Costol, Costic acid, 
Aplotaxene, a costene B costene. 
 
4/!gi<gmgsqr<gq;< << << < !
OuXohbv<gt<;< << << < !gx<gimgsqr<gq!
Botanical name: Rhus succedanea. 
Family name: Anacardiaceae. 
English name: Gall. 
Part used: Gall. 
Sju;!Kui<h<H!
<ke<jl;<<< !giv<h<H!
hqvqU;!giv<h<H!
!
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ohiKg<G{l<;< << << < !
!!!!!!!!!!gi<gmg!sqr<gq!ghr<gisl<!=jtobiM!
!!!!!!!!!!Lg<gz<!gqvi{q!Lkqvqjvs<sz<.ohig<ogeOu!
!!!!!!!!!!siMgqe<x!OhkqjbBR<!siMl<!nvqjubjvg<!
!!!!!!!!!!%Mkqxr<!ogiMg<Gr<!%X.!
osb<jg;<<< !Kuv<h<hq,!dvlig<gq,!ouh<hL{<mig<gq/!
Chemical Constituents: Essential oil,Tannin. 
 
5/!gqvil<H<<< !
OuXohbv<gt<;< << << < !nR<Sgl< ,!dx<gml,<!gVuib<g<gqvil<H,!Osisl, <!kqvtq,!uvir<gl</!
Botanical name: Syzygium aromaticum 
Family name:Myrtaceae 
English name: Cloves 
Part used: Flower 
Sju;!giv<h<H!
ke<jl;<<< !ouh<hl<!
hqvqU;!giv<h<H!
ohiKg<G{l<;< << << < !
!!!!!!!!!!!!hqk<k!lbg<gl<!OhkqobiM!uif<kqBl<Ohil<!
!!!!!!!!!!!!Sk<kuqvk!<kg<gMh<Hf<!Okie<XOli.olk<k!
!!!!!!!!!!!!-zur<gr<!ogi{<muVg<!Ogx<!SgliGl<!
!!!!!!!!!!!!lzlr<Og!gm<Mole!uip<k<K/!
osb<jg;<<< !-squgx<xq,!ngm<Muib<ugx<xq,!hsqk<kQk<K~{<c//!
Chemical Constituents: Essential oil,B-caryophyllene,eugenyl acetate. 
 
5.!gqs<sqzqg<gqpr<G< < << < << < < !
OuXohbv<gt<;< << << < !H,zir<gqpr<G,!gs<Osizl, <!gv<s<$vl</!
Botanical name: Curcuma zedoria 
Family name: zingiberaceae 
English name: Round zedory 
Part used: Tubers 
Sju;!jgh<H!!
ke<jl;<<< !ouh<hl<!
hqvqU;!giv<h<H!
!
!
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ohiKg<G{l<;< << << < !
!!!!!!!!)ym<Ml<*fx<!gqs<sqzqbq!o{i{<gqpr<!Gr<ghLl<!
!!!!!!!!H,m<MLm!Ll<H{<[l<!Ohil</!
osb<jg;<<< !ouh<hL{<mig<gq,!ngm<Muib<ugx<xq,!hsqk<kQk<K~{<c/!
Chemical Constituents: Organic acids, Cumin arabins, Albuminoids,essential oil. 
 
6.!Yll<;< << !
OuXohbv<gt<;< << << < !nsOlikl< ,!kqh<hqbl</!
Botanical name: Trachyspermum ammi 
Family name:Apiaceae 
English name: Bishop’s weed 
Part used: Seeds!!
Sju;!giv<h<H 
ke<jl;<<< !ouh<hl<!
hqvqU;!giv<h<H 
ohiKg<G{<<< l<;!<<< !
!!!!!!!!!!sQkSvr<!gisR<!osvqbilf<!kl<ohiVlz<!
!!!!!!!!!!Ohkqbqjvs<!sz<gMh<H!Ohvill<.YkqVlz<!
!!!!!!!!!!hz<oziMhz<!&zl<!hglqjuOfi!obe<osBOli@!
!!!!!!!!!!osiz<oziMOhil<!Yloles<!osiz</!
osb<jg;<<< ! hsqk<kQk<K~{<c,  npgzgx<xq,! dvlig<gq, ouh<hL{<mig<gq,!
ngm<Muib<ugx<xq,!-squgx<xq/ 
Chemical Constituents: Essential oil,Thymol 
 
8/nvk<jk<<< !
OuXohbv<gt<;!< << << < sqx<xvk<jk!
Botanical name: Alpinia galanga 
Family name: Zingiberaceae 
English name: Java galangal  
Part used:!Rhizome 
Sju;!giv<h<H!
ke<jl;!<<< ouh<hl<!
hqvqU;!giv<h<H!
ohiKg<G{l<;!< << << < !
!!!!!!!!!!!oki{<jmbqx<gm<!Mr<ghk<jkk<!Kvk<!Kvk<kquqMl<!
!!!!!!!!!!!h{<jms<sQ!kk<jkh<!hxg<gcg<Gl<.og{<jmuqpq!
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!!!!!!!!!!!lqe<Oe"!gvh<hjeOu!xig<Gl<!hsqogiMg<Gl<!
!!!!!!!!!!!osie<Oeil<!nvk<jks<!Sgl<!
osb<jg;<<< !Ogijpbgx<xq,!ouh<hgx<xq,!hsqk<kQk<K~{<c/!
Chemical Constituents: Campheride, Glangin and Alpinin 
 
8.!uiZTju;!
OuXohbv<gt<;< << << < !gr<G{q,!liz<gr<G{q,!nkqhxqs<sl</!!
Botanical name: Celastraus paniculatus 
 Family name: Celastraceae 
English name: Climbing staff plant 
Part used:!Seeds 
Sju;!jgh<H!
ke<jl;<<< !ouh<hl<!
hqvqU;!giv<h<H!
ohiKg<G{l<;< << << < !
!! ubqx<Xg<!gMh<Huzq!lixig<!gqvi{q!
!! hbqk<kqr<!gislz!hf<kR<.!sbqg<goui{is<!
!! $kqgi!uikLl<!Ohif<!okiz<ui!ZTjuuqjkg<!
!! Gikqfu!sqk<kv<!bil</!
osb<jg;<<< ! ouh<hL{<mig<gq,! uqbv<juohVg<gq,! ficBvlig<gq,! dmx<Okx<xq,!
gill<ohVg<gq/!
Chemical Constituents: Tannin 
 
:/!giv<Ohigvqsq<<< !
OuXohbv<gt<;< << << < !giv<Hui!nvqsq,!hiGsq/!
Botanical name: Psoralea corylifolia 
Family name: Fabaceae 
English name: Babchi Seeds 
Part used:!Seeds 
Sju;!jgh<H!
ke<jl;<<< !ouh<hl<!
hqvqU;!giv<h<H!
ohiKg<G{l<;!< << << < !
!!!!!!!!!!giv<Ohig!lilvqsq!g{<mix<!gvh<hie<H{<!
!!!!!!!!!!hQv<sGu!fR<sqjuOhil<!hqk<kL{<mil<.!hiv<lQkqz<!
!
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!!!!!!!!!!uik!ghfjls<sz<!ue<osixqsq!vr<GlXR<!
!!!!!!!!!!sQk!lzv<g<Gpib<!osh<H/!!!!
osb<jg;<<< !lzlqtg<gq,!ouh<hL{<mig<gq/!
Chemical Constituents: Essential oil,Albumin,Sugar,Magnese 
!
21/!gMGOvigq{q!
OuXohbv<gt<;< << << < !gMOvigq{q,!gmgOvigq{q/!
Botanical name: Picrorhiza kurroa. 
Family name: Plantaginaceae. 
English name: Green Hellbore Rhizome.  
Part used: Rhizome!
ohiKg<G{l<;!< << << < !
!!!!!!!!!!!lif<kR<!Svjlbl<!uiBSvh<!hieilR<!
!!!!!!!!!!!Osv<f<klzg<!gm<M!kqvqOkiml<.!Ohif<kohim<Mh<!
!!!!!!!!!!!H{<ubqX!OfibqjuOhil<!ohix<ogicOb.!OhkqB{<mil<!
!!!!!!!!!!!kq{<gMG!Ovig{qg<Gk<!Okv<!
osb<jg;<<< ! Ljxouh<hgx<xq,! ohVr<gpqs<sZ{<mig<gq,! hsqk<kQk<K~{<c,!
Gmx<HPugx<xq/!
Chemical Constituents: Wax, Cathartic acid,Glucoside-picorrhizin,Glucose. 
 
11.!gMg<gib<hqR<S< < << < << < < ;!
OuXohbv<gt<;< << << < ! nvqkgq,! njhbe<,! hk<kqbl,<! nLkl, <! nu<uqbki,! Oskgq,!
ueKv<g<gq,Oskgq,!nf<ke<,!nzqbe,<!nl<Vki,!gM,!squi,!Ovigq{q,!Olgl</!
Botanical name: Terminalia chebula. 
Family name: Combretaceae. 
English name: Chebulic Myrobalam Ink nut. 
Part used:!Dried immature fruit. 
Sju;!Kuv<h<H,!-eqh<H,!Htqh<H,!giv<h<H,!jgh<H/!!
ke<jl;<<< !ouh<hl</!
hqvqU;!-eqh<H!
ohiKg<G{l<;!< << << < !
!!!!!!!!!!!kijm!gPk<kg<gq!kiZ!Gxqbquqmh<!
!!!!!!!!!!!hQjm!sqzqhkLx<!OhkqLml<.!Njmobm<mik<!
!!!!!!!!!!!K~zlqc!H{<uik!Osi{qgi!
!!!!!!!!!!!mizlqc!Ohil<uvqg<gi!biz</!
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osb<jg;!<<< ! !
Chemical Constituent: Astringent, Tannic acid,Gallic acid,Chebulinic acid 
!!
23/-f<Kh<H< << << < !
OuXohbv<gt<;< << << < ! jsf<kul,<! sqf<K~vl< ,! sf<kqvEh<H,! lkq%v<jl,! lkqBh<H,!
lqf<kis<osiz</!
English name: Sodium chloride lmpura!         
ohiKg<G{l<;!!< << << < !
!!!!!!!!!!!!!“nm<mGe<l!lf<kl<!nsqv<g<gvR<$v<!sQkhqk<kf<!
!!!!!!!!!!!!!Km<jubl<!fich<H{<!Omimr<gt<.ogm<mlzg<!
!!!!!!!!!!!!!gm<Muqm!uqf<jkbg<!gilqbOfib<!ue<gvh<hie<!
!!!!!!!!!!!!!uqm<Muqm!uqf<Kh<jh!uqt</’’!
osb<jg;<<< !lzlqtig<gq,!ngm<Muib<ugx<xq,!sqXfQv<ohVg<gq,!hsqk<kQk<K~{<c/!!!
Chemical Constituents:   
 
13.!wt<tqe<!ofb<;< < << < << < < !
Botanical name: Sesamum indigum 
Family name: Pedaliaceae 
English name: Gingley oil 
Part used: Seeds. 
osb<jg;<<< !lzlqtg<gq,!dt<tpix<xq,!VKU{<mig<gq,!hix<ohVg<gq/ 
Chemical Constituents: 70%liquids,60% of glycosides of olecacid,linoleic 
acid,fats,stearin,palmitin. 
25/!Nm<Mh<hiz<< < << < << < < 
Zoological name: Capra aegagrus hircus 
ohiKG{l<;<<< !
!!!!!!!!!out<tim<M!hiZg<GOluqbfx<!xQhelif<!
!!!!!!!!!kt<tiM!uikhqk<kR<!sif<klil<.dt<tqjvh<Hs<!
!!!!!!!!!sQklkq!sivR<!sqOz]<llXl<!H{<{iXl<!
!!!!!!!!!uik!sqOz]<lLh<Ohi!lib<f<K/!
Chemical constituents; β-lactalbulin, χ-casein, αs2- casein, potassium, chloride, 
vitamin B6 and vitamin B12. 
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ANNEXURES -II 
QUALITATIVE AND QUANTITATIVE ANALYSIS 
BIO-CHEMICAL ANALYSIS OF MILAGU LEGIYAM (IN POWDER FORM) 
Preparation of the extract:   
  5gms of the drug was weighed accurately and placed in a 250ml clean beaker.  
Then 50ml of distilled water is added and dissolved well.  Then it is boiled well for 
about 10 minutes.  It is cooled and filtered in a 100ml volumetric flask and then it is 
made to 100ml with distilled water.  This fluid is taken for analysis. 
 
QUALITATIVE ANALYSIS 
S.NO EXPERIMENT OBSERVATION INFERENCE 
1.  
TEST FOR CALCIUM 
2ml of the above prepared extract is taken 
in a clean test tube. To this add 2ml of 4% 
Ammonium oxalate solution. 
A white precipitate is 
formed. 
Indicates the 
presence of 
calcium. 
2. 
TEST FOR SULPHATE 
2ml of the extract is added to 5% Barium 
chloride solution. 
A white precipitate is 
formed. 
Indicates the 
presence of 
sulphate. 
3.  
TEST FOR CHLORIDE 
The extract is treated with silver nitrate 
solution. 
A white precipitate is 
formed. 
Indicates the 
presence of 
chloride. 
4. 
TEST FOR CARBONATE 
The substance is treated with 
concentrated HCL. 
No Brisk 
effervescence is 
formed 
Absence of 
carbonate 
5. 
 
TEST FOR STARCH 
The extract is added with weak iodine 
solution. 
No Blue colour is 
formed. 
Absence of 
starch. 
6.  
TEST FOR FERRIC IRON 
The extract is acidified with Glacial 
acetic acid and potassium ferro cyanide. 
No blue colour is 
formed. 
Absence of ferric 
iron. 
7. 
TEST OF FERROUS IRON  
The extract is treated with concentrated 
Nitric acid and Ammonium thio cyanide 
solution. 
Blood red colour is 
formed. 
Indicates the 
presence of 
ferrous iron. 
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8.  
TEST FOR PHOSPHATE 
The extract is treated with Ammonium 
Molybdate and concentrated nitric acid. 
No yellow 
precipitate is formed. 
Absence of 
phosphate. 
9.  
TEST FOR ALBUMIN 
The extract is treated with Esbach’s 
reagent. 
No Yellow 
precipitate is formed. 
Absence of 
Albumin. 
10.  
TEST FOR TANNIC ACID 
The extract is treated with ferric chloride. 
No Blue black 
precipitate is formed. 
Absence of 
tannic acid. 
11.  
TEST FOR UNSATURATION 
Potassium permanganate solution is 
added to the extract. 
It gets decolourised. 
 
Indicates the 
presence of 
unsaturated 
compound. 
12.  
TEST FOR THE REDUCING SUGAR 
5ml of Benedict’s qualitative solution is 
taken in a test tube and allowed to boil for 
2 mts and add 8-10 drops of the extract 
and again boil it for 2 minutes. 
Colour change 
occurs. 
Indicates the 
presence of 
Reducing sugar. 
13.  
TEST FOR AMINO ACID 
One or two drops of the extract is placed 
on a filter paper and dried well. After 
drying, 1% Ninhydrin is sprayed over the 
same and dried it well. 
 Violet colour is 
formed. 
Indicates the 
presence of 
Amino acid. 
14. 
TEST FOR ZINC 
The extract is treated with Potassium 
Ferrocyanide. 
No white precipitate 
is formed 
Absence of Zinc. 
 
Inference: 
  The given sample of “MILAGU LEGIYAM” contains Calcium, Sulphate, 
Chloride, Ferrous iron,  Unsaturated compound, Reducing sugar, Amino acid. 
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PHARMACOLOGICAL ANALYSIS 
EFFECT OF MILAGU LEGIYAM WITH HONEY/GHEE ON CARRAGEENAN-
INDUCED LOCALISED INFLAMMATORY PAIN IN RATS 
 
SUMMARY 
The study plan was developed based on the guidelines of Vogel1 and also it has reference to 
Chao Ma and Jun-Ming Zhang2 and Walker et al. 3, Winter CA, Risley EA, Nuss GW. 
Carrageenin induced edema in hind paw of the rat as an assay for anti-inflammatory 
drugs. Proc Soc Exp Biol Med. 1962;111:544–7. 
 
Objective 
  To study the anti-inflammatory effect of MILAGU LEGIYAM were prepared WITH 
HONEY/GHEE in the rat model of Carrageenan-induced localized inflammation.  
 
Methods: 
Test System 
Species : Rat   
Strain : Albino Wister 
Age : 6-8 weeks at the time of dosing 
Total no. of Rats : 24 
Sex : Male 
Weight                   :    150 gm 
 
 The animals were housed in polypropylene cages with stainless steel top grills having 
facilities for holding pellet food and drinking water in bottle with stainless steel sipper tube. 
Each cage contained 6 rats. All rats had free access to potable water and standard pelleted 
laboratory animal diet ad libitum. Paddy husk was used as bedding material. The animals were 
divided into 5 groups (6 rats/group). Localized inflammatory pain was induced in all groups of 
animals by intraplantar injection of carrageenan (50 µl of 3% suspension).  
 One day before the experiment, three basal readings of hind paw in each rat were 
recorded. Group 1 received vehicle orally, Group 2 received a standard drug Diclofenac 
sodium (10 mg/kg i.p), whereas groups 3,4and 5 received MILAGU LEGIYAM. The doses of 
MILAGU LEGIYAM  were prepared WITH HONEY/GHEE, whereas Diclofenac sodium 
was dissolved in normal saline. After 30 min, the rats were challenged with subcutaneous 
116 
 
injection of 0.1 ml of 1% w/v solution of carrageenan into the sub plantar region of left paw. 
The paw was marked with ink at the level of lateral malleolus and immersed in mercury up to 
the mark. The paw volume was measured at 0, 1, 2, 3, 4, 5 and 6th hr after carrageenin injection 
using Digital Plethysmometer. The difference between initial and subsequent reading gave the 
actual edema volume.  
 
DOSAGE SCHEDULE: 
 The required dose for mice/rat will be calculated by using the standard dose calculation 
procedure from recommended clinical dose. 
 
CONVERSION FORMULA: 
Human dose is 6000 mg /kg day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 150 gm of Rat 
6000 mg x 2(a) x 0.018 (b) = 108 (c) /150 gm of Rat 
108/1000x150 = 16.2 mg  
Experimental Doses Calculated as per the standard procedures are 
 
S.No Groups Dose /kg, weight 
 
Volume of administration 
 
1 Vehicle Control -- 
1 ml 
 
2 Therapeutic Dose 
16.2 mg /kg 
 
1 ml 
3 Middle  Dose 81mg/kg 
1 ml 
 
4 High Dose 405mg/kg 1 ml 
 
EXPERIMENTAL DESIGN: 
Group-I:   Served as a negative control (0.1ml of 1% carrageenin) 
Group-II: Served as standard received Diclofenac sodium (10mg/kg, i.p) + 
                  (0.1ml of 1% carrageenin) 
Group-III: Received MILAGU LEGIYAM were prepared WITH HONEY/GHEE  
        (16.2 mg /kg) + (0.1ml of 1% carrageenin) 
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Group IV: Received MILAGU LEGIYAM were prepared WITH HONEY/GHEE  
                   (81 mg/kg ) + (0.1ml of 1% carrageenin) 
Group V: Received MILAGU LEGIYAM were prepared WITH HONEY/GHEE  
                   (405 mg/kg ) + (0.1ml of 1% carrageenin) 
 
TABLE: EFFECT OF MILAGU LEGIYAM WITH HONEY/GHEE ON 
Carrageenin -INDUCED PAW EDEMA IN RATS- BODY WEIGHT in gms 
 
 
Group 
 
 
Only 
Carrageenan 
 
 
Carrageenan+ 
Diclofenac 
10mg/kg 
Carrageenan+ 
ML L.D 
Carrageenan 
+ML M.D 
Carrageenan+ 
ML H.D 
 
INITIAL 
BODY 
WEIGHT 
 
134±1.155 136±4 146.3±2.028* 144.7±1.764* 135.7±2.028 
 
Values are expressed as the mean ± S.D. Statistical significance (p) calculated 
by one way ANOVA followed by dunnett’s. ns- not significant **P< 0.05 calculated 
by comparing treated group with control group 
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TABLE: EFFECT OF MILAGU LEGIYAM WITH HONEY/GHEE ON 
Carrageenin -INDUCED PAW EDEMA IN RATS 
 
 
Group 
Mean 
paw 
volume 
before 
carragee
nan 
injection 
Paw Volume after 
induction with 
carrageenin Increase in 
paw volume (ml) after 
carrageenan injection 
(mean ± SEM) 
 
Paw Volume after induction with 
carrageenin 
Increase in paw volume (ml) after 
carrageenan injection (mean ± SEM) 
 
0 min 30 min 1hr 2hr 3h 4h 5h 6h 
Only 
Carragee
nan 
 
3.497± 
0.1225 
 
7.163± 
0.4528 
 
7.847
± 
0.238
4 
8.167
± 
0.134
8 
8.447
± 
0.059
25 
8.447± 
0.04055 
8.23± 
0.04726 
8.093± 
0.05207 
 
Carragee
nan + 
Standard 
 
 
3.367± 
0.07424 
6.72± 
0.302**
* 
7.8± 
0.190
8 
7.2± 
0.061
1* 
 
7.203
± 
0.131
7* 
 
6.873± 
0.02906
*** 
 
6.54± 
0.1724*
** 
5.993± 
0.07513
*** 
 
Carragee
nan + 
ML L.D 
 
3.237± 
0.133 
7.06± 
0.1026*
** 
7.587
± 
0.168
3 
8.337
± 
0.299
2 
8.333
± 
0.480
7 
8.16± 
0.1405 
7.967± 
0.07688 
7.44± 
0.2948 
 
Carragee
nan + 
ML M.D 
3.427± 
0.2483 
6.92± 
0.04619
*** 
7.353
± 
0.070
55 
7.533
± 
0.296
9 
 
7.113
± 
0.063
6** 
7.193± 
0.2136*
** 
 
6.44± 
0.04619
*** 
5.973± 
0.07424
*** 
 
Carragee
nan 
+ML 
H.D 
4.133± 
0.1618 
7.093± 
0.1122*
** 
7.3± 
0.151 
7.2± 
0.140
5* 
 
7.06± 
0.136
1** 
6.88± 
0.08327
*** 
 
6.26± 
0.1311*
** 
5.587± 
0.208**
* 
 
Values are expressed as the mean ± S.D. Statistical significance (p) calculated by one 
way ANOVA followed by dunnett’s. ns- not significant **P< 0.05 calculated by comparing 
treated group with control group 
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EFFECT OF MILAGU LEGIYAM WITH HONEY/GHEE ON Carrageenin -INDUCED 
PAW EDEMA IN RATS 
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FIG- EFFECT OF MILAGU LEGIYAM WITH HONEY/GHEE ON Carrageenin -
INDUCED PAW EDEMA IN RATS 
 
       
                  Only Carrageenin                                        Carrageenin+ STD 
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Carrageenin+ ML H.D 
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EFFECT OF MILAGU LEGIYAM WITH HONEY/GHEE ON ACETIC ACID INDUCED 
WRITHING IN MICE1 
1. Kaneria MS, Naik SR, Kohli RK. Anti-inflammatory,antiarthritic and analgesic activity of a 
herbal formulation. Indian J.Experimental Biol. 2007; 45: 279. 
 
       Acetic acid induced writhing method was adopted for evaluation of analgesic activity. 
Writhing is defined as a stretch, tension to one side, extension of hind legs, contraction of the 
abdomen so that the abdomen of mice touches the floor, turning of trunk (twist). Any writhing is 
considered as a positive response. 
MATERIAL AND METHODS 
ANIMALS: 
          Healthy Swiss albino rats of either sex weighing 20-25g were used in this study. All the 
animals were obtained from Animal house of the KMCH College of Pharmacy, Coimbatore. The 
animals were housed comfortably in a group of six in a single clean plastic cage with a metal 
frame lid on its top. They were housed under standard environmental conditions of temperature 
(24±1°C) and relative humidity of 30-70 %. A 12:12 h light dark cycle was followed. All 
animals had free access to water and standard pelletized laboratory animal diet ad libitum. All 
the experimental procedures and protocols used in this study were reviewed and approved via the 
Approval No. ----------------------------- by the Institutional Animal Ethical Committee (IAEC) of 
KMCH College of Pharmacy, Coimbatore (685/PO/Re/S/2002/CPSCEA Dated 21st August 2002 
constituted in accordance with the guidelines of the CPCSEA, Government of India. 
DRUGS: 
         Acetic acid (Sigma Chemical Co. Bangalore, India) and Indomethacin  were purchased 
from (Ranbaxy, India). All drugs were dissolved in saline. The different doses of 
VATHATHIRKU LEGHIYAM were prepared WITH HONEY/GHEE.The control group 
received vehicle as control. All drugs were prepared just before use. 
 PREPARATION OF ACETIC ACID: 
         A solution of acetic acid (1% v/v) in distilled water was prepared. 
DOSAGE SCHEDULE: 
  The required dose for mice/rat will be calculated by using the standard dose calculation 
procedure from recommended clinical dose. 
 
CONVERSION FORMULA: 
Human dose is 6000 mg /kg day 
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Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 30 gm of mice 
6000 mg x 2(a) x 0.018 (b) = 108 (c) /30 gm of mice 
108/1000x30 = 3.24 mg  
Experimental Doses Calculated as per the standard procedures are 
 
 
S.No 
 
Groups 
 
Dose /kg, weight 
 
Volume of administration 
1 Vehicle Control -- 0.5 ml 
2 Therapeutic Dose 3.24 mg /kg 0.5 ml 
3 Middle  Dose 16.2mg/kg 0.5 ml 
4 High Dose 81mg/kg 0.5 ml 
 
EXPERIMENTAL PROCEUDRE: 
 
       GROUP 1 – CONTROL (IP injection of 0.1 ml 1% acetic acid) 
       GROUP 2 -- IP injection of 0.1 ml 1% acetic acid + Indomethacin (5mg/kg, i.p) 
       GROUP 3 -- 0.1 ml 1% acetic acid (ip) + MILAGU LEGIYAM WITH HONEY/GHEE  
                                   3.24mg /kg(po)                        
                                      
       GROUP 4 -- 0.1 ml 1% acetic acid (ip) + MILAGU LEGIYAM WITH HONEY/GHEE     
                                   16.2mg/kg(po) 
      GROUP 5 -- 0.1 ml 1% acetic acid (ip) + MILAGU LEGIYAM WITH HONEY/GHEE  
                                   81mg/kg(po) 
 PROCEDURE: 
            Wister albino mice of either sex were divided into five different groups each containing  
Six animals, the animals were marked individually. Food was withdrawn 12 hours prior to drug 
administration till completion of experiment. The animals were weighed and numbered 
appropriately. The test and standard drugs were given orally. After 60 minutes writhing was 
induced by intra-peritoneal injection of 1% acetic acid in volume of 0.1 ml/10g body weight. The 
writhing episodes were recorded for 30 minutes; stretching movements consisting of arching of 
the back, elongation of body and extension of hind limbs were counted. 
  Anti-nociceptive  activity was expressed as the percentage inhibition of abdominal 
constrictions using the ratio:     (Control mean – Treated mean) × 100/Control mean 
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EFFECT OF MILAGU LEGIYAM WITH HONEY/GHEE ON ACETIC ACID INDUCED 
WRITHING IN MICE1 
 
GROUP 
 
No of Writhing (30min) 
 
Inhibition (%) 
 
 
CONTROL 
 
 
45.33±4.807 
 
--- 
 
Indomethacin (5mg/kg, i.p) 
 
 
22.67±1.764*** 
 
49.98 % 
 
ML+ LOW DOSE 
0.028mg/kg(po) 
 
 
48±5.292 
 
5.89 % 
 
 
ML  + MIDDLE DOSE 
0.014mg/kg(po) 
 
 
32±1.732 
 
29.40 % 
 
ML + HIGH DOSE 
0.28mg/kg(po) 
 
 
26±2.309 
 
42.64 % 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated 
by one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, 
***P < 0.05 calculate by comparing treated group with CONTROL group.      
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EFFECT OF MILAGU LEGIYAM WITH HONEY/GHEE ON HOT PLATE METHOD 
IN MICE1 
 
1. Turner RA. Screening methods in pharmacology. In: Turner, R., Hebborn, P. (eds.). Academic 
press, New York. 1965; 100.  
 
            The paws of mice and rats are very sensitive to heat at temperatures which are not                 
damaging the skin. The responses are jumping, withdrawal of the paws and licking of the paws. 
 MATERIAL AND METHODS 
ANIMALS: 
          Healthy Swiss albino rats of either sex weighing 20-25g were used in this study. All the 
animals were obtained from Animal house of the KMCH College of Pharmacy, Coimbatore. The 
animals were housed comfortably in a group of six in a single clean plastic cage with a metal 
frame lid on its top. They were housed under standard environmental conditions of temperature 
(24±1°C) and relative humidity of 30-70 %. A 12:12 h light dark cycle was followed. All 
animals had free access to water and standard pelletized laboratory animal diet ad libitum. All 
the experimental procedures and protocols used in this study were reviewed and approved via the 
Approval No. ----------------------------- by the Institutional Animal Ethical Committee (IAEC) of 
KMCH College of Pharmacy, Coimbatore (685/PO/Re/S/2002/CPSCEA Dated 21st August 2002 
constituted in accordance with the guidelines of the CPCSEA, Government of India. 
      The hot plate, which is commercially available, consists of a electrically heated surface. The 
temperature is controlled for 55° to 56 °C. This can be a copper plate or a heated glass surface. 
The animals are placed on the hot plate and the time until either licking or jumping occurs is 
recorded by a stop-watch. 
 
EXPERIMENTAL PROCEUDRE: 
       GROUP 1 – CONTROL  
       GROUP 2 – Pentazocine (10mg/kg, I.P) 
       GROUP 3 -- MILAGU LEGIYAM WITH HONEY/GHEE  
                                   3.24 mg /kg(po)           
      GROUP 4 – MILAGU LEGIYAM WITH HONEY/GHEE     
                                      16.2mg/kg(po) 
      GROUP 5 -- MILAGU LEGIYAM WITH HONEY/GHEE     
                                      81mg/kg(po) 
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PROCEUDRE: 
  Mice were screened by placing them on a hot plate maintained at 55±1ºC and recording 
the reaction time in seconds for forepaw licking or jumping. Only mice which reacted within 
15sec and which did not show large variation when tested on four separate occasions, each 
15min apart, were taken for the test. The time for forepaw licking or jumping on the heated plate 
of the analgesiometer maintains at 55ºC was taken as the reaction time. Prior to treatment, the 
reaction time of each mouse (licking of the forepaws or jumping response) was done at 0- and 
10-min interval. The average of the two readings was obtained as the initial reaction time (Tb). 
The reaction time (Ta) following the administration of the ---------------, Pentazocine and distilled 
water was measured at 0.5, 1, 2, and 3h after latency period of 30min. 
 
The following calculation was:  
          Percentage analgesic activity = Ta-Tb/Tb × 100 
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EFFECT OF MILAGU LEGIYAM WITH HONEY/GHEE ON HOT PLATE 
METHOD IN MICE 
 
 
GROUP 
 
Reaction time in seconds at time (minutes) (mean ± sem) (mean ± 
sem) 
 
O mints 60 mints 90 mints 120 mints 180 mints 
 
CONTROL 
 
3.26±0.0
660 
 
4.65±0.138 
 
4.29±0.0683 
 
4.58±0.085 
 
4.36±0.136 
 
 
STANDARD 
 
3.14±0.0
918 
 
5.66±0.049*
** 
 
6.88±0.149*
** 
 
7.83±0.106*
** 
 
7.77±0.146*
** 
 
 
ML + LOW 
DOSE 
 
3.02±0.0
143 
 
7.44±0.061*
** 
 
7.98±0.118*
** 
 
8.22±0.169*
** 
 
7.55±0.055*
** 
 
 
ML + 
MIDDLE 
DOSE 
 
3.23±0.0
409 
 
7.66±0.072*
** 
 
7.43±0.118*
** 
 
7.42±0.124*
** 
 
7.16±0.132*
** 
 
 
ML + HIGH 
DOSE 
 
3.22±0.1
37 
 
6.22±0.108*
** 
 
6.89±0.084*
** 
 
7.66±0.073*
** 
 
7.0±0.157**
* 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by one 
way ANOVA  followed by dunnett’s ***P< 0.001, **P < 0.01,*P < 0.05 calculated by 
comparing treated group with CONTROL group. 
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ACUTE TOXICITY STUDY IN FEMALE WISTER RATS TO EVALUATE 
TOXICITY PROFILE OF MILAGU LEGIYAM WITH HONEY/GHEE 
 
Table 1. Test substance details 
Name of the test substance 
 
MILAGU LEGIYAM 
Colour of the test substance -Light brown 
Nature of the test substance Powder 
 
Table 2. Experimental protocol 
Name of the study Acute toxicity 
Guideline followed 
OECD 423 method-acute toxic class 
method 
Animals 
Healthy young adult female wister rats, 
nulliparous, non-pregnant 
Body weight 150-200 g 
Sex                       female 
Administration of dose and volume 
6000 mg/kg in 200g body weight, single 
dose in 1 ml 
Number of groups and animals 
5 groups and 3 animals in each group 
1000,2000,3000,5000and 6000mg/kg 
Route of administration Oral Cavage (po) 
Vechicle Honey/Ghee 
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Table3. Housing and feeding conditions 
Room temperature 22°C  ±  3°C 
Humidity 40-60% 
Light 12 h : 12h (light : dark cycle) 
Feed 
Standard laboratory animal food pellets 
with water ad libitum 
 
Table 4. Study period and observation parameters 
Initial once observation First 30 minutes and periodically 24 h 
Special attention First 1-4 h after drug administration 
Long term observation Upto 14 days 
Direct observation parameters 
Tremors, convulsions, salivation, 
diarrhea, lethargy, sleep and coma. 
Additional observation parameters 
Skin and fur, eyes and mucous 
membrane, respiratory, circulatory, 
autonomic and central nervous systems, 
somato motor activity and behavior 
pattern etc. 
  
The time of death, if any, is recorded. (Complete observations: annexure I). After 
administration of the drug, food is withheld for a further 1-2 hours. 
 
Study procedure 
  Acute oral toxicity was performed as per organization for economic co-
operation for development (OECD) guideline 423 method. The MILAGU 
LEGIYAM WITH HONEY/GHEE was administered in a single dose by tuberculin 
syringe. Animals are fasted 3 h prior to dosing (food was withheld for 3 h but not 
water). Following the period of fasting animals was weighed and test substance was 
administered orally at a dose of 1000,2000,3000,5000 and 6000mg/kg. After the 
MILAGU LEGIYAM WITH HONEY/GHEE administration, food was withheld 2 
h in mice. Animals are observed individually after at least once during the first 30 
minutes, periodically during the first 24 hrs, with special attention given during the 
first 4 hrs, and daily thereafter, for a total of 14 days.  
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REPORT 
Toxicological evaluation of MILAGU LEGIYAM WITH HONEY/GHEE 
Table:5 Effect of MILAGU LEGIYAM With Honey/Ghee on acute toxicity test in 
female rats. 
S.N 
 
 
Response 
Head Body Tail 
Before After Before After Before After 
1 Alertness Normal Normal Normal Normal Normal Normal 
2 Grooming Absent Absent Absent Absent Absent Absent 
3 Touch response Absent Absent Absent Absent Absent Absent 
4 Torch response Normal Normal Normal Normal Normal Normal 
5 Pain response Normal Normal Normal Normal Normal Normal 
6 Tremors Absent Absent Absent Absent Absent Absent 
7 Convulsion Absent Absent Absent Absent Absent Absent 
8 Righting reflux Normal Normal Normal Normal Normal Normal 
9 Gripping strength Normal Normal Normal Normal Normal Normal 
10 Pinna reflux Present Present Present Present Present Present 
11 Corneal reflux Present Present Present Present Present Present 
12 Writhing Absent Absent Absent Absent Absent Absent 
13 Pupils Normal Normal Normal Normal Normal Normal 
14 Urination Normal Normal Normal Normal Normal Normal 
15 Salivation Normal Normal Normal Normal Normal Normal 
16 Skin colour Normal Normal Normal Normal Normal Normal 
17 Lacrimation Normal Normal Normal Normal Normal Normal 
 
RESULT: 
  From acute toxicity study it was observed that the administration of MILAGU 
LEGIYAM WITH HONEY/GHEE to Female Wister rats did not induce drug-
related toxicity and mortality in the animals up to 6000mg/kg in 200g female Wister 
rats. So No-Observed-Adverse-Effect- Level (NOAEL) of MILAGU LEGIYAM 
with Honey/Ghee is 6000 mg/kg equal to human dose 
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DISCUSSION 
MILAGU LEGIYAM WITH HONEY/GHEE was administered single time 
at the doses of 1000,2000,3000,5000 and 6000mg/kg to female Wister rats and 
observed for consecutive 14 days after administration. Doses were selected based on 
the pilot study and literature review. All animals were observed daily once for any 
abnormal clinical signs. Weekly body weight and food consumption were recorded. 
No mortality was observed during the entire period of the study. Data obtained in this 
study indicated no significance physical and behavioral signs of any toxicity due to 
administration of MILAGU LEGIYAM WITH HONEY/GHEE at the doses of 
1000,2000,3000,5000 and 6000mg/kg to female Wister rats  
At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand held 
activity were observed. Home cage activities like Body position, Respiration, Clonic 
involuntary movement, Tonic involuntary movement, Palpebral closure, Approach 
response, Touch response, Pinna reflex, Sound responses, Tail pinch response were 
observed. Handheld activities like Reactivity, Handling, Palpebral closure, 
Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominal tone, Limb tone 
were observed. Functional and behavioral examination was normal in all treated 
groups. Food consumption of all treated animals was found normal as compared to 
normal group. 
 
SUMMARY & CONCLUSION: 
Summary: 
The present study was conducted to know single dose toxicity of MILAGU 
LEGIYAM WITH HONEY/GHEE on female Wister rats. The study was conducted 
using 15 female Wister rats. The female animals were selected for study of 8- 12 
weeks old with weight range of within ± 20 % of mean body weight at the time of 
randomization. The groups were numbered as group I, II, III, IV and V and dose with 
1000,2000,3000,5000 and 6000mg/kg of MILAGU LEGIYAM WITH 
HONEY/GHEE. The drug was administered by oral route single time and observed 
for 14 days. Daily the animals were observed for clinical signs and mortality.  
There were no physical and behavioral changes observed in Female Wister 
rats during 14 days. Mortality was not observed in any treatment groups. 
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Conclusion: 
The study shows that MILAGU LEGIYAM WITH HONEY/GHEE did not 
produce any toxic effect at dose of 1000,2000,3000,5000 and 6000mg/kg to rats. So 
No-Observed-Adverse-Effect-Level (NOAEL) of MILAGU LEGIYAM WITH 
HONEY/GHEE is 6000 mg/kg. 
 
7.0 ABBREVIATIONS 
No.   Number 
Mg  Milligram 
Kg   Kilogram 
LD50  Lethal Dose 50 
p.o  peros 
ML  Milliliter 
%   percentage 
R&D   Research and Development 
g%   Gram percentage 
g  Gram 
NOAEL  No-Observed-Adverse-Effect-Level 
MLD   Minimum Lethal Dose 
MTD   Maximum Tolerated Dose 
OECD Organisation of Economic Co-operation and Development 
CPCSEA  Committee for the Purpose of Control and Supervision of Experiments 
on Animals 
 
8.0 REFERENCES: 
1. OECD. Guideline for Testing of Chemicals 423, Acute oral toxicity (acute 
toxic class method). December 2001. 
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SUB-ACUTE TOXICITY STUDY IN WISTER RATS TO EVALUATE 
TOXICITY PROFILE OF MILAGU LEGIYAM WITH HONEY/GHEE  
 
Objective 
 The objective of this study is to evaluate the toxic effects, if any, as a result of 
the repeated once daily oral administration of MILAGU LEGIYAM WITH 
HONEY/GHEE to Wister Albino rats for a minimum period of 28 consecutive days. 
This study will provide information on any major toxic effects, target organs and a 
rationale for concluding the No-Observed-Adverse-Effect-Level (NOAEL) and/or No 
Observed Effect Level (NOEL) / LOEL (Low Observed Effect Level) and risk 
assessment in humans. 
 
1. Test Guidelines  
This study plan is prepared as per the following guidelines: 
Schedule – Y, Amendment version 2005, Drugs and Cosmetics Rules, 1945. 
OECD – 407 – Repeated dose 28-day Oral Toxicity Study in Rodents, Adopted 3 
October, 2008. 
 
1.1. Test System Details 
Species : Rat 
Strain  : Wister Albino  
Source    : Sree Venkateshwara Enterprises Pvt Ltd, Bangalore  
Age : 6-8 weeks  
Sex : Male / Female (nulliparous and non-pregnant) 
Body weight   : 0to 180.0 g 
0 
1.2.  Acclimatization 
Animals will be allowed to acclimatize to the experimental room conditions for five 
days prior to the commencement of dosing. During the acclimatization period, the 
animals will be observed daily for any apparent adverse clinical signs. Prior to 
assignment to the study and commencement of treatment, a detailed physical health 
examination will be performed on all animals by a veterinarian and animals with any 
evidence of ill health or poor physical condition will not selected for the study. 
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1.3. Randomization and Grouping 
On the starting day of dosing, the animals will be weighed and health examination 
will be performed by veterinarian. Animals will be randomly allocated to different 
groups according to their body weight by using MS-Excel sheet as described in the 
randomization SOP. Animals will be divided into four groups (vehicle control, low, 
intermediate, and high dose). At the initiation of the treatment, the body weight 
variation between the groups did not exceed ±20% of the mean weight of each sex. 
1.4. Animal Identification 
In each cage, animals will be identified with numbers by marking at the base of the 
ear. The cages will be identified with an attached colored cage label showing study 
number, study code, group number, sex, dose, strain, species, cage number, route of 
administration and animal number. 
 
2. Animal Husbandry 
2.1. Animal Welfare and approval 
The study was approved by the IAEC (SLS) and Committee for the Purpose of 
Control and Supervision of Experiments on Animals (CPCSEA registration number: 
Abc14).Their recommendations regarding animal care and handling will be followed. 
 
2.2. Environmental Conditions 
The temperature of the experimental room will be maintained at 22±30C and the 
relative humidity between 30-70 %. The photoperiod will be 12 hours light and 12 
hours dark cycles  
 
2.3. Housing Conditions 
Two animals will be housed in autoclaved polypropylene rat cages (Size in mm=L x 
W x H: 430 x 290 x 160) using paddy husk as the bedding material. Each cage will be 
fitted with a top grill having provision for keeping rodent pellet feed and an 
autoclaved polypropylene water bottle with stainless steel drinking nozzle. Cages will 
be placed on 3-tier racks and cage rotation will be performed every week. Cages will 
be changed at least twice a week. The cages and water bottles will be cleaned and 
autoclave sterilized. 
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2.4. Sanitation 
Each day, the floor of the animal room will be swept and mopped. Cages and bedding 
material will be changed once in three days and water bottles will be changed daily. 
All the experimental procedures will be done in a clean environment. 
 
2.5. Feed 
The experimental animals will be provided with irradiated rodent pellet feed ad 
libitum supplied from Sai feeds Pvt ltd, Chennai . Feed will be withheld for four hours 
prior to blood collection and necropsy. 
 
2.6. Drinking Water 
Animals will be provided with filtered drinking water ad libitum  passed through 
water filter system (Aquaguard™) in autoclaved polypropylene bottles. Water bottles 
will be changed daily. Microbial analysis of water will be carried out once monthly 
and the report is maintained in the study file. 
 
3. Personnel Safety 
All personnel handling animals undergo regular medical examination. Protective 
clothing like apron, face mask, head cap, and gloves will be used to maintain hygienic 
conditions. 
 
4. Materials and Methods  
4.1. Preparation of Dose formulation 
The dose formulation will be prepared under aseptic conditions as per SLS, SOP.  
4.2. Route of Administration and Justification 
Administration will be by oral gavage, as it is one of the possible routes of exposure. 
4.3. Frequency and Duration of Administration  
Once daily for 28 consecutive days 
4.4. Dosing Procedure 
The test item will be administered in once daily by oral gavage using a suitable 
intubation cannula fitted with a graduated syringe. The scheme of dosing and sacrifice 
time points are presented in the below below Table. 
4.5. Experimental Procedures 
All experimental procedures will be performed in accordance with the Study plan and 
Standard Operating Procedures (SOPs) of SLS. 
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4.6 DOSAGE SCHEDULE: 
  The required dose for mice/rat will be calculated by using the standard dose 
calculation procedure from recommended clinical dose. 
 
CONVERSION FORMULA: 
Human dose is 6000 mg /kg day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 150 gm of Rat 
6000 mg x 2(a) x 0.018 (b) = 108 (c) /150 gm of Rat 
108/1000x150 = 16.2 mg  
Experimental Doses Calculated as per the standard procedures are 
 
S.No 
 
Groups 
 
Dose /kg, weight 
 
Volume of 
administration 
 
1 Vehicle Control -- 1 ml 
2 Therapeutic Dose 16.2 mg /kg 1 ml 
3 Middle  Dose 81mg/kg 1 ml 
 
4 High Dose 405mg/kg 1 ml 
 
Experimental Design 
 
 
Group 
No. Group 
Dose                          
(mg/kg 
b.wt /day) 
No. of Animals 
Male Female 
G1 Vehicle control HONEY/GHEE 5 5 
G2 
Low dose of  MILAGU 
LEGIYAM WITH 
HONEY/GHEE 
16.2m g /kg 
 
5 5 
G3 
Intermediate dose MILAGU 
LEGIYAM WITH 
HONEY/GHEE 
81mg/kg 5 5 
G4 
High dose  MILAGU 
LEGIYAM WITH 
HONEY/GHEE 
405mg/kg 5 5 
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5. Observations 
Animals will be observed daily throughout the treatment period at regular intervals. 
During the treatment period, animals will be observed twice daily for any clinical 
signs of toxicity, morbidity and mortality. All the surviving animals will be sacrificed 
at the end of scheduled period and subjected to gross necropsy and histopathological 
evaluations. 
5.1.Clinical Signs 
All the animals will be subjected to cage-side (home-cage) observations twice a day 
for any clinical signs of toxicity, preferably at the same time each day and considering 
the peak period of anticipated effect. In addition to home cage observations, a detailed 
clinical examination will be performed once prior to dosing and weekly thereafter 
during treatment period.  
5.2. Morbidity/ Mortality 
All animals will be examined twice a day for mortality and signs of morbidity.  
5.3. Body Weights 
Body weights will be recorded at the beginning of acclimatization, before 
randomization, there after at weekly intervals and at the time of necropsy. 
5.4. Feed Consumption 
Feed consumption will be calculated on a weekly basis throughout the study period. 
5.5. Haematology and Clinical Biochemistry  
Hematology and clinical biochemistry tests will be performed with terminally 
collected blood samples on day-29 from all animals. Animals will be deprived of feed 
overnight and blood samples will be collected by tapping the ear for visibility of the 
vein site and inserted the needle into the marginal ear vein and collected the blood 
into micro centrifuge tube. Approximately 0.5 ml of blood will be collected in vials 
containing 1% EDTA (20µl) as an anticoagulant for hematological analysis. 
Approximately 2 ml blood will be collected from each animal in micro centrifuge 
tubes containing 15µl of heparin (19 units) and the plasma will be separated by 
centrifugation at 4000 rpm for ten minutes at 4oC. The plasma will be stored at -20 oC 
± 2 and used for all clinical chemistry analysis. 
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5.6. Hematology 
Erythrocyte count (RBC), Total Leucocyte count (WBC), Hemoglobin (Hb), 
Hematocrit (HCT), Mean Corpuscular Volume (MCV), Mean Corpuscular 
Hemoglobin (MCH), Mean Corpuscular Hemoglobin Concentration (MCHC) and 
Platelet (PLTC). 
5.7. Clinical Biochemistry  
Glucose, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), 
Alkaline phosphatase (ALP), Total protein, Albumin, Creatinine, Urea, Cholesterol, 
Triglycerides, Sodium, Potassium, Calcium, and  Chloride. 
5.8 Pathology 
All animals will be euthanized by CO2 asphyxiation and subjected to necropsy under 
the supervision of the veterinary pathologist. Different tissues/organs of thoracic, 
abdominal and cranial cavities will be examined for any gross pathological changes. 
Tissues from vehicle control and high dose groups will be subjected to detailed 
histopathological analysis (Ovaries/ testes,  kidneys, liver, lungs). The organs will be 
fixed using Bouin’s (reproductive organs) and 10% neutral buffered formalin 
(kidneys, liver, spleen, lungs).Processing of tissue will be done by spin tissue 
processer, embedding of the tissue by tissue embedder. The tissues will be initially 
trimmed to 10-20µ thickness and later 3-6µ to obtain thinner tissue sections by using 
rotary microtome. Haematoxylin and Eosin staining will be performed for all tissues. 
5.8. Organ Weights 
Absolute weights of adrenal glands, brain, ovaries/testes, epididymis/uterus, heart, 
kidneys, liver, spleen and lungs will be recorded for all the animals after trimming 
adherent tissue immediately after dissection from the animal. Paired organs will be 
weighed together. Relative weights of these organs against fasting animal body 
weights will be calculated and reported. 
6. Data Compilation  
Data will be summarised in a tabular form showing the number of animals, 
experimental design, dose groups, dose volume and concentrations, test item and 
vehicle control details. All findings like clinical signs, mortality and morbidity data, 
time of death, body weights, feed consumption, clinical signs, and necropsy and 
pathology observations will be recorded and given in the final report. One original 
copy of the final report is issued to the sponsor.  
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7. Statistical Analysis 
All the parameters of treated groups of both sex, viz. body weight, feed consumption, 
organ weights (absolute and relative), biochemical parameters, and hematology 
parameters will be analyzed using SPSS software, version 16.0 by using one-way 
ANOVA test with multiple comparison (vehicle controls treated groups) in the study 
report, and p value < 0.05 is considered as statistically significant.  
8. References 
1. Committee for the Purpose of Control and Supervision of Experiments on Animals 
(CPCSEA) guidelines for Laboratory Animal Facility, The Gazette of India, 1998. 
2. Hayes AW, 2000. Principles and Methods of Toxicology, 4
th
 ed., Taylor and Francis, 
London. 
3. Karl-Heinz Diehl, R. H. (2001). A Good Practice Guide to the Administration of 
Substances and Removal of Blood, Including Routes and Volumes. journal of applied 
toxicology , 15-23. 
4. OECD – 407 - Repeated dose 28-day oral Toxicity Study in Rodents, Adopted    
October 3, 2008. 
5. Schedule – Y, Amendment version 2005, Drugs and Cosmetics Rules, 1945. 
 
MATERIALS AND METHODS 
         ESTIMATION OF HEMATOLOGICAL PARAMETERS: 1 
Collection of blood for hematological studies 
After the treatment period the animals were anaesthetized by ketamine hydrochloride 
and the blood was collected from Retro-orbital sinus by using capillary into a 
centrifugation tube which contains EDTA for haematological parameters The 
haematological parameters like RBC, WBC and Hb percentage, Differential cell 
count, MCV, MCHC, Hematocrit, MCH, platelet count were estimated by the 
following procedures. 
1. ENUMERATION OF RED BLOOD CELLS: 1    Ramnic 2007) 
Reagents : RBC diluting fluid 
       Procedure: 
         Using a red blood cell pipette of haemocytometer, well mixed blood was drawn 
up to 0.5 mark and RBC diluting fluid was taken up to mark II. The fluid blood 
mixture was shaken and transferred onto the counting chamber. The cells were 
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allowed to settle to the bottom of the chamber for 2 min. See the fluid does not get 
dried. Using 45X or high power objective the RBC’s were counted uniformly in the 
larger corner squares.   
The cells were expressed as number of cells x1012/l 
2. ENUMERATION OF WBC: 2    John 1972) 
      Reagents: 
 Turk’s fluid: Turk’s fluid was prepared by mixing 2ml of acetic acid with 100 
ml of distilled water. To this 10 drop of aqueous methylene blue 3 %    w/v) was 
added. This solution haemolysis the red cells due to acidity so that counting of white 
cells becomes easy. 
Procedure:     
              Using a white blood cell pipette of haemocytometer, well mixed blood was 
drawn up to 0.5 mark and WBC diluting fluid was taken up to mark II. The fluid 
blood mixture was shaken and transferred onto the counting chamber. The cells were 
allowed to settle to the bottom of the chamber for 2 min. See the fluid does not get 
dried. 
 Using 10X or low power objective the WBC’s were counted uniformly in the 
larger corner squares.  
 The cells were expressed as number of cells/10mm. 
3. DIFFERENTIAL LEUCOCYTE COUNT: 3      John 1972) 
Reagent: 
              Leishmann’s stain: 150mg of powdered leishmann’s stain was dissolved in 
133ml of acetone free methanol. 
Procedure: 
 A blood film stained with leishmann’s stain was examined under oil 
immersion and the different types of WBCs were identified. The percentage 
distribution of these cells was then determined. Smears were made from anticoagulant 
blood specimens and stained with leishmann’s stain. The slides were preserved for 
counting the number of lymphocytes and neutrophils, per 100 cells were noted.  
 From the different Leukocyte count and WBC count, absolute lymphocyte and 
neutrophil count were calculated. 
                                 Number of neutrophils  
 Absolute neutrophil count =   _______________________________   x  TWBC 
                             100  
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                                                                  Number of lymphocytes  
 Absolute lymphocyte count =   _______________________________ x TWBC 
                             100 
 
 
DETERMINATION OF BIOCHEMICAL PARAMETERS: 
 
For assessment of biochemical parameters, blood samples were collected from the 
animals by puncturing the retro-orbital plexus and centrifuged. The serum collected 
after centrifugation was analyzed for various biochemical parameters like SGOT, 
SGPT, ALP,TC.TG,HDL All of the above biochemical parameters were estimated 
using semi autoanalyzer (Photometer 5010 V5+, Germany) with enzymatic kits 
procured from Piramal Healthcare limited, Lab Diagnostic Division, Mumbai, India. 
1. Total Cholesterol (TC)  
 Principle 
Determination of cholesterol is done after enzymatic hydrolysis and oxidation. 
The colorimetric indicator is quinoneimine, which is generated from 4-
aminoantipyrine and phenol by hydrogen peroxide under the catalytic action of 
peroxidase (trinder’s reaction). 
Cholesterol ester + H2O       CHE       Cholesterol + Fatty acid 
Cholesterol + O2          CHO      Cholesterol-3-one +H2O2 
2H2O2  + 4- Amino antipyrine + Phenol      POD          Quinonelimine + 4 H2O2 
Method  
 CHOD-PAP: Enzymatic photometric test 
Table 6: Reagents 
Goods buffer (pH 6.7) 50 mmol/ l 
Phenol 5 mmol/l 
4-aminoantipyrine 0.3 mmol/l 
Cholesterol estrase >  200 U/l 
Cholesterol oxidase >  100 U/l 
Peroxidase 3 KU/l 
Standard (5.2 mmol/l) 
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Assay procedure 
a. 1 ml (1000 µl) of reagent-1 is taken in a 5 ml test tube. 
b.  Added 0.01 ml (10 µl) of serum. 
c. Mixed well and incubated at 37◦C   for 5 min. 
d. Read the test sample. 
NORMAL RANGE: < 200 mg/dl in serum.      
1. Deeg R, Ziegenhorn J, Kinetic enzymatic method for automated determination of total 
cholesterol in serum, Clin. Chem., 1983, 29:1798-802. 
2. Triglycerides 
Principle 
Determination of triglycerides (TG) alters enzymatic splitting with lipoprotein 
lipase. Indicator is quinoneimine which is generated from 4-aminoantipyrine and 4- 
chlorophenol by hydrogen peroxidase under the catalytic action of peroxidase. 
Triglycerides              LPL           Glycerol + fatty acid 
Glycerol + ATP              GK            Glycerol-3-phosphate+ ADP 
Glycerol-3-phosphate +O2         GPO         Dihydroxyaceton phosphate + H2O2 
2H2O2  + 4- Amino antipyrine + 4- chlorophenol         POD     Quinonelimine + HCL + 
4H2O2 
Method 
 Colorimetric enzymatic test using glycerol-3-phosphate-oxidase (GPO). 
Reagents 
Components and concentrations in the test Goods buffer pH 7.2, 50 mmol/ l 
Table 7: Reagents 
4-chloroPhenol 4 mmol/l 
ATP 2 mmol/l 
Mg2+ 15 mmol/l 
Glycerokinase > 0.4 Kµ/l 
Peroxidase > 2 Kµ/l 
Lipoprotein lipase > 4 Kµ/l 
4-aminoantipyrine 0.5 mmol/l 
Glcerol-3-phosphate- oxidase > 1.5Kµ/l 
Standard (2.3 mmol/l) 
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Assay procedure 
a.  1 ml (1000 µl) of reagent-1 is taken in a 5 ml test tube. 
b. Added 0.01 ml (10 µl) of serum. 
c. Mixed well and incubated at 37◦C for 15 min. 
d. Read the test sample. 
 Normal Range: < 200 mg/dl in serum. 
1. Cole T.G, Klotzsch S.G, Mcnarmara J, Measurement of triglyceride concentration, In 
Rifai N, Warnick G.R, Dominiczak M.H, Handbook of lipoprotein testing, 
Washington:AACC, Press, 1997, 115-26. 
3. HDL Cholestrol 
 Principle  
Chylomicrons, VLDL and LDL are precipitated by adding phosphotungstic acid 
and magnesium ions to the sample. Centrifugation leaves only the HDL in the 
supernatant. The cholesterol content in it is determined enzymatically. 
Method 
Phosphotungstic acid precipitation method. 
Table 8: Reagents 
Phosphotungstic acid 0.55 mmol/l 
Magnesium chloride 25 mmol/l 
Assay procedure 
A.  Preparation of supernatant for the HDL-CHL estimation 
    Added 200 µl of serum to the 500 µl of HDL-Cholesterol precipitating reagent 
(from HDL kit) in 1.5 ml centrifuge tube and mixed well. Centrifuged the above 
solution at 4000 rpm for 10 min. 
B. Preparation of test sample for the estimation of HDL-Cholesterol 
a. Taken 1000 µl of reagent-1 (from cholesterol kit) in a 5 ml test tube. 
b. Added, 100 µl of supernatant from above centrifuged solution 
c. Mixed well and incubated at 37◦C for 15 min. 
d. Read the test sample.  
Normal Range: > 60 mg/dl in serum. 
1. Friedewald W.T, Levy R.T, Frederickson D.S, Estimation of VLDL and LDL 
cholesterol, Clin. Chem., 1972, 18:499-502. 
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4. ESTIMATION OF SERUM GLUTAMATE PYRUVATE TRANSAMINASES 
(SGPT/ ALT) 
1. Determination of aspartate aminotransferase (AST) 
      Aspartate aminotransferase, also known as Glutamate Oxaloacetate 
Transaminase (GOT) catalyses the transamination of L-aspartate and α keto glutarate 
to form oxaloacetate and L- glutamate. Oxaloacetate formed is coupled with 2,4- 
Dinitrophenyl hydrazine to form hydrazone, a brown coloured complex in alkaline 
medium which can be measured colorimetrically. 
Reagents  
Buffered aspartate  (pH 7.4); 2,4- DNPH reagent;  4N sodium hydroxide;  working 
pyruvate standard; solution I (prepared by diluting 1 ml of reagent 3 to 10 ml with 
purified water). 
Procedure  
 Rietman and Frankle method was adopted for the estimation of SGOT. 
(Reitmann S, Frankel S, 1957. A colorimetric method for the determination of serum 
oxaloacetic and glutamic pyruvate transminases. American Journal of Clinical 
Pathology.28: 56-63.The reaction systems used for this study included blank, 
standard, test (for each serum sample) and control (for each serum sample). 0.25 ml of 
buffered aspartate was added into all the test tubes. Then 0.05 ml of serum was added 
to the test group tubes and 0.05 ml of working pyruvate standard into the standard 
tubes. After proper mixing, all the tubes were kept for incubation at 37oC for 60 min, 
after which 0.25 ml each of 2,4- DNPH reagent was added into all the tubes. Then, 
0.05 ml of distilled water and 0.05 ml of each serum sample was added to the blank 
and the serum control tubes respectively. The mixture was allowed to stand at room 
temperature for 20 min. After incubation, 2.5 ml of solution I was added to all test 
tubes. Mixed properly and optical density was measured in a spectrophotometer at 
505 nm within 15 min. 
The enzyme activity was calculated as:-  
AST (GOT) activity in IU/L) = [(Absorbance of test - Absorbance of control)/ 
(Absorbance of standard - Absorbance of blank)] x concentration of the standard         
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2.  Determination of alanine aminotransferase (ALT) 
 Alanine aminotransferase, also known as Glutathione Peroxidase (GPT) 
catalyses the transamination of L-alanine and α keto glutarate to form pyruvate and L- 
Glutamate. Pyruvate so formed is coupled with 2,4 – Dinitrophenyl hydrazine to form 
a corresponding hydrazone, a brown coloured complex in alkaline medium which can 
be measured colorimetrically. 
Reagents 
Buffered alanine (pH 7.4), 2,4–DNPH, 4N sodium hydroxide, working pyruvate 
standard, solution I (prepared by diluting 1 ml of reagent 3 to 10 ml with purified 
water). 
Procedure  
 Rietman and Frankle method was dopted for the estimation of SGPT. The 
reaction systems used for this study included blank, standard, test (for each serum 
sample) and control (for each serum sample). 0.25 ml of buffered alanine was added 
into all the test tubes. This was followed by the addition of 0.05 ml of serum into the 
test group tubes and 0.05 ml of working pyruvate standard into the standard tubes. 
After proper mixing, all the tubes were kept for incubation at 37oC for 60 minutes, 
after which 0.25 ml each of 2,4- DNPH reagent was added into all the tubes. Then, 
0.05 ml of distilled water and 0.05 ml of each serum sample was added to the blank 
and the serum control tubes respectively. The mixture was allowed to stand at room 
temperature for 20 min. After incubation, 2.5 ml of solution I was added to all test 
tubes. Mixed properly and optical density was read against purified water in a 
spectrophotometer at 505 nm within 15 min. 
The enzyme activity was calculated as:- ALT (GPT) activity in IU/L) = [(Absorbance 
of test - Absorbance of control)/ (Absorbance of standard - Absorbance of blank)] x 
concentration of the standard.        
 
 3. Determination of alkaline phosphatase (ALP) 
  Alkaline phoshatase from serum converts phenyl phosphate to inorganic 
phosphate and phenol at pH 10.0. Phenol so formed reacts in alkaline medium with 4-
aminoantipyrine in presence of the oxidising agent potassium ferricyanide and forms 
an orange-red coloured complex, which can be measured spectrometrically. The color 
intensity is proportional to the enzyme activity. 
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Reagents: 
Buffered substrate 
Chromogen Reagent 
Phenol Standard, 10 mg% 
Procedure: 
  ALP was determined using the method of Kind (Kind PRM, King EJ, 1972. 
In-vitro determination of serum alkaline phosphatase. Journal of Clinical Pathology 7: 
321-22\). The working solution was prepared by reconstituting one vial of buffered 
substrate with 2.2 ml of water. 0.5 ml of working buffered substrate and 1.5 ml of 
purified water was dispensed to blank, standard, control and test. Mixed well and 
incubated at 370C for 3 min. 0.05 ml each of serum and phenol standard were added 
to test and standard test tubes respectively. Mixed well and incubated for 15 min at 
370C. Thereafter, 1 ml of chromogen reagent was added to all the test tubes. Then, 
added 0.05 ml of serum to control. Mixed well after addition of each reagent and the 
O.D of blank, standard, control and test were read against purified water at 510 nm. 
Serum alkaline phosphatase activity in KA units was calculated as follows  
[(O.D. Test-O.D. Control) / (O.D. Standard- O.D. Blank)] x 10 
 
4. Determination of bilirubin  
  In toxic liver, bilirubin levels are elevated. Hyperbilirubinemia can result from 
impaired hepatic uptake of unconjugated bilirubin, such a situation can occur in 
generalized liver cell injury, certain drugs (e.g Rifampin and probenecid) interfere 
with the rat uptake of bilirubin by the liver cell and may produce a mild unconjugated 
hyperbilirubinemia. Bilirubin level rises in diseases of hepatocytes, obstruction to 
bilirubin excretion into duodenum, in haemolysis and defects of hepatic uptake and 
conjugation of Bilirubin pigment such as Gilbert’s disease.  
 
Elevation of total serum bilirubin may occur due to:  
1. 1.Excessive haemolysis or destruction of the red blood cells.Eg:Haemolytic 
disease of the new born. 
2. 2.Liver diseases.Eg.Hepatitis and cirrhosis. 
3. 3.Obstruction of the biliary tract.Eg.Gall stones. 
  The method is based on the reaction of Sulfonilic acid with sodium nitrite to 
form azobilirubin which has maximum absorbance at 546nm in the aqueous solution. 
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The intensity of the color Produced is directly proportional to the amount of direct or 
total bilurubin concentration present in the sample. 
 
Reagents 
1. Diazo A-(Reagent-R1) :Ready to use 
2. Diazo B-(Reagent-R2):Ready to use 
3. Bilirubin Activater :Ready to use 
Procedure 
  Kind & King’s method was followed for the estimation of Bilirubin. Five 
hundred µl of working reagent was added to 50 µl of rat serum & incubated for 5 min 
at 37°C. Absorbance was measured AT 546 NM in semi auto analyzer against the 
standard. 
  The Bilirubin content was calculated using the following equation: 
  Total bilirubin (mg/dt) = Abs of the sample blank x 15. 
  Direct Bilirubin(mg/dt) = Abs of sample blank x 10. 
 
5. ESTIMATION OF UREA 
Urea is the nitrogen-containing end product of protein catabolism. States 
associated with elevated levels of urea in blood are referred to as hyper uremia or 
azotemia.  
Method 
  Estimation of urea was done by Urease-GLDH: enzymatic UV test.  
Principle 
Urea + 2H2O     Urease       2NH4 + 2HCO3 
2- Oxoglutarate +NH4+ +NADH      GLDH      L- Glutamate +NAD+ + H2O                                        
Table 14. Reagents 
 
 
 
 
 
 
 
 
R 1 
TRIS pH 7.8 120  mmol/l 
2-Oxoglutarate 7 mmol/l 
ADP 0.6 mmol/l 
Urease ≥ 6 KU/l 
GLDH ≥ 1 KU/l 
R 2 NADH 0.25 mmol 
R 3 Standard 40 mg/dl 
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Procedure 
a. Take 1000 µl of reagent-1 and 250 µl of reagent-2 in 5 ml test tube. 
b. To this, add 10 µl of serum. 
c. Mix well and immediately read the test sample at 340 nm Hg 334 nm Hg 
365 nm optical path 1 cm against reagent blank (2-point kinetic). 
d. And note down the value. 
Normal range: 10 – 50 mg/dl. 
 
6. ESTIMATION OF URIC ACID 
Uric acid and its salts are end products of the purine  metabolism. In gout the 
most common complication of  hyperuricemia, ie. Increased serum levels of uric acid 
lead to formation of  monosodium urate crystal around the joints. 
 
Method  
  Enzymatic photometric test using  TOOS (N ethyl- N (hydroxyl -3- 
sulfopropyl)-m- toluidin) 
 
Principle  
Uric acid + H2O + O2       uricase         Allantoin +CO2 +H2O2 
TOOS + 4 aminoantipyrine + 2H2O2      POD       Indamine + 3H2O 
Table 15.reagents 
R1 Phosphate buffer pH 7.0 100mmol/l 
TOOS 1mmol/l 
Ascorbate oxidase ≥1 KU/l 
R2 Phosphate buffer pH 7.0 100mmol/l 
4- amino antipyrine 0.3mmol/l 
K4 (Fe( CN)6) 10µmol/l 
Peroxidase ≥1KU/l 
Uricase ≥50U/l 
Procedure 
a. Take 800µl of  reagents -1 in a2ml centrifuge tube. 
b. To this add 20µl of serum. 
c. Mix well and incubate at 30°c for 5 minutes. 
d. Then add 200µl of reagent2 
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e. Mix well incubate for 5min at 37°c 
f. Measure the not down the values. 
Normal range: 1.9-8.2mg/dl 
 
 7. ESTIMATION OF CREATININE:  
Principle: 
  Creatinine forms a coloured complex with picrate in alkaline medium.  
The rate of formation of the complex is measured.  
Reagents: 
Reagent 1    Standard Creatinine (2mg/100ml) 
Reagent 2    Picric acid solution. 
Reagent 3     sodium hydroxide solution  
Procedure: 
 Take 500 µl of reagent -2 and 500 µl of reagent -3 in a 5ml test tube. To this 
add 100 µl of serum. Mix well and immediately read the test sample at Hg 492 nm 
1cm light path and note down the values.  
Normal range is 0.6 -1.1 mg/dl. 
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TABLE: 1   EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MILAGU 
LEGIYAM WITH HONEY/GHEE ON BODY WEIGHT IN Gram (PHYSICAL 
PARAMETER) 
GPs 
Control Low Dose Middle Dose High Dose 
Male Female Male Female Male Female Male Female 
1stwk 126.3±2.963 127±1 
126.3±2.
963 
126±1.15
5 
131±3.21
5 
126.3±2.
963 
129±1.73
2 
126.7±2.
906 
2ndw
k 
131.3±2.
848 
135±2.0
82 
133.3±2.
963 
136±1.15
5 
136.3±3.
18 
133.3±2.
028 
135.3±1.7
64 
131.3±2.
404 
3rdwk 139±1.732 
142±2.3
09 
141±3.21
5 144±2 
142.3±2.
404 
144±2.64
6 
143.3±2.1
86 
138±1.15
5 
 
4thwk 
149±2.3
09 
151.3±3.
283 
149.7±4.
055 
154±1.52
8 
151±2.51
7 
152.3±2.
728 
151±1.15
5 
145±1.52
8 
 
Values are expressed as the mean ± S.D 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MILAGU LEGIYAM WITH 
HONEY/GHEE ON FOOD INTAKE In Gram  
Groups Control Low Dose Middle Dose High Dose 
 
DAY 
Male Female Male Female Male Female Male Female 
Day 1 36 60 28 54 32 36 27 54 
DAY2 37 42 56 57 28 38 56 58 
DAY3 42 32 34 52 66 28 44 14 
Day 4 45 22 42 24 18 76 34 22 
DAY5 34 58 38 6 44 28 18 26 
Day 6 56 38 58 68 32 14 53 64 
DAY7 50 34 62 88 58 14 61 74 
DAY8 32 53 58 40 26 44 18 62 
Day 9 80 56 56 68 48 56 22 64 
DAY10 74 74 24 56 64 62 45 58 
Day 11 44 62 70 58 30 54 68 56 
DAY12 54 64 62 62 56 48 38 48 
DAY13 72 74 54 44 57 56 32 67 
Day 14 38 74 72 45 16 19 54 56 
DAY15 48 56 56 56 82 36 64 28 
Day 16 56 80 56 42 56 56 54 84 
DAY17 56 56 56 37 44 38 64 74 
DAY18 45 89 62 56 72 52 34 54 
Day 19 50 48 62 56 88 64 64 58 
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DAY20 16 35 20 75 35 56 72 34 
DAY21 34 56 47 68 56 56 34 18 
Day 22 64 45 62 58 64 46 28 64 
DAY23 78 56 42 56 22 54 42 34 
DAY24 58 18 34 78 46 40 50 55 
Day 25 64 30 68 44 56 60 42 56 
DAY26 80 34 64 64 52 68 45 32 
DAY27 46 58 56 38 56 58 26 45 
DAY28 68 56 58 32 32 45 36 58 
 
Values are expressed as the mean ± S.D 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MILAGU LEGIYAM WITH 
HONEY/GHEE  ON WATER INTAKE IN ml 
Groups Control Low Dose Middle Dose High Dose 
 
DAY Male Female Male Female Male Female Male Female 
Day 1 50 130 60 70 90 55 90 70 
DAY2 50 70 75 50 70 55 75 60 
DAY3 80 55 130 20 130 85 70 85 
Day 4 40 130 70 50 60 70 50 60 
DAY5 55 70 60 60 70 30 40 40 
Day 6 50 70 90 50 65 60 60 65 
DAY7 50 70 50 130 60 70 90 55 
DAY8 140 105 50 70 75 50 70 55 
Day 9 165 130 80 55 130 20 130 85 
DAY10 40 65 55 50 70 50 60 70 
Day 11 65 60 85 65 60 60 70 30 
DAY12 20 60 65 80 45 80 60 40 
DAY13 50 65 30 70 120 20 95 30 
Day 14 40 70 30 60 50 65 60 30 
DAY15 65 60 40 90 80 65 60 40 
Day 16 125 120 20 95 115 125 120 20 
DAY17 95 50 65 60 90 95 50 65 
DAY18 60 80 65 60 60 85 130 90 
Day 19 70 115 125 120 40 60 105 70 
DAY20 70 90 95 50 65 60 75 50 
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DAY21 70 60 85 130 90 50 95 85 
Day 22 125 120 40 105 70 140 40 60 
DAY23 95 50 65 65 80 60 95 60 
DAY24 85 130 90 60 70 110 90 75 
Day 25 60 105 70 110 85 130 60 125 
DAY26 60 65 80 60 50 70 110 90 
DAY27 75 60 70 70 40 70 90 50 
DAY28 125 110 85 60 85 65 50 110 
 
Values are expressed as the mean ± S.D 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MILAGU LEGIYAM WITH 
HONEY/GHEE ON ORGAN WEIGHT in gm 
 
 
Values arae expressed as mean ± SEM Statistical significance (p) calculated 
by one way ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
 
GROUP CONTROL 
 
Low Dose 
 
Middle Dose 
 
High Dose 
LIVER  
WEIGHT 
6.659±0.231 6.103±0.679 5.954±0.0775 6.449±0.383 
KIDNEY 
WEIGHT 
L 
0.8405±0.05
15 
0.798±0.075 0.7575±0.0255 0.7805±0.0155 
R 0.909±0.025 
0.7295±0.052
5 
0.687±0.002 0.772±0.09 
HEART 
WEIGHT 
0.83±0.062 0.841±0.152 0.7265±0.0055 0.997±0.232 
LUNGS  
WEIGHT 
1.388±0.404
5 
0.791±0.102 0.812±0.044 1.559±0.7695 
TESTIS 
WEIGH 
2.593±0.505 2.903±0.121 1.888±0.46 2.005±0.0225 
UTERUS 
0.4905±0.03
15 
0.4215±0.033
5 
0.4375±0.0855 0.514±0.188 
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F MILAGU LEGIYAM WITH 
HONEY/GHEE ON HAEMATOLOGICAL PARAMETERS 
 
Groups Control Low Dose Middle Dose High Dose 
Rbc (X106/µl)  
 
6.36±1.02 
 
6.335±0.555 
 
5.835±1.055 
 
5.305±0.415 
 
Wbc(X103/µl)  
 
12.55±1.21 
 
12.2±2.6 
 
12.7±0.9 
 
11.7±1.1 
 
 
Hb (g/dl) 
15.25±1.55 
 
17.1±0.3 
 
13.7±0.9 
 
13.8±0 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated 
by one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, 
***P < 0.05 calculate by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F MILAGU LEGIYAM WITH 
HONEY/GHEE ON BIOCHEMICAL PARAMETER (LIVER PROFILE) 
 
Groups Control Low Dose Middle Dose High Dose 
Total 
Bilirubin(mg/dl) 
 
0.755±0.125 
 
0.88±0.1 
 
0.61±0.05 
 
0.8±0.06 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated 
by one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, 
***P < 0.05 calculate by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F MILAGU LEGIYAM WITH 
HONEY/GHEE ON BIOCHEMICAL PARAMETER (LIVER PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
 
SGOT (U/L) 
 
83.7±11.1 
 
132.2±33.85 
 
78.6±10.8 
 
78.9±3.7 
 
SGPT (U/L) 64.65±13.75 
 
43.55±3.35 
 
43.2±13.6 
 
40.85±3.95 
 
ALP (U/L) 267.1±21.45 
 
256.1±0.85 
 
221.6±23 
 
222.5±11.5 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p) calculated 
by one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, 
***P < 0.05 calculate by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F MILAGU LEGIYAM WITH 
HONEY/GHEE ON BIOCHEMICAL PARAMETER (KIDNEY PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
Urea (mg/dl) 20.7±1.8 
 
36.35±1.55 
 
36.2±3.6 
 
24.6±1.8 
 
Uric acid 
(mg/dl) 
1.495±0.175 
 
1.2±0.12 
 
1.62±0.16 
 
1.65±0.33 
 
Creatinin 
(mg/dl) 
0.19±0.03 
 
0.385±0.045 
 
0.3±0.02 
 
0.24±0.02 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated 
by one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, 
***P < 0.05 calculate by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F MILAGU LEGIYAM WITH 
HONEY/GHEE ON BIOCHEMICAL PARAMETER (LIPID PROFILE) 
 
Groups Control Low Dose Middle Dose High Dose 
Total 
cholesterol 
(mg/dl) 
31.8±2.9 
 
45.75±2.05 
 
39±6.2 
 
34.65±2.15 
 
Triglycerides 
(mg/dl) 
96.69±2.09 
 
69.3±5.6 
 
64.35±0.55 
 
68.35±10.55 
 
HDL-
Cholesterol 
(mg/dl) 
9.25±0.35 
 
7.2±1.4 
 
5.55±0.85 
 
5.2±0.4 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated 
by one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, 
***P < 0.05 calculate by comparing treated group with CONTROL group.         
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RESULTS: 
    CLINICAL SIGNS: 
All animals in this study were free of toxic clinical signs throughout the 
dosing   period of 28 days. 
 Mortality: 
All animals in control and in all the treated dose groups survived throughout 
the dosing period of 28 days. 
 Body weight: 
Results of body weight determination of animals Table-1 from control and 
different dose groups exhibited comparable body weight gain throughout the dosing 
period of 28 days. 
Food consumption: 
During dosing and the post-dosing recovery period, the quantity of food 
consumed by animals from different dose groups was found to be comparable with 
that by control animals. 
Organ Weight: 
Group Mean Relative Organ Weights (% of body weight) are recorded in 
Table No.4 Comparison of organ weights of treated animals with respective control 
animals on day 29 was found to be comparable similarly. 
Hematological investigations: 
The results of hematological investigations (Table 4) conducted on day 29 
revealed following significant changes in the values of different parameters 
investigated when compared with those of respective controls; however, the increase 
or decrease in the values obtained was within normal biological and laboratory limits 
or the effect was not dose dependent. 
Biochemical Investigations: 
Results of Biochemical investigations conducted on days 29 and recorded in 
Table 2 revealed the following significant changes in the values of hepatic serum 
enzymes studied. When compared with those of respective control. However, the 
increase or decrease in the values obtained was within normal biological and 
laboratory limits. 
Histopathology: 
In histopathological examination, revealed normal architecture in comparison 
with control and treated animal. 
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 DISCUSSION: 
1)  All the animals from control and all the treated dose groups up to 500 mg/kg 
survived throughout the dosing period of 28 days. 
2)  No signs of toxicity were observed in animals from different dose groups during 
the dosing period of 28 days. 
3)  Animals from all the treated dose groups exhibited comparable body weight gain 
with that of controls throughout the dosing period of 28 days. 
4) Food consumption of control and treated animals was found to be comparable 
throughout the dosing period of 28 days 
5)   Haematological analysis conducted at the end of the dosing period on day 29, 
revealed no abnormalities attributable to the treatment. 
6) Biochemical analysis conducted at the end of the dosing period on day 29 no 
abnormalities attributable to the treatment. 
7) Organ weight data of animals sacrificed at the end of the dosing period was found 
to be comparable with that of respective controls. 
8) Histopathological examination revealed normal architecture in comparison with 
control and treated animal. 
 
 SUMMARY AND CONCLUSION:  
In conclusion MILAGU LEGIYAM WITH HONEY/GHEE can be 
considered safe, as it did not cause either any lethality or adverse changes with 
general behavior of rats and also there were no observable detrimental effects (100 to 
300 mg/kg body weight) over a period of 28 days. Our results have demonstrated that 
the MILAGU LEGIYAM WITH HONEY/GHEE is relatively safe when 
administered orally in rats. 
 
9.0 ABBREVATION 
No.   Number 
Mg  Milligram 
Kg   Kilogram 
LD50  Lethal Dose 50 
p.o.  peros 
mL  Milliliter 
%   percentage 
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R&D   Research and Development 
EDTA  Ethylene Diamine Tetra Acetic Acid 
M   Male 
g%   Gram percentage 
g  Gram 
NOAEL  No-Observed-Adverse-Effect-Level 
MLD   Minimum Lethal Dose 
MTD   Maximum Tolerated Dose 
OECD  Organisation of Economic Co-operation and Development 
CPCSEA  Committee for the Purpose of Control and Supervision of Experiments  
on Animals 
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HISTOPATHOLOGY   -  TOXICITY STUDY 
SPECIMEN     : A) Liver.    Group –    : Milagu legiyam 
 
                                                       
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
 Section from liver shows lobular architecture with interface hepatitis. Individual Hepatocytes 
shows reactive atypia. Portal triad shows no significant pathology. Central vein and Sinusoids 
show dilatation. 
10x shows altered architecture 10x shows interface hepatitis with 
cytoplasmic vacuolation and binucleation 
10x shows mild altered architecture with interface 
hepatitis 
40x shows bile duct hyperplasia 
40x shows central vein congestion 40x shows cytoplasmic vacuolation and bile duct 
hyperplasia 
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SPECIMEN    :  B) spleen. 
Group – :  Milagu legiyam 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
        Section studied from spleen shows normal white pulp and red pulp. Red pulp shows pigment 
laden macrophages and congested vessels. White pulp shows lymphocytic infiltrates forming 
germinal centre. The pencillar artery shows normal morphology. Megakaryocytes 
    
10x shows normal red pulp and white pulp 10x shows normaL SPLEEN 
40x shows lymphocytic infiltration 40x shows lymphocytic infiltration 
40x shows red pulp with pigment laden 
macrophages 
40x shows red pulp 
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SPECIMEN  :  C)  Kidney. 
Group – :  Milagu legiyam 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE: 
 
 Section from kidney shows both cortex and medulla. Glomeruli and tubules shows no significant 
pathology. Interstitium shows no significant pathology. Blood vessels show congestion. There is 
no evidence of toxic changes. 
10x shows normal cortex 10x shows normal kidney with cortex and 
medulla 
40x shows normal glomeruli (2) 40x shows normal glomeruli with blood vessel 
congestion 
40x shows normal glomeruli 
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SPECIMEN  :  D) Testis 
Group – :  Milagu legiyam 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
          Section from testes with seminiferous tubules showing maturation arrest with lacking of 
spermatogenesis.  
  
 
10x shows focal tubules shows maturation arrest 40x shows  tubules 
40x shows seminiferous tubules shows maturation 
arrest 
40x shows seminiferous tubules 
40x shows tubules with sertoli cells (2) 
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Name   : 
Ref. No. : [H0 327A/18] 
 
 
Rec.On :  21/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
              TOXICITY STUDY            
 
 
SPECIMEN                   :  A) Liver 
    
Group –                   : D.Subathra – M.L.  
 
GROSS APPEARANCE: 
 
                     Received a specimen of liver measuring 3.4x2.0x1.4cms.                     
  
(PE): Two bits – One block. 
 
MICROSCOPIC APPEARANCE:  
 
                     Section from liver shows mild altered architecture with interface hepatitis. 
Individual hepatocytes shows cytoplasmic vacuolation and binucleation. Portal triad shows 
bile duct hyperplasia. Central vein shows congestion. Sinusoids show dilatation. 
 
 
        
                                                                                                                                             
Dr.C.R.Ajeethkumar.M.D. (Path). 
             
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path),   Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
 
Checked 
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Name   : 
Ref. No. : [H0 327B/17] 
 
Rec.On :  21/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
         Toxicity study                
 
SPECIMEN                   :  B) spleen. 
    
Group –                 : D.Subathra – M.L. 
 
GROSS APPEARANCE:  
 
                     Received a specimen of spleen measuring 2.2x0.7x0.5cms. 
 
 (PE): Two bits – One block. 
 
MICROSCOPIC APPEARANCE:  
 
                     Section studied from spleen shows normal white pulp and red pulp. Red pulp 
shows pigment laden macrophages and congested vessels. White pulp shows lymphocytic 
infiltrates forming germinal centre. The pencillar artery shows normal morphology. There is 
no evidence of toxic changes. Megakaryocytes are also seen. 
 
 
 
    
 
                                                                                      
                                                                                Dr.C.R.Ajeeth kumar. M.D. 
(Path), 
 
 
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path), Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
 
 
Checked 
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Name   :   
Ref. No. : [Ho 327C/18]                      
 
Rec.On :  21/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
                                 Toxicity study 
SPECIMEN                          : Kidney. 
 
Group –                       : D.Subathra – M.L. 
 
GROSS APPEARANCE    : 
 
Received specimen of kidneys each measuring 1.4x0.7x0.4cms and 1.3x0.6x0.4cms. 
 
PE : Two bits – One block.                                                            
 
MICROSCOPIC APPEARANCE:  
 
                     Section from kidney shows both cortex and medulla. Glomeruli and tubules 
shows no significant pathology. Interstitium shows no significant pathology. Blood vessels 
show congestion. There is no evidence of toxic changes. 
 
 
                                                                       Dr. C.R.Ajeeth kumar.M.D. (Path). 
 
 
 
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path),   Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
 
 
Checked 
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Name   :   
Ref. No. : [Ho 327D/18]                      
 
Rec.On :  21/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
                                 Toxicity study 
SPECIMEN                          : Testis. 
 
Group –                       : D.Subathra – M.L.   
 
GROSS APPEARANCE    : 
 
Received specimen of both testis measuring each 1.0x0.6x0.5cms and 1.0x0.5x0.4cms. 
 
PE : Two bits – One block.                                                            
 
MICROSCOPIC APPEARANCE:  
 
                     Section from testes with focal seminiferous tubules shows maturation arrest and 
lacking spermatogenesis. There is no evidence of granuloma/ malignancy seen. 
 
 
 
                                                                       Dr. C.R.Ajeeth kumar.M.D. (Path). 
 
 
 
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path),   Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
 
 
 
 
